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In chapter 2, the gold-catalyzed C-H annulation of anthranil derivatives with alkynes 
offers a facile, flexible, and atom-economical one-step route to unprotected 
7-acylindoles. An intermediate a-imino gold carbene, generated by an intermolecular 
reaction, promotes ortho-aryl C-H functionalization to afford the target products. The 
transformation proceeds with a broad range of substrates under mild conditions. 
Moreover, the obtained functionalized indole products represent a versatile platform 




In chapter 3, a gold-catalyzed cascade annulation of propargylic silyl ethers with 
anthranils proceeds through a sequential ring 
opening/1,2-H-shift/protodeauration/Mukaiyama aldol cyclization. This method offers 
a regiospecific and modular access to 2-aminoquinolines and other quinoline 
derivatives under mild conditions and with a broad functional-group tolerance. The 
conversion is possible on a gram scale, which underlines the synthetic practicability 





In chapter 4, gold and platinum-catalyzed counteranion-directed divergent [4+2] 
V 
 
annulations have been described, enabling the convergent assembly of densely 
substituted quinoxaline and quinoxaline N-oxide from benzofurazans and ynamides. A 
broad scope of functional groups was well tolerated, delivering high regioselectivity. 
The quinoxaline N-oxides were suitable for the further C-H functionalization. 
Mechanism studies suggested the counteranion-tuned distinct cyclization pathways 




In chapter 5, the gold-catalyzed oxidative [2+2+1] annulation of two molecules of 
ynamide with 2, 3-quinoxaline N-oxide, enables the facile and convergent assembly 
of fully-substituted symmetric and unsymmetric furan frameworks. A wide range of 
functional groups is well compatible due to the mild condition. The strategy works 
also for the intramolecular macrocyclization of di-ynamides for the synthesis of 











In Kapitel 2, die goldkatalysierte C-H-Anellierung von Anthranilderivaten mit 
Alkinen eröffnet eine einfache, flexible und atomökonomische einstufige Route zu 
ungeschützten 7-Acylindolen. Über eine α-Iminogoldcarben-Zwischenstufe, die in 
einer intermolekularen Reaktion generiert wird, erfolgt eine 
ortho-Aryl-C-H-Funktionalisierung zur Zielverbindung. Die Transformation zeichnet 
sich durch ein breites Substratspektrum und milde Bedingungen aus. Darüber hinaus 





In Kapitel 3, die Gold-katalysierte Kaskaden-Anellierung propargylischer Silylether 
mit Anthranilen verläuft sequenziell über eine 
Ringöffnung/1,2-H-Verschiebung/Protodesaurierung/Mukaiyama-Aldol-Cyclisierung. 
Dieses Protokoll bietet einen regiospezifischen und modularen Zugang zu 
2-Aminochinolinen und anderen Chinolinderivaten unter milden Bedingungen bei 
guter Kompatibilität mit funktionellen Gruppen. Die Reaktionen gelingen im 
Gramm-Maßstab, was den präparativen Nutzen der Methode unterstreicht. Die 







In Kapitel 4, sind die Gold- und Platinkatalysierte Gegenanion-dirigierenden 
divergenten [4+2] Anellierungen beschrieben, die den konvergenten Aufbau von 
dicht-substituierten Chinoxalin und Chinoxalin N-Oxiden von Benzofurazanen und 
Ynamiden ermöglicht. Ein breites Substratspektrum von funktionellen Gruppen 
wurde sehr gut toleriert und lieferte eine hohe Regioselektivität. Die Chinoxalin 
N-Oxide waren für weitere C-H Funktionalisierungen geeignet. Mechanistische 
Studien wiesen auf einen Gegenanion-abgestimmten eindeutigen Cyclisierungspfad 




In Kapitel 5, ermöglicht die gold-katalysierte oxidative [2+2+1] Anellierung von zwei 
Ynamid Molekülen mit Chinoxalin N-Oxid den leichten und konvergenten Aufbau 
von durchgehend substituierten symmetrischen und unsymmetrischen Furan 
Grundgerüsten. Eine große Bandbreite von funktionellen Gruppen ist aufgrund der 
milden Reaktionsbedingungen gut kompatibel. Die Strategie funktioniert auch für 






Chapter 1: General Introduction  
1.1 Gold Carbene Species in Homogeneous Gold Catalysis 
Gold was recognized as currency decoration thousands of years ago. However, the 
catalytic activity of gold compounds has been ignored until the last century.
[1]
 During 
the past decades, homogeneous gold catalysis has been booming and afforded various 
flexible, versatile and atom-economic strategies for the construction of complex 
molecular frameworks.
[2]
 Due to the pronounced carbophilicity of gold complexes, 
enormous efforts in this field referred to gold-catalyzed alkyne activation and 
transformation
[3]
, with high functional group tolerance and mild reaction condition. In 
these reaction mechanisms, gold carbenes are often involved and considered as a key 




The first reaction involving gold carbene intermediates was the furan-yne 
transformation for Hashmi phenol synthesis.
[5a]
 Subsequently, the nature of gold 







 et al. A bonding model for gold carbenes was 
described by Toste’s group in 2009.[5g] The gold core can accept two pairs of electrons 
from the ligand and carbene respectively to produce a three-center four-electron 
-hyperbond. Meanwhile, two -backdonations are formed by electrons transfer from 
two filled 5d orbitals on gold to empty π*-antibonding orbitals of the ligand and the 
carbene. The most common approaches to gold carbenes are summarized in Scheme 1, 
including: a) 1, 2-acyloxy migration of propargylic carboxylates;
[6]
 b) the 
decomposition of diazo compounds;
[7]
 c) the direct alkyne oxidation and amination;
[8]
 
d) ring-opening of cyclopropenes;
[9]
 e) intramolecular cycloisomerization of 
enynes.
[10] 





In this chapter, gold carbenes resulting from alkyne amination and oxidation are 
highlighted (Scheme 1, c). A range of gold carbene-triggered intramolecular and 




Scheme 1. General approaches to gold carbenes. 
 
1.2 -Imino Gold Carbene-Mediated Syntheses of Heterocyclic 
Compounds 
The first report on the generation of an -imino gold carbene by the intramolecular 
acetylenic Schmidt reaction of alkynes with an tethered azide was developed by Toste 
and co-workers (Scheme 2, a).
[11]
 In this work, the -imino gold carbene was invoked 
by the intramolecular nucleophilic azide addition to an alkyne followed by losing 
nitrogen. Through 1,2-hydride/alkyl migration pyrrole products were furnished. 
Inspired by this reaction, Zhang and Gagosa’s group reported indole and 3-indolinone 
synthesis via analogous -imino gold carbene intermediates, in which the gold 
carbene was trapped by aryl nucleophiles or allyl alcohols (Scheme 2, b).
[12]
 Further, 









Scheme 2. -Imino gold carbene generated via intramolecular azide addition. 
Instead of azides, Gagosz et al. found 2H-azirines as alternative nitrene precursor to 
access -imino gold carbene via intramolecular cyclization followed by strained 
ring-opening (Scheme 3).
[15]
 A broad scope of functionalized pyridines was obtained 
in excellent yields. 
 
Scheme 3. -Imino gold carbene generated via intramolecular 2H-azirines attack. 
Compared with intramolecular cyclizations toward heterocyclic compounds, the 
intermolecular formal cycloaddition for heterocycle construction is more flexible and 
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versatile without tedious steps in the synthesis of substrates. In 2011, by incorporation 
of ynamides into the gold-catalyzed nitrene transfer, Davies’s group reported the 
gold-catalyzed [3+2] annulation of ynamides with iminopyridium yields densely 
substituted oxazoles
[16a]
 with the gold(III) complex
[16b]
 as catalyst (Scheme 4, a). As 
well as aryl substituents, alkyl substituted (R
1
) ynamides were also suitable for the 
reaction without -H elimination products, which suggested that the C-O bond 
formation might be faster than N-N bond cleavage. Subsequently, the methodology 
was expanded to the synthesis of fused imidazodiazines and imidazopyridines, in 





Scheme 4. -Imino gold carbenes generated via intermolecular nitrene transfer. 
In 2015, Huang and Liu’s group exploited the intermolecular [3+2] annulation of 
ynamides with 2H-azirines, enabling the atom-economic synthesis of various 
2-aminopyrroles (Scheme 5, a).
[18]
 Furthermore, the nucleophilic vinyl azide turned 






Scheme 5. 2H-azirines as a nitrene equivalent. 
 
In the same year, Ye’s group published an alternative intermolecular [3+2] annulation 
towards 2-aminopyrroles taking advantage of isoxazoles as a nitrene equivalent 
(Scheme 6).
[20]
 The -imino gold carbene was produced by gold-promoted N-O bond 
cleavage and then underwent a 4-electrocyclization/deauration processes. The 
structure of the final product was depended on the R
3
-substitutents. 3-Acyl pyrroles 
were gained followed by 1, 3 H-shift, while water-assisted deacylated products were 
observed in the case of alkyl and aryl substituents. 
 
Scheme 6. Isoxazoles as a nitrene equivalent. 
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In 2016, another intermolecular nitrene transfer reagent, dioxazole, was described by 
Liu’s group.[21] The -imino gold carbene might be produced via a tandem N-O bond 
cleavage/ acetone releasing process. The gold-catalyzed intermolecular formal [3+2] 
cycloaddition provided a novel protocol to oxazole derivatives under mild conditions 
(Scheme 7, a). Moreover, an intramolecular cascade cyclization was conducted to 
demonstrate the generation of an -imino gold carbene intermediate (Scheme 7, b).  
 
Scheme 7. Dioxazoles as a nitrene equivalent. 
 
Ye and co-workers reported the first instance on gold-catalyzed intermolecular 
transformation of ynamides with benzyl azides.
[22]
 Remarkably, the kind of benzyl 
azides has a crucial influence on final products and yields. Generally, treatment of 
3-bromobenzyl azide and N-aryl substituted ynamides led to 2-aminoindoles in good 
to excellent yields even at room temperature, whereas Boc-protected indolyl azides 
offered a [4+2] annulation toward 3-amino-β-carbolines proceeded by AgOAc 
oxidation (Scheme 8). Subsequently, the benzyl azide was employed to the reaction 








Scheme 8. Gold-catalyzed intermolecular reaction of ynamides with azides. 
 
 
Scheme 9. Ynamide amination-initiated aza-Nazarov cyclization 
 
Besides of ynamides, Ballesteros et al. reported an -imino gold carbene-mediated 
three component cascade reaction involving common terminal alkynes (Scheme 
10).
[24]
 A highly nucleophilic dipolar triazapentalene derivative was in-situ generated 
via gold-aided 5-endo-dig cyclization of the propargylic benzotriazole and enabled the 
reaction with gold-activated terminal alkyne to provide -imino gold carbene 
intermediates. Then, the gold carbene could be easily captured by the external nitrile 





Scheme 10. Gold-catalyzed three component cascade reaction of alkyne, nitrile and 
propargylic benzotriazole. 
1.3 -Oxo Gold Carbene-Mediated Syntheses of Cyclic Compounds 
In 2008, Hashmi and Liu et al. independently reported that an internal epoxide can 
oxidize an alkyne leading to an -oxo gold carbene, which is involved by in a further 
cyclization with the nascent C–C double bond. (Scheme 11, a).[25] Subsequently, Liu’s 
group disclosed a formal [2+2+1] cycloaddition of a nitroso species, external alkenes 
and -oxo gold carbenoids, which results from intramolecular oxidation via nitro 







Scheme 11. Intramolecular generation of a presumed -oxo gold carbene.  
 
In 2010, Zhang’s group reported the intermolecular generation of -oxo gold carbenes 
via the reaction of alkynes with pyridine N-oxides (Scheme 12). The resulting gold 
carbene could be trapped by the tethered O- and N-nucleophile to give a variety of 
functionalized heterocyclic compounds.
[27]
 Especially, highly strained 4-member rings 
were afforded in good to excellent yields.  
 
Scheme 12. Intramolecular trapping of -oxo gold carbene by 
heteroatom-nucleophiles 
 
In 2013, Hashmi and co-workers described the gold-catalyzed oxidative cyclization of 
diynes (Scheme 13).
[28]
 The -oxo gold carbene accessed by alkyne oxidation was 
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transferred across the adjacent alkyne undergoing a 1, 5-carbene shift. The resulting 
vinyl gold carbene could be quenched by 1, 2-alkyl migration. Moreover, the 
oxidation of the vinyl carbene intermediate proved the 1, 5-carbene shift process. 
 
 
Scheme 13. -Oxo gold carbene-initiated intramolecular 1, 5-carbene shift. 
 
Lately, Zhang et al successfully achieved the intramolecular cyclopropanation of an 
alkene with an -oxo gold carbene.[29] Taking advantage of a newly designed chiral P, 
N-bidentate ligand enabled the gold-catalyzed enantioselective synthesis of polycyclic 
cyclopropane derivatives (Scheme 14).  
 
 




Due to the high electrophilicity, -oxo gold carbenes can also induce a sp2-C-H 
insertion. Zhang’s group reported the intramolecular attack of an electron-rich 
benzene onto a presumed gold carbene in the aryl propargyl ether oxidation (Scheme 
15).
[30]
 A large array of valuable chroman-3-ones was gained in moderate to good 
yields with sterically hindered ligands on the gold catalyst.  
 
 
Scheme 15. Intramolecular trapping of -oxo gold carbenes by electron-rich arenes. 
 
Recently, a notable progress in -oxo gold carbene-triggered the unactivated sp3-C-H 
bond functionalization was disclosed by Zhang’s group.[31] Ynones were used as 
substrates to generate -diketone--gold carbenes. These highly electrophilic carbene 
species are capable of common sp
3
-C-H insertion to offer versatile spiro-, bridged and 
fused cyclopentanones (Scheme 16). The Thorpe-Ingold effect on substrate 
conformation is a key factor for cyclized efficiency.  
 
 
Scheme 16. Intramolecular trapping of -oxo gold carbene by unactivated sp3 C-H. 
 
Compared to the myriad of intramolecular trapping pathways, intermolecular 
cycloadditions of -oxo gold carbenes is still limited to the cascade reaction with 
nitriles and amides. In 2011, Zhang’s group reported the first instance on 
12 
 
intermolecular trapping of -oxo gold carbenes by nitrile solvents, enabling a 
convergent [2+2+1] synthesis of 2, 5-disubstituted oxazoles from terminal alkynes, 
nitriles and quinoline N-oxides (Scheme 17, a).
[32]
 Owing to the high electrophilicity, 
gold carbenes are easily over-oxidized by N-oxides, which disable the subsequent 
reaction. In 2012, a bidentate ligand was developed to temper the reactivity of 
terminal -oxo gold carbenes suitable for trapping by stoichiometric external 
amides.
[33]
 A [3+2] annulation was furnished to access diverse 2, 4-disubstituted 
oxazoles (Scheme 17, b).  
 
Scheme 17. Intermolecular trapping of -oxo gold carbene by nitriles and amides. 
1.4 Research Objectives and Thesis Outline 
The research projects exhibited in this thesis focus on gold carbene-mediated 
intermolecular annulations toward various heterocyclic compounds, which are 
difficult to prepare by conventional methods. Novel and atom-economy approaches to 
-imino gold carbenes are also described. Moreover, platinum carbenes will be 
discussed under some special conditions. 
 
In chapter 2, a gold-catalyzed formal [3+2] cycloaddition of alkynes with anthranils is 
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presented to offer synthetically valuable N-unprotected 7-acylindoles. Chapter 3 
describes a gold-catalyzed [4+2] annulation towards the 2-aminoquinoline framework 
via the umpolung of a gold carbene carbon. Chapter 4 discloses a 
counteranion-controlled gold and platinum-catalyzed divergent [4+2] annulation of 
ynamides with benzofurazans to selectively access quinoxaline N-oxides and 
quinoxalines. In chapter 5, the -oxo gold carbene-triggered oxidative [2+2+1] 
approach to full-substituted furans and macrocyclic furan derivates is developed by 
taking advantage of the amphoteric character of ynamides. 2, 3-dichloroquinoxaline 
N-oxide is found to suit the cascade reaction. 
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Chapter 2: Gold-Catalyzed C-H Annulation of Anthranils 
with Alkynes: a Facile, Flexible and Atom-Economical 
Synthesis of N-unprotected 7-Acyl Indoles 
2.1 Introduction  
Indoles have attracted immense attention owing to their ubiquitous presence in natural 
products, drug molecular and materials.
[1] 
Among indoles, 7-acylindoles serve not 
only as a class of bioactive molecules (Scheme 1), but also as key building blocks 
with orthogonal chemical reactivity.
[2]
 However, conventional methodologies,
[3]
 such 
as the Fischer, Larock and Bartoli syntheses, usually show low functional group 
tolerance and difficulties in installing aldehydes and ketones make it a challenge to 
construct 7-acylindoles. Hence, the development of a general synthetic strategy for 
the efficient construction of a diversified scaffold of 7-acylindole would be highly 
desirable. 
 
Scheme 1. Selected bioactive compounds based on 7-acylindoles 
 





 especially has had a 
strong impact on this field of synthetic chemistry. For example, gold-catalyzed 
intramolecular annulation
[5]







 skeletons, based on -imino gold carbenoids as 
electrophilic key intermediates. However, the access towards -imino gold carbenoids 
by intramolecular nitrene transfer can limit the generality and flexibility of the 
obtained products. Regarding this drawback, an intermolecular approach for the 
generation of an imino gold carbene species en route to functionalized heterocyclic 
compounds would represent an attractive strategy. In line with this principle, Davies 
et al. and Ye et al. successfully accomplished gold-catalyzed intermolecular 





Very recently, the gold-catalyzed intermolecular transformation of benzyl azides with 
ynamides was also reported by Ye’s group.[7d] However, the -imino gold carbenes 
that are produced through the intermolecular approach have so far been limited to 
polarized alkynes. Inspired by these reports and in continuation of our work on indole 
chemistry,
[8]
 we envisioned that a gold-catalyzed intermolecular transformation of 
anthranil with alkynes could produce-imino gold carbene intermediates. Based on 
the high electrophilicity of the -imino gold carbenoid, an intramolecular ortho-aryl 
C-H insertion could then afford the desired 7-formyl indoles (Scheme 2). Herein, we 
report our results on the unprecedented gold-catalyzed C-H annulation of anthranils 
with alkynes under mild reaction condition. Remarkably, the reaction also proceeds 
smoothly with ynamides, non-polarized alkynes, and non-terminal alkynes. The 
process enables a facile, flexible and atom-economical synthesis of 7-acylindolyl 
frameworks. 
 




2.2 Results and Discussion 
2.2.1 Optimization of the Reaction Conditions 
Initially, we conducted a screening of the reaction conditions with ynamide 1a, since 
such substrates usually possess high reactivity in gold catalyzed reaction as a result of 
their electronic properties
[7a-d,9]
 (Table 1). Treatment of ynamide 1a and anthranil 2a 
with Ph3PAuCl/AgNTf2 at 0 
o
C provided the expected product 3a in 36 % yield (entry 
1). Among the screened gold catalysts, the catalyst with an NHC ligand (entry 6) 
showed higher activity than those with phosphane and phosphite ligands (entries 2-4). 
AuBr3 was less efficient as well (entry 5). The yield increased to 84 % upon 
decreasing the reaction temperature to - 20 
o
C (entry 7). Further, improvement was 
achieved by taking advantage of different silver salts (entry 8, 9) and solvents (entry 
10-17). Finally, up to 90 % yield of 3a was gained by employing 5 mol% 
IPrAuCl/AgNTf2 as catalyst in PhCF3 at - 20 
o
C (entry 11). The control experiment 
without catalyst showed no reaction even at room temperature (entry 18). 
 




Entry Catalyst Solvent Temperature Yield % 
[b]
 
1 Ph3PAuCl/AgNTf2 ClCH2CH2Cl 0 
o
C 36 










 (ArO)3PAuCl /AgNTf2 ClCH2CH2Cl 0 
o
C 64 
5 AuBr3 ClCH2CH2Cl 0 
o
C 35 
6 IPrAuCl/AgNTf2 ClCH2CH2Cl 0 
o
C 73 





8 IPrAuCl/AgSbF6 ClCH2CH2Cl -20 
o
C 74 
9 IPrAuCl/AgBF4 ClCH2CH2Cl -20 
o
C 58 
10 IPrAuCl/AgOTf ClCH2CH2Cl -20 
o
C 32 





12 IPrAuCl/AgNTf2 PhMe -20 
o
C 81 
13 IPrAuCl/AgNTf2 PhCl -20 
o
C 71 
14 IPrAuCl/AgNTf2 CH2Cl2 -20 
o
C 72 
15 IPrAuCl/AgNTf2 CH3CN -20 
o
C 22 
16 IPrAuCl/AgNTf2 THF -20 
o
C 46 
17 IPrAuCl/AgNTf2 Et2O -20 
o
C 30 
18 none ClCH2CH2Cl rt ND 
[a] Reaction conditions: 1a (0.3 mmol), 1b (0.2 mmol); a solution (1 ml) of 1a was 
added over 3 mins to a solution (1 ml) of 1b and the catalyst at the according 
temperature, reaction time 1 h. [b] Measured by 
1
H NMR using 
4-(dimethylamino)benzaldehyde as the internal standard. [c] Ar = 2, 
4-di-tert-butylphenyl. [d] Isolated yield. 
 
2.2.2 Scope and Limitation 
With the optimized condition in hand, the scope of the reaction was explored (Table 
2). Ynamides reacted with excellent to moderate yields (3a-3j). A broad set of 
substitutents at the ynamide nitrogen atom turned out to be compatible. 7-Formyl 
indole 3e which was prepared from N-(2-bromophenyl) ynamide in good yield, is a 
potential precursor for the synthesis of 1,2-fused indoles according to a method from 
Perumal’s group.[4g] Among the tested protecting groups on the ynamides, besides 
tosyl and mesyl, the oxazolidinone-derived ynamide also underwent the annulation to 
afford the product 3j in moderate yield. Non-terminal ynamides were also 
investigated and the targeted product (3k) was prepared from phenyl-substituted 
ynamide in good yield, the alkyl-substituted ynamide afforded the H elimination 
product 3l’ rather than 3l. Various substituted anthranils were empolyed for the 
synthesis of diversified 7-acylindoles (3m-3y). Owing to the mild reaction conditions, 
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a large array of functional groups, including ester (3n), acetal (3o), chloride 3p, 
bromide (3q, 3r), alkene (3v) and-unsaturaed ketones (3w-3y) were all tolerated, 
which enormously enhances the range of the obtained substrates. The reaction of 
anthranils with electron-donating groups usually proceeded with higher yields, which 
suggests an electrophilic aromatic substitution mechanism. For a structural 
confirmation of the 7-acylindolyl framework, a single crystal X-ray structure 
analysis
[10]
 of 3q was performed (Figure 1). 
 





3a, X = H, 85 % 
3b, X = Me, 80 % 
3c, X = OMe, 74 % 
3d, X = Cl, 77 % 
  
3e, 74 % 
3f, 88 % 
    





, 84 %      3l, 0 %           3l’[c], 81 %      3m, 74 % 
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3r, 53 % 3s, 80 % 
3t, 85 % 
3u, 83 % 
 
   
3v, 74 % 3w 
[d]
, 73 % 3x 
[d]
, 79 % 3y 
[d]
, 65 % 
[a] Reaction conditions: 1 (0.3 mmol), 2 (0.2 mmol); a solution (1 ml) of 1 was added 
over 3 mins to a solution (1 ml) of 2 and 5 mol% IPrAuCl/AgNTf2 at -20 
o
C, then 
stirred for an additional 1 h. [b] Isolated yields. [c] Reaction temperature: 65 
o
C, 4 Å 
MS was added. [d] a mixture of ClCH2CH2Cl (0.5 ml) and PhCF3 (1.5 ml) was as 
solvent.  
 
Figure 1. Solid-state molecular structure of 3q. 
 
The transformation was not only limited to ynamides. The reaction of anthranil and 
aryl alkynyl ether 4a under the standard reaction condition furnished 2-oxyl product 
5a in 63 % yield (Scheme 3, Step 1). 7-Formyl oxindole 5a’, a promising novel 
antioxidant
[11]
, was easily gained by the hydrolysis of 5a under acid condition 
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(Scheme 3, Step 2). 
 
Scheme 3. The reaction of anthranil with aryl alkynyl ether 
 
To extend the scope of substrates further, the non-polarized alkynes were used as well. 
However, owing to their decreased reactivity, the reaction did not work under the 
standard condition. But by raising the temperature and extending the reaction time, 
the yield of the expected product could be gradually increased.
[12]
 By the addition of 
10 mol% MsOH, which might facilitate the deauration process and by using an excess 
of alkyne (MsOH alone is not catalytically active) enabled a more efficient conversion 
rate of anthranil, delivering the products in moderate yields. Under the adjusted 
conditions, both alkyl and aryl alkynes were suitable for the construction of 
C2-functionalyzed and C2, C3-diarylated products (Table 3, 7a-7i). The 7-substituted 
indole 7j, which is a key precursor for synthesizing pyrrolquinolone derivatives,
[13]
 
could facilely be prepared despite the conjugated double bond.  
 




    










7i, 50 % 7j, 66 %  
[a] Reaction conditions: 6 (0.8 mmol) and 2 (0.2 mmol) were heated for 4 h at 65 
o
C 
in 2 ml PhCF3. [b] Isolated yields. 
 
 
Scheme 4. Conversion of an unsymmetrical alkyne. 
 
Finally, an unsymmetrically alkyl/aryl-substituted alkyne was used. In this case, a low 
yield of 2-alkyl-3-aryl indol 7k was obtained (assigned by NOE) and no other indole 
isomer was formed (Scheme 4). The low yield might result from a competing 
hyride-shift pathway if the carbenoid is formed next to the alkyl tether (similar to the 
formation of 3l’). 
2.2.3 Further Derivatisation  
 
Owing to the presence of both electrophilic and nuclephilic sites, 7-formly indoles 
have been utilized as flexible scaffolds for the syntheses of 1, 7-fused indoles, most of 
which exhibit significant biological activity.
[13,14]
 While numerous studies have 
focused on the reactions of indoles with electrophiles, we turned our attention on 
nucleophilic transformations of 7-acyl indoles. For instance, the reduction of 3g 
afforded the 7-alkylated product 3g’ and the unprotected 7-alkynyl indole 3g’’ could 






Scheme 5. Application to the preparation of diverse 7-substituted indoles 
2.3 Summary  
In summary, we decribed a novel, short, and atom-economical synthesis of 7-acyl 
indoles through gold-catalyzed C-H annulation of anthranils with alkynes. The 
substrate scope is remarkably broad and the benign reaction conditions tolerate a 
diverse set of functional groups, which further strengthens the synthetic impact of this 
method. The obtained indoles are highly interesting building blocks for the synthesis 
of 7-substiuted indolyl and fused indolyl frameworks. Based on the availability of the 
starting materials and the enormous gain in molecular complexity, we believe that this 
method will serve as powerful tool for organic synthesis. 
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2.5 Experimental Section 
General information: Chemicals were purchased from commercial suppliers and 




 have been prepared according to the 
literature. Dry solvents were dispensed from the solvent purification system MB 
SPS-800. Deuterated solvents were bought from Euriso-Top. NMR spectra were, if 
not mentioned otherwise, recorded at room temperature on the following 
spectrometers: Bruker Avance-III-300, Bruker Avance DRX-300, Bruker-Avance 
DRX-500 and Bruker Avance-III-500. Chemical shifts are given in ppm and coupling 
constants in Hz. The following abbreviations were used for 
1
H NMR spectra to 
indicate the signal multiplicity: s (singlet), brs (broad singlet), d (doublet), t (triplet), q 
(quartet), quint (quintet), sext (sextet), sept (septet) and m (multiplet) as well as 
combinations of them. When combinations of multiplicities are given the first 
character noted refers to the biggest coupling constant. All 
13
C NMR spectra were 
measured with 
1
H-decoupling. The multiplicities mentioned in these spectra [s 
(singlet, quaternary carbon), d (doublet, CH-group), t (triplet, CH2-group), q (quartet, 
CH3-group)] were determined by DEPT135 and HSQC spectra. Mass spectra (MS and 
HRMS) were determined at the chemistry department of the University of Heidelberg 
under the direction of Dr. J. Gross. EI
+ 
-spectra were measured on a JOEL JMS-700 
spectrometer. For ESI
+
-spectra a Bruker ApexQu FT-ICR-MS spectrometer was 
applied. Infrared Spectroscopy (IR) was processed on an FT-IR Bruker (IF528), IR 
Perkin Elmer (283) or FT-IR Bruker Vector 22. The solvent or matrix is denoted in 
brackets. For the most significant bands the wave number ν (cm-1) is given. X-ray 
crystal structure analyses were measured at the chemistry department of the 
University of Heidelberg under the direction of Dr. F. Rominger on a Bruker Smart 
CCD or Bruker APEX-II CCD instrument using Mo-Kα-radiation. Diffraction 
intensities were corrected for Lorentz and polarization effects. An empirical 
absorption correction was applied using SADABS based on the Laue symmetry of 
reciprocal space. Heavy atom diffractions were solved by direct methods and refined 
against F2 with full matrix least square algorithm. Hydrogen atoms were either 
isotropically refined or calculated. The structures were solved and refined by Dr. F. 
Rominger using the SHELXTL software package. Gas Chromatography / Mass 
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Spectrometry (GC/MS) spectra were measured on two different hardware systems: 1. 
HP 5972 Mass Selective Detector, coupled with a HP 5890 SERIES II plus gas 
chromatograph. 2. Agilent 5975C Mass Selective Detector, coupled with an Agilent 
7890A gas chromatograph. In both cases, as a capillary column, an OPTIMA 5 
cross-linked Methyl Silicone column (30 m x 0.32 mm, 0.25 µm) was employed and 
helium was used as the carrier gas. Gas Chromatography (GC) was carried out on a 
HP 5890 SERIES II plus gas chromatograph. As a capillary column, an OPTIMA 5 
cross-linked Methyl Silicone column (30 m x 0.32 mm, 0.25 µm) was employed and 
nitrogen was used as the carrier gas. Melting Points were measured in open glass 
capillaries in a Büchi melting point apparatus (according to Dr. Tottoli) and were not 
corrected. Flash Column Chromatography was accomplished using Silica gel 60 (0.04 
- 0.063 mm / 230 - 400 mesh ASTM) purchased from Macherey-Nagel or Aluminium 
oxide (neutral or basic) purchased from Macherey-Nagel. As eluents, mixtures of 
petroleum ether (PE), ethyl acetate (EA), dichloromethane (DCM) and diethylether 
(Et2O) were used. Analytical Thin Layer Chromatography (TLC) was carried out on 
precoated Macherey-Nagel POLYGRAM
®
 SIL G/UV254 or POLYGRAM
®
 ALOX 
N/UV254 plastic sheets. Detection was accomplished using UV-light (254 nm), 
KMnO4 (in 1.5 M Na2CO3 (aq.)), molybdatophosphoric acid (5 % in ethanol), 
vanillin/H2SO4 (in ethanol) or anisaldehyde/HOAc (in ethanol). IUPAC names of the 




Optimization of the Reaction Conditions (Table S1) 













1 IPrAuCl/AgNTf2 none 1.5 equiv. 1 h -20 0 
2 IPrAuCl/AgNTf2 none 4 equiv. 1 h -20 0 
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3 IPrAuCl/AgNTf2 none 4 equiv. 1 h rt trace 
4 IPrAuCl/AgNTf2 none 4 equiv. 4 h rt 8 
5 IPrAuCl/AgNTf2 none 4 equiv. 24 h rt 17 
6 IPrAuCl/AgNTf2 none 4 equiv. 1 h 50 18 
7 IPrAuCl/AgNTf2 none 4 equiv. 4 h 50 28 
8 IPrAuCl/AgNTf2 none 4 equiv. 4 h 65 36 
9 IPrAuCl/AgNTf2 none 4 equiv. 24 h 65 29 
10
[c]
 (ArO)3PAuCl/AgNTf2 none 4 equiv. 4 h 65 29 
11 IPrAuCl/AgSbF6 none 4 equiv. 4 h 65 30 
12 IPrAuCl/AgNTf2 10 mol% AgNTf2 4 equiv. 4 h 65 63 
13 IPrAuCl/AgNTf2 10 mol% 
Zn(OTf)2 
4 equiv. 4 h 65 57 
14 IPrAuCl/AgNTf2 10 mol% 
Fe(OTf)3 
4 equiv. 4 h 65 13 
15 IPrAuCl/AgNTf2 20 mol% 
Zn(OTf)2 
4 equiv. 4 h 65 64 
16 IPrAuCl/AgNTf2 10 mol% MsOH 4 equiv. 4 h 65 68 
17 IPrAuCl/AgNTf2 10 mol% HNTf2 4 equiv. 4 h 65 34 
18 IPrAuCl/AgNTf2 20 mol% MsOH 4 equiv. 4 h 65 60 
19 IPrAuCl/AgNTf2 1 equiv. MsOH 4 equiv. 4 h 65 trace 
20 none 10 mol% MsOH 4 equiv 4 h 65 0 
[a] Reaction conditions: 6a and 2a (0.2 mmol) were heated in PhCF3 (2ml). [b] 
isolated yield. [c] Ar = 2, 4-di-tert-butylphenyl. 
 
Experimental Procedure 1: Synthesis of substituted anthranils 
 
The syntheses of substituted anthranils was referred to the report of S. Fletcher’s 
group 
[5]
 with a little modification.  
 
A round bottom flask equipped with a magnetic stirrer bar was charged with the 
substituted 2-nitroacylbenzene (3.00 mmol) in EtOAc–MeOH (1:1; 20 mL). 
SnCl2 
.
H2O (9.00 mmol) was added and the reaction was stirred at room temperature 
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for 24 h. The reaction was quenched by saturated NaHCO3 (20 ml), and filtered. The 
aqueous phase was extracted with EtOAc (3 × 10 mL) and the organic portions 
combined, washed with H2O (20 mL), saturated aqueous NaCl (20 mL), dried over 
NaSO4, filtered and reduced in vacuo. The residue was purified by column 
chromatography (SiO2, hexanes/EtOAc) to provide the title compound. The 
characterization of unknown compounds has been listed in part 4.  
 
Experimental Procedure 2: Gold-catalyzed C-H annulation of anthranils with 
ynamides or aryl alkynyl ethers 4a  
 
A round bottom flask equipped with a magnetic stirrer bar was charged with IPrAuCl 
(5 mol%, 6.2 mg), AgNTf2 (5 mol%, 4 mg), and solvent (1 ml). The mixture was 
stirred for 5 minutes at room temperature. Then the reaction was cooled to -20 
o
C and 
the anthranil (0.2 mmol) was added. The alkyne (0.2 mmol) dissolved in solvent (1 ml) 
was added dropwise over 3 minutes at -20 
o
C, and reacted at -20 
o
C for 1h. The 
solvent was reduced in vacuo, and the residue was purified by column 
chromatography (SiO2, hexanes/EtOAc) to provide the title compound. For the 
non-terminal ynamides, 4 Å MS was added and reacted at 65 oC for 1 h. The 
characterization of products has been listed in part 4.  
 
Experimental Procedure 4: Gold-catalyzed C-H annulation of alkynes with 
anthranils 
 
A round bottom flask equipped with a magnetic stirrer bar was charged with IPrAuCl 
(5 mol%, 6.2 mg), AgNTf2 (5 mol%, 4 mg), MsOH (10 mol%, 2 mg) and solvent (1 
ml). The mixture was stirred 5 minutes at room temperature. Then the anthranil (0.2 
mmol) and alkyne (0.2 mmol) dissolved in solvent (1 ml) were added. The reaction 
was stirred at 65 
o
C for 4 h. The solvent was reduced in vacuo, and the residue was 
purified by column chromatography (SiO2, hexanes/EtOAc) to provide the title 
compound. The characterization of products has been listed in part 4. 
 




To the solution of 5a in MeOH (1 ml) was added dropwise 2 N HCl (1 ml). The 
reaction was stirred at room temperature until the reagent disappeared, monitored by 
TLC. The reaction was quenched by saturated NaHCO3. The aqueous phase was 
extracted with EtOAc (3 × 5 mL) and the organic portions combined, washed with 
H2O (10 mL), saturated aqueous NaCl (10 mL), dried over NaSO4, filtered and 
reduced in vacuo. The residue was purified by column chromatography (SiO2, 
hexanes/EtOAc) to provide the title compound. The characterization of product has 
been listed in part 4. 
 
Experimental Procedure 6: Seyferth-Gilbert homologation of 3g 
 
To the mixture of 3g (0.2 mmol), Cs2CO3 (0.5 mmol), MeOH (1 ml) and THF (1 ml) 
was added dropwise the dimethyl (1-diazo-2-oxopropyl)phosphonate (0.4 mmol) at 0 
o
C. Then, the reaction was stirred 6 h at room temperature. The mixture was washed 
with H2O (10 mL), and extracted with EtOAc (3 × 5 mL). The organic portions were 
combined and washed with saturated aqueous NaCl (10 mL), dried over NaSO4, 
filtered and reduced in vacuo. The residue was purified by column chromatography 
(SiO2, hexane/EtOAc) to provide the title compound. The characterization of product 
has been listed in part 4. 
 
Experimental Procedure 7: Reduction reaction of 3g 
 
To the solvent of 3g (0.2 mmol) and EtOH (2 ml) was added the NaBH4 (0.4 mmol), 
then stirred 2 h at room temperature. The reaction was quenched by H2O (10 ml), and 
filtered. The aqueous phase was extracted with EtOAc (3 × 5 mL) and the organic 
portions combined, washed with H2O (10 mL), saturated aqueous NaCl (10 mL), 
dried over NaSO4, filtered and reduced in vacuo. The residue was purified by column 
chromatography (SiO2, hexane/EtOAc) to provide the title compound. The 
characterization of product has been listed in part 4. 
Characterization  
 
Compound 2c: Yield 88 %, colourless soild, mp: 78-80 
o




H NMR (500 MHz, CDCl3) δ = 9.13 (s, 1 H), 7.66 (d, J = 9 Hz, 1 H), 7.31 (s, 1 H), 
7.08 (d, J = 9.5 Hz, 1 H), 2.34 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 169.4 
(s), 154.8 (d), 154.6 (s), 146.9 (s), 128.3 (d), 117.7 (s), 116.7 (d), 109.3 (d), 21.1 (q) 
ppm; IR (reflection): ṽ = 3142, 3080, 2939, 1750, 1652, 1619, 1567, 1523, 1473, 1432, 
1413, 1372, 1360, 1328, 1259, 1216, 1176, 1140, 1104, 1048, 1016, 954, 926, 08, 872, 
808, 785, 754, 736, 681, 611 cm
-1




Compound 2e: Yield 78 %, colourless soild, mp: 76-78 
o
C; Rf = 0.54 (PE/EA = 5:1); 
1
H NMR (500 MHz, CDCl3) δ = 9.03 (s, 1 H), 7.57-7.45 (m, 2 H), 7.21-7.14 (m, 1 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 154.6 (s), 154.1 (d), 132.8 (d), 130.3 (s), 118.4 
(s), 117.8 (d), 116.8 (d) ppm; IR (reflection): ṽ = 3109, 1911, 1728, 1638, 1546, 1515, 
1462, 1408, 1317, 1252, 1231, 1154, 1115, 1057, 1043, 923, 879, 864, 857, 803, 772, 
733, 692, 644, 627, 610 cm
-1




Compound 2f: Yield 88 %, light yellow soild, mp: 98-99 
o
C; Rf = 0.60 (PE/EA = 5:1); 
1
H NMR (500 MHz, CDCl3) δ = 9.07 (s, 1 H), 7.55-7.47 (m, 1 H), 7.15-7.06 (m, 2 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 156.2 (s), 156.1 (d), 131.5 (d), 126.8 (d), 
121.0 (s), 114.3 (d), 112.5 (s) ppm; IR (reflection): ṽ = 3178, 3120, 3096, 1767, 1633, 
1546, 1512, 1438, 1398, 1349, 1255, 1198, 1184, 1157, 120, 1014, 946, 912, 868, 819, 
782, 729, 616 cm
-1




Compound 2g: Yield 84 %, light yellow soild, mp: 55-56 
o
C; Rf = 0.46 (PE/EA = 5:1); 
1
H NMR (500 MHz, CDCl3) δ = 9.06 (s, 1 H), 7.79 (s, 1 H), 7.40 (d, J = 9 Hz, 1 H), 
7.02 (d, J = 9.5 Hz, 1 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 156.6 (s), 155.3 (d), 
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128.8 (d), 125.8 (s), 121.0 (d), 117.2 (d), 116.7 (s) ppm; IR (reflection): ṽ = 3124, 
3106, 3089, 1897, 1741, 1684, 1658, 1634, 1541, 1499, 1456, 1431, 1406, 1375, 1289, 
1232, 1203, 1145, 1115, 1031, 917, 866, 855, 843, 828, 789, 771, 757, 734, 669, 627, 
609 cm
-1
; HRMS (EI) m/z calcd for C7H4BrNO: 196.9476; found: 196.9470. 
 
 
Compound 2h: Yield 85 %, colourless soild, mp: 171-173 
o
C; Rf = 0.46 (PE/EA = 
5:1); 
1
H NMR (500 MHz, CDCl3) δ = 9.15 (s, 1 H), 7.80-7.78 (m, 1 H), 7.67-7.61 (m, 
3 H), 7.56-7.52 (m, 2 H), 7.37-7.34 (m, 1 H), 1.40 (s, 9 H) ppm ; 
13
C NMR (125 MHz, 
CDCl3) δ = 156.9 (s), 154.3 (d), 151.6 (s), 143.6 (s), 137.2 (s), 127.0 (d, 2 C), 126.0 (d, 
2 C), 125.8 (d), 119.8 (d), 117.6 (s), 111.4 (d), 34.7 (s), 31.3 (q, 3C) ppm; IR 
(reflection): ṽ = 3137, 3122, 3061, 2960, 2901, 1738, 1643, 1562, 1520, 1461, 1405, 
1382, 1363, 1307, 1269, 1203, 1151, 1123, 1105, 1024, 950, 926, 862, 841, 825, 797, 
780, 741, 667, 649, 632 cm
-1
; HRMS (ESI) m/z calcd for C17H17NO [M+H]
 +
: 
252.1383; found: 252.1382. 
 
 
Compound 2l: Yield 83 %, yellow soild, mp: 122-123 
o
C; Rf = 0.5 (PE/EA = 5:1); 
1
H 
NMR (500 MHz, CDCl3) δ = 7.61-7.56 (m, 1 H), 7.56-7.47 (m, 2 H), 7.46-7.42 (m, 2 
H), 7.26-7.14 (m, 4 H), 6.97-6.93 (m, 1 H), 2.32 (s, 3 H) ppm; 
13
C NMR (125 MHz, 
CDCl3) δ = 163.8 (s), 157.4 (s), 139.8 (s), 135.2 (d), 133.0 (s), 130.9 (d), 129.7 (d, 2 
C), 127.3 (d, 2 C), 123.9 (d), 119.9 (d), 115.6 (s), 115.3 (d), 111.1 (d), 21.5 (q) ppm; 
IR (reflection): ṽ = 3070, 3025, 2919, 1903, 1737, 1638, 1605, 1571, 1522, 143, 1412, 
1397, 1378, 1308, 1277, 1226, 1181, 1152, 1139, 1112, 1060, 1038, 962, 944, 918, 
857, 835, 803, 753, 742,711, 669, 649, 626, 610 cm
-1





: 236.1070; found: 236.1069. 
 
 
Compound 2m: Yield 80 %, yellow soild, mp: 122-124 
o
C; Rf = 0.3 (PE/EA = 5:1); 
1
H NMR (500 MHz, CDCl3) δ = 7.59-7.53 (m, 1 H), 7.53-7.44 (m, 4 H), 7.25-7.17 (m, 
1 H), 7.14-7.07 (m, 1 H), 6.95-6.90 (m, 1 H), 6.89-6.84 (m, 2 H), 3.78 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 164.0 (s), 160.7 (s), 157.4 (s), 134.9 (d), 130.9 (d), 
128.8 (d, 2 C), 128.5 (s), 123.7 (d), 120.0 (d), 115.4 (s), 115.2 (d), 114.5 (d, 2 C), 
109.9 (d), 55.4 (q) ppm; IR (reflection): ṽ = 3009, 2841, 1658, 1636, 1602, 1574, 
1548, 1511, 1452, 1422, 1401, 1309, 1280, 1254, 1180, 1152, 1137, 1112, 1056, 1020, 
985, 965, 907, 841, 825, 813, 788, 746, 718, 637, 609 cm
-1
; HRMS (ESI) m/z calcd 
for C16H13NO2 [M+H]
+
: 252.1019; found: 252.1018. 
 
 
Compound 3a: Yield 85 %, colourless solid, mp: 132-133 
o
C; Rf = 0.36 (PE/EA = 
5:2); 
1
H NMR (300 MHz, CDCl3) δ = 10.24 (brs, 1 H), 9.93 (s, 1 H), 7.70-7.65 (m, 1 
H), 7.51-7.45 (m, 1 H), 7.32-7.08 (m, 6 H), 6.23 (d, J = 2.4 Hz, 1 H), 4.82 (s, 2 H), 
2.89 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 193.0 (d), 135.6 (s), 135.5 (s), 
131.4 (s), 128.8 (d, 2C), 128.7 (d), 128.22 (d), 128.18 (d, 2C), 128.1 (s), 127.4 (d), 
120.2 (s), 120.0 (d), 95.5 (d), 54.5 (t), 38.0 (q) ppm; IR (reflection): ṽ = 3403, 3012, 
2870, 1670, 1608, 1592, 1544, 1454, 1437, 1357, 1328, 1289, 1272, 1238, 1199, 1187, 
1149, 1088, 1049, 1027, 974, 957, 903, 881, 850, 791, 771, 732, 721, 693, 665, 621, 
610 cm
-1





Compound 3b: Yield 80 %, colourless solid, mp: 131-132 
o
C; Rf = 0.44 (PE/EA = 
2:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.22 (brs, 1 H), 9.94 (s, 1 H), 7.70-7.65 (m, 1 
H), 7.51-7.46 (m, 1 H), 7.20-7.08 (m, 3 H), 7.03-6.97 (m, 2 H), 6.23 (d, J = 2.4 Hz, 1 
H), 4.78 (s, 2 H), 2.88 (s, 3 H), 2.19 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 
193.0 (d), 138.0 (s), 135.6 (s), 132.5 (s), 131.4 (s), 129.4 (d, 2C), 128.7 (d), 128.2 (d, 
2C), 128.1 (s), 127.3 (d), 120.2 (s), 120.0 (d), 95.6 (d), 54.3 (t), 38.0 (q), 21.1 (q) ppm; 
IR (reflection): ṽ = 346, 3349, 3124, 3023,2928, 2818, 2735, 1709, 1672, 1609, 1592, 
1546, 1516, 1491, 1451,1412, 1358, 236, 1221, 1195, 1153, 1119, 1047, 1021, 957, 
882, 89, 806, 769, 747, 726, 684, 657 cm
-1
; HRMS (EI) m/z calcd for C18H18N2O3S: 
342.1038; found: 342.1025. 
 
 
Compound 3c: Yield 74 %, colourless solid, mp: 137-139 
o
C; Rf = 0.30 (PE/EA = 
2:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.18 (brs, 1 H), 9.97 (s, 1 H), 7.74-7.68 (m, 1 
H), 7.55-7.50 (m, 1 H), 7.25-7.12 (m, 3 H), 6.79-6.71 (m, 2 H), 6.24 (d, J = 2.4 Hz, 1 
H), 4.77 (s, 2 H), 3.67 (s, 3 H), 2.89 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 
193.0 (d), 159.5 (s), 135.5 (s), 131.4 (s), 129.7 (d, 2C), 128.7 (d), 128.1 (s), 127.5 (s), 
127.3 (d), 120.2 (s), 120.0 (d), 114.1 (d, 2C), 95.8 (d), 55.3 (q), 54.1 (t), 38.1 (q) ppm; 
IR (reflection): ṽ = 3425, 3355, 3011, 2932, 2837, 2737, 1670, 1610, 1591, 1544, 
1514, 1490, 1453, 1411, 1357, 1304, 1249, 1195, 1178, 1157, 1113, 1048, 957, 882, 
846, 768, 746, 704, 684, 656 cm
-1




Compound 3d: Yield 77 %, colourless solid, mp: 126-128 
o
C; Rf = 0.30 (PE/EA = 
2:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.26 (brs, 1 H), 9.95 (s, 1 H), 7.71-7.66 (m, 1 
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H), 7.54-7.49 (m, 1 H), 7.24-7.10 (m, 5 H), 6.22 (d, J = 2.4 Hz, 1 H), 4.79 (s, 2 H), 
2.92 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 193.0 (d), 135.2 (s), 134.1 (s), 
131.4 (s), 129.5 (d, 2C), 128.94 (d, 2C), 128.9 (d), 128.0 (s), 127.4 (d), 120.2 (s), 
120.1 (d), 114.1 (s), 95.6 (d), 53.7 (t), 37.9 (q) ppm; IR (reflection): ṽ = 3444, 3376, 
3057, 2954, 2927, 2856, 2731, 1666, 1606, 1592, 1555, 1489, 1454, 1383, 1350, 1290, 
1232, 1201, 1175, 1141, 1107, 1046, 1004, 797, 742, 688, 660 cm
-1 ; HRMS (EI) m/z 
calcd for C17H15ClN2O3S: 362.0492; found: 362.0477. 
 
 
Compound 3e: Yield 74 %, colourless solid, mp: 151-153 
o
C; Rf = 0.54 (PE/EA = 
5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.39 (brs, 1 H), 9.97 (s, 1 H), 7.69-7.64 (m, 1 
H), 7.53-7.48 (m, 1 H), 7.45-7.38 (m, 2 H), 7.18-7.09 (m, 2 H), 7.03-6.96 (m, 1 H), 
6.20 (d, J = 2.4 Hz, 1 H), 4.99 (s, 2 H), 2.99 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) 
δ = 193.0 (d), 135.4 (s), 134.6 (s), 132.8 (d), 131.5 (s), 129.4 (d), 129.1 (d), 128.7 (d), 
128.1 (s), 127.9 (d), 127.3 (d), 123.0 (s), 120.2 (s), 120.1 (d), 94.8 (d), 53.7 (t), 37.8 (q) 
ppm; IR (reflection): ṽ = 3419, 3356, 3018, 2930, 220, 2736, 1667, 1608, 1592, 1543, 
1491, 1471, 1442, 1412, 1351, 1236, 1195, 1152, 1046, 1024, 956, 882, 838, 799, 733, 
701, 682, 656 cm
-1




Compound 3f: Yield 88 %, colourless solid, mp: 142-143 
o
C; Rf = 0.24 (PE/EA = 5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.01 (s, 1 H), 9.87 (brs, 1 H), 7.79-7.73 (m, 1 H), 
7.60 (d, J = 8.4Hz, 3 H), 7.20 (dd, J = 2.7, 8.1Hz, 3 H), 6.14 (d, J = 2.4 Hz, 1 H), 
4.51 (m, 1 H), 2.34 (s, 3 H), 1.01 (d, J = 6.6Hz, 6 H) ppm; 
13
C NMR (75 MHz, CDCl3) 
δ = 193.0 (d), 143.8 (s), 137.2 (s), 131.7 (s), 130.8 (s), 129.6 (d, 2C), 129.5 (d), 128.0 
(d), 127.9 (s), 127.5 (d, 2C), 120.3 (s), 119.8 (d), 102.7 (d), 52.0 (d), 21.8 (q, 2C), 
21.6 (q) ppm; IR (reflection): ṽ =3323, 2982, 2929, 2815, 2739, 1670, 1611, 1592, 
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1544, 1493, 1447, 1387, 1368, 1346, 1304, 1238, 1208, 1187, 1173, 1157, 1112, 1086, 
1050, 1029, 991, 93, 862,812, 782, 750, 711, 670, 641 cm
-1
; HRMS (EI) m/z calcd for 
C19H20N2O3S: 356.1195; found: 356.1172. 
 
 
Compound 3g: Yield 84 %, colourless solid, mp: 147-148 
o
C; Rf = 0.28 (PE/EA = 
5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.29 (brs, 1 H), 10.01 (s, 1 H), 7.70-7.64 (m, 1 
H), 7.56-7.52 (m, 1 H), 7.46-7.40 (m, 2 H), 7.18-7.10 (m, 3 H), 5.91 (d, J = 2.4 Hz, 1 
H), 3.46 (t, J = 6.9Hz, 2 H), 2.30 (s, 3 H), 1.52-1.40 (m, 2 H), 1.34-1.21(m, 2 H), 0.79 
(t, J = 7.2Hz, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 193.0 (d), 144.1 (s), 136.0 
(s), 134.2 (s), 131.3 (s), 129.6 (d, 2C), 128.6 (d), 128.2 (s), 127.6 (d, 2C), 127.3 (d), 
120.2 (s), 119.8 (d), 95.2 (d), 50.5 (t), 30.1 (t), 21.6 (q), 19.7 (t), 13.6 (q) ppm; IR 
(reflection): ṽ = 3425, 2953, 2932, 2870, 2804, 2724, 1672, 1610, 1595, 1535, 1490, 
1454, 1414, 1382, 1354, 1309, 1293, 1237, 1197, 1162, 1089, 1060, 1048, 1007, 974, 
945, 873, 852, 816, 797, 733, 714, 666, 647 cm
-1
; HRMS (EI) m/z calcd for 
C20H22N2O3S: 370.1351; found: 370.1327. 
 
 
Compound 3h: Yield 86 %, colourless solid, mp: 152-153 
o
C; Rf = 0.34 (PE/EA = 
5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.01 (s, 1 H), 9.79 (brs, 1 H), 7.78-7.72 (m, 1 
H), 7.65-7.55 (m, 3 H), 7.24-7.14 (m, 3 H), 6.12 (d, J = 2.1 Hz, 1 H), 4.13-3.99 (m, 1 
H), 2.35 (s, 3 H), 1.86-1.39 (m, 5 H), 1.33-0.97(m, 4 H), 0.85-0.67 (m, 1 H) ppm; 
13
C 
NMR (75 MHz, CDCl3) δ = 193.0 (d), 143.7 (s), 137.6 (s), 131.7 (s), 131.4 (s), 129.7 
(d, 2C), 129.5 (d), 128.0 (d), 127.9 (s), 127.4 (d, 2C), 120.3 (s), 119.8 (d), 102.9 (d), 
59.8 (d), 32.5 (t, 2C), 25.8 (t, 2C), 25.0 (t), 21.6 (q) ppm; IR (reflection): ṽ = 3351, 
2935, 2856, 2810, 2731, 1663, 1608, 1590, 1492, 1449, 1397, 1382, 1352, 1298, 1266, 
1234, 1201, 1162, 1120, 1092, 1067, 1047, 120, 1003, 93, 882, 842, 807, 738, 709, 
668, 639 cm
-1





Compound 3i: Yield 83 %, colourless solid, mp: 146-148 
o
C; Rf = 0.26 (PE/EA = 5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.26 (brs, 1 H), 10.01 (s, 1 H), 7.72-7.65 (m, 1 H), 
7.59-7.52 (m, 1 H), 7.49-7.41 (m, 2 H), 7.21-7.10 (m, 3 H), 5.93 (d, J = 2.7 Hz, 1 H), 
5.74-5.59 (m, 1 H), 5.01-4.90 (m, 2 H), 3.54 (t, J = 6.9Hz, 2 H), 2.30 (s, 3 H), 
2.29-2.20(m, 2 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 193.0 (d), 144.2 (s), 135.7 
(s), 134.3 (s), 134.1 (d), 131.3 (s), 129.7 (d, 2C), 128.7 (d), 128.1 (s), 127.6 (d, 2C), 
127.4 (d), 120.2 (d), 119.9 (d), 117.6 (t), 95.7 (d), 50.3 (t), 32.6 (t), 21.6 (q) ppm; IR 
(reflection): ṽ = 3435, 3341, 3067, 2979, 2925, 2816, 2735, 1920, 1671, 1608, 1592, 
1543, 1492, 1452, 1408, 1362, 1306, 1235, 1197, 1164, 1120, 1090, 1047, 1019, 993, 
973, 916, 883, 862, 812, 747, 719, 688, 671 cm
-1
; HRMS (EI) m/z calcd for 
C20H20N2O3S: 368.1195; found: 368.1213. 
 
 
Compound 3j: Yield 50 %, colourless solid, mp: 190-192 
o
C; Rf = 0.53 (CH2Cl2/EA = 
10:1); 
1
H NMR (500 MHz, CDCl3) δ = 11.40 (brs, 1 H), 10.04 (s, 1 H), 7.07-7.66 (m, 
1 H), 7.52-7.47 (m, 1 H), 7.19-7.14 (m, 1 H), 5.77 (d, J = 2.5 Hz, 1 H), 4.55 (t, J = 8 
Hz, 2 H), 4.03 (t, J = 8 Hz, 2 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 192.9 (d), 
154.8 (s), 136.0 (s), 130.9 (s), 128.3 (s), 127.1 (d), 126.0 (d), 120.0 (s), 119.9 (d), 85.0 
(d), 62.7 (t), 44.4 (t) ppm; IR (reflection): ṽ = 3415, 3115, 2990, 287, 2739, 1739, 
1676, 1616, 1594, 1574 1491, 1473, 1460, 1436, 1417, 1390, 1372, 1304, 1252, 1216, 
1184, 1119, 1063, 1045, 978, 908, 877, 793, 764, 732, 667, 643 cm
-1
; HRMS (EI) m/z 





Compound 3k: Yield 84 %, colourless solid, mp: 216-218 
o
C; Rf = 0.24 (PE/EA = 
5:1); 
1
H NMR (500 MHz, CDCl3) δ = 10.14 (brs, 1 H), 10.06 (s, 1 H), 7.77-7.73 (m, 1 
H), 7.65-7.61 (m, 1 H), 7.57-7.51 (m, 2 H), 7.23-7.13 (m, 6 H), 6.87-6.82 (m, 2 H), 
3.01 (s, 3 H), 2.38 (s, 3H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 193.0 (d), 144.4 (s), 
134.6 (s), 132.3 (s), 132.1 (s), 130.8 (s), 130.0 (d, 2 C), 129.6 (d), 129.4 (d, 2 C), 
128.4 (d, 2 C), 127.8 (s), 127.6 (d, 2 C), 127.1 (d), 126.8 (d), 120.1 (s), 120.0 (d), 
112.3 (s), 38.6 (q), 21.7 (q) ppm; IR (reflection): ṽ = 3346, 2941, 2847, 1736, 1666, 
1603, 1574, 1495, 1448, 1427, 1408, 1367, 1333, 1216, 1184, 1151, 1107, 1089, 1072, 
1050, 1034, 989, 883, 812, 798, 778, 753, 741, 722, 703, 676, 646 cm
-1
; HRMS (EI) 
m/z calcd for C23H20N2O3S: 404.1195; found: 404.1182. 
 
 
Compound 3l’: Yield 81 %, colourless liquid; Rf = 0.4 (PE/EA = 5:1); 
1
H NMR (300 
MHz, CDCl3) δ =, 9.68 (s, 1 H), 7.74-7.63 (m, 3 H), 7.43-7.34 (m, 1 H), 7.28-7.20 (m, 
2 H), 7.10-7.00 (m, 1 H), 6.60 (d, J = 8.1 Hz, 1 H), 6.21 (dd, J = 8.1 and 15.6 Hz, 1 
H), 5.71 (d, J = 15.6 Hz, 1 H), 3.13 (s, 3 H), 2.43-2.25 (m, 4 H), 1.68-1.55 (m, 2H), 
1.54-1.34 (m, 4 H), 1.22-1.05 (m, 2 H) ppm ; 
13
C NMR (75 MHz, CDCl3) δ = 190.8 
(d), 157.2 (s), 152.3 (d), 151.3 (s), 144.4 (s), 134.77 (d), 134.72 (s), 129.5 (d, 2 C), 
128.2 (d), 128.1 (d, 2 C), 126.4 (s), 123.8 (d), 121.3 (d), 118.7 (d), 43.3 (q), 36.3 (d), 
32.3 (t, 2 C), 25.2 (t, 2 C), 21.6 (q) ppm; IR (reflection): ṽ = 2953, 2917, 2868, 1689, 
1644, 1595, 1450, 1357, 1276, 1161, 1088, 915, 834, 814, 771, 718, 669, 611 cm
-1
; 





Compound 3m: Yield 74 %, yellow solid, mp: 145-147 
o
C; Rf = 0.56 (PE/EA = 2:1); 
1
H NMR (500 MHz, CDCl3) δ = 10.06 (s, 1 H), 9.76 (brs, 1 H), 7.71-7.67 (m, 2 H), 
7.38-7.28 (m, 4 H), 6.16 (d, J = 2.5 Hz, 1 H), 4.60 (m, 1 H), 3.91 (s, 3 H), 2.45 (s, 3H), 
1.11 (d, J = 7.0 Hz, 6 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 192.7 (d), 153.8 (s), 
143.8 (s), 137.2 (s), 131.2 (s), 129.7 (d, 2 C), 128.5 (s), 127.5 (d, 2 C), 127.1 (s), 
120.4 (s), 117.9 (d), 111.2 (d), 102.2 (d), 56.3 (q), 52.0 (d), 21.9 (q, 2 C), 21.6 (q) 
ppm; IR (reflection): ṽ = 3437, 3336, 3137, 3054, 2963,2927, 2853, 2305,1676, 1616, 
1597, 1550, 1482, 1458, 1420, 1386, 1349, 1336, 1265, 1242, 1213, 1185, 1163, 1118, 
1088, 1071, 1040, 996, 940, 891, 855, 813, 733, 704, 671 cm
-1
; HRMS (EI) m/z calcd 
for C20H22N2O4S: 386.1300; found: 386.1297. 
 
 
Compound 3n: Yield 81 %, colourless solid, mp: 152-154 
o
C; Rf = 0.50 (PE/EA = 
2:1); 
1
H NMR (500 MHz, CDCl3) δ = 10.33 (brs, 1 H), 9.78 (s, 1 H), 7.45-7.42 (m, 2 
H), 7.40-7.37 (m, 1 H), 7.31-7.29 (m, 1 H), 7.17-7.13 (m, 2 H), 5.87 (d, J = 2.5 Hz, 1 
H), 3.47 (t, J = 7.5 Hz, 2 H), 2.31 (s, 3 H), 2.27 (s, 3 H), 1.50-1.43 (m, 2 H), 1.33-1.23 
(m, 2 H), 0.80 (t, J = 7.5 Hz, 3 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 192.1 (d), 
170.3 (s), 144.3 (s), 143.9 (s), 137.3 (s), 134.0 (s), 129.7 (d, 2 C), 129.3 (s), 128.7 (s), 
127.5 (d, 2 C), 121.4 (d), 119.9 (s), 119.8 (d), 94.8 (d), 50.3 (t), 29.9 (t), 21.6 (q), 21.1 
(q), 19.7 (t), 13.6 (q) ppm; IR (reflection): ṽ = 3425, 3344, 3066, 2959, 2932, 2872, 
2733, 1763, 1675, 1613, 1597, 1542, 1480, 1415, 1355, 1202, 1163, 1130, 1083, 1013, 
971, 909, 855, 813, 733, 706, 668 cm
-1
; HRMS (EI) m/z calcd for C22H24N2O5S: 
428.1406; found: 428.1429. 
 
 
Compound 3o: Yield 75 %, light yellow solid, mp: 206-208 
o





H NMR (500 MHz, CDCl3) δ = 10.01 (brs, 1 H), 9.78 (s, 1 H), 7.63-7.59 (m, 2 
H), 7.25-7.20 (m, 2 H), 7.17-7.14 (m, 1 H), 6.07 (d, J = 2.5 Hz, 1 H), 6.06 (s, 2 H), 
4.50 (m, 1 H), 2.37 (s, 3H), 1.02 (d, J = 7.0 Hz, 6 H) ppm ; 
13
C NMR (125 MHz, 
CDCl3) δ = 190.2 (d), 145.2 (s), 143.9 (s), 140.7 (s), 137.1 (s), 132.4 (s), 131.7 (s), 
129.8 (d, 2 C), 127.5 (d, 2 C), 113.2 (s), 112.0 (s), 110.1 (d), 102.1 (t), 98.1 (d), 52.1 
(d), 21.9 (q, 2 C), 21.6 (q) ppm; IR (reflection): ṽ = 3323, 2982, 2922, 2885 2814, 
2722, 1661, 1640, 1593, 1544, 1502, 1489, 1425, 1389, 1354, 1343, 1282, 1244, 1210, 
1183, 1164, 1128, 1091, 1084, 1045, 1028, 999, 974, 938, 913 890, 863, 842, 818 795, 
784, 748, 742, 709, 672 cm
-1




Compound 3p: Yield 61 %, colourless solid, mp: 135-136 
o
C; Rf = 0.33 (PE/EA = 
5:1); 
1
H NMR (500 MHz, CDCl3) δ = 9.97 (s, 1 H), 9.90 (brs, 1 H), 7.74-7.70 (m, 1 
H), 7.60-7.55 (m, 3 H), 7.24-7.19 (m, 2 H), 6.08 (d, J = 2.5 Hz, 1 H), 4.52 (m, 1 H), 
2.36 (s, 3H), 1.02 (d, J = 6.5 Hz, 6 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 192.0 
(d), 143.9 (s), 136.9 (s), 132.3 (s), 130.1 (s), 129.7 (d, 2 C), 129.1 (s), 128.8 (d), 127.5 
(d, 2 C), 127.2 (d), 125.4 (s), 120.7 (s), 102.1 (d), 52.2 (d), 21.9 (q, 2 C), 21.6 (q) ppm; 
IR (reflection): ṽ = 3306, 3223, 2975, 2925, 2852, 1681, 1670, 1600, 1548, 1495, 
1459, 1369, 1344, 1324, 1291, 1213, 1188, 1158, 1117, 1089, 1064, 1032, 1001, 899, 
871, 812, 769, 750, 709, 666 cm
-1
; HRMS (EI) m/z calcd for C19H19ClN2O3S: 
390.0805; found: 390.0833. 
 
 
Compound 3q: Yield 64 %, yellow solid, mp: 152-153 
o
C; Rf = 0.72 (PE/EA = 2:1); 
1
H NMR (500 MHz, CD2Cl2) δ = 10.64 (brs, 1 H), 10.42 (s, 1 H), 7.50-7.46 (m, 1 H), 
7.43-7.39 (m, 2 H), 7.27-7.23 (m, 1 H), 7.19-7.15 (m, 2 H), 5.84 (d, J = 2.5 Hz, 1 H), 
3.46 (t, J = 6.0 Hz, 2 H), 2.31 (s, 3 H), 1.50-1.42 (m, 2 H), 1.33-1.23 (m, 2 H), 0.80 (t, 
J = 6.0 Hz, 3 H) ppm ; 
13
C NMR (125 MHz, CD2Cl2) δ = 193.9 (d), 144.5 (s), 136.7 
43 
 
(s), 134.0 (s), 133.1 (s), 129.7 (d, 2 C), 127.9 (s), 127.7 (d), 127.4 (d, 2 C), 124.7 (d), 
121.7 (s), 117.0 (s), 94.2 (d), 50.2 (t), 29.9 (t), 21.3 (q), 19.7 (t), 13.3 (q) ppm; IR 
(reflection): ṽ = 3413, 3142, 2955, 2934, 2867, 1736, 1659, 1599, 1584, 1535, 1454, 
1384, 1350, 1297, 1239, 1163, 1120, 1091, 974, 947, 911, 877, 854, 812, 748, 716, 
677, 665, 610 cm
-1






Compound 3r: Yield 53 %, yellow solid, mp: 155-157 
o
C; Rf = 0.48 (PE/EA = 2:1); 
1
H NMR (500 MHz, CDCl3) δ = 10.38 (brs, 1 H), 9.93 (s, 1 H), 7.36-7.29 (m, 2 H), 
7.22-7.18 (m, 2 H), 7.06-7.01 (m, 2 H), 6.27 (d, J = 2.5 Hz, 1 H), 4.82 (s, 2 H), 2.92 (s, 
3 H), 2.22 (s, 3 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 191.1 (d), 137.1 (s), 135.4 
(s), 131.1 (s), 130.1 (s), 128.5 (d, 2 C), 128.1 (s), 127.9 (d), 127.1 (d, 2 C), 122.2 (d), 
121.2 (s), 118.2 (s), 93.9 (d), 53.1 (t), 37.1 (q), 20.1 (q) ppm; IR (reflection): ṽ = 3393, 
3142, 3023, 2936, 2920, 2853, 1737, 1671, 1603, 1583, 1541, 1481, 1441, 1420, 1344, 
1327, 1229, 1198, 1141, 1118, 1061, 1049, 1028, 970, 955, 939, 923, 833, 784, 772, 
725, 669, 616, 605 cm
-1




Compound 3s: Yield 80 %, colourless solid, mp: 178-180 
o
C; Rf = 0.78 (PE/EA = 2:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.55 (brs, 1 H), 10.16 (s, 1 H), 7.75-7.71 (m, 1 H), 
7.63-7.51 (m, 6 H), 7.37-7.32 (m, 1 H), 7.32-7.26 (m, 2 H), 6.18 (d, J = 2.4 Hz, 1 H), 
3.59 (t, J = 7.2 Hz, 2 H), 2.44 (s, 3 H), 1.65-1.54 (m, 2 H), 1.46-1.35 (m, 11 H), 0.92 
(t, J = 7.2 Hz, 3 H) ppm ; 
13
C NMR (75 MHz, CDCl3) δ = 192.6 (d), 151.3 (s), 144.1 
(s), 140.8 (s), 136.9 (s), 136.1 (s), 134.3 (s), 132.0 (s), 129.6 (d, 2 C), 129.1 (d), 128.5 
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(d, 2 C), 127.7 (d, 2 C), 126.2 (s), 125.7 (d, 2 C), 119.9 (d), 118.9 (s), 95.4 (d), 50.5 
(t), 34.7 (s), 31.4 (q, 3 C), 30.2 (t), 21.6 (q), 19.7 (t), 13.6 (q) ppm; IR (reflection): ṽ = 
3436, 3334, 3032, 2958, 2870, 2730, 2251, 1919, 1737, 1663, 1601, 1543, 1495, 1461, 
1408, 1340, 1291, 1269, 1228, 1197, 1167, 1116, 1090, 1052, 1017, 937, 881, 847, 
810, 770, 744, 718, 679, 654 cm
-1




Compound 3t: Yield 85 %, colourless soild, mp: 154-155 
o
C; Rf = 0.46 (PE/EA = 2:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.64 (brs, 1 H), 7.82-7.73 (m, 3 H), 7.64-7.48 (m, 4 
H), 7.47-7.40 (m, 2 H), 7.40-7.24 (m, 3 H), 7.18-7.10 (m, 1 H), 6.37 (d, J = 2.4 Hz, 1 
H), 4.98 (s, 2 H), 3.04 (s, 3 H) ppm ; 
13
C NMR (75 MHz, CDCl3) δ = 197.5 (s), 138.8 
(s), 135.6 (s), 135.4 (s), 133.6 (s), 131.6 (d), 129.4 (d, 2 C), 128.8 (d, 2 C), 128.5 (s), 
128.3 (d, 2 C), 128.2 (d, 3 C), 128.0 (d), 126.4 (d), 119.23 (d), 119.21 (s), 95.4 (d), 
54.4 (t), 38.1 (q) ppm; IR (reflection): ṽ = 3428, 3063, 3031, 2929, 1733, 1634, 1600, 
1588, 1542, 1491, 1444, 1411, 1356, 1275, 1212, 1188, 1154, 1085, 1049, 1024, 955, 
909, 893, 855, 807, 749, 720, 699, 677, 647, 628 cm
-1
; HRMS (EI) m/z calcd for 
C23H20N2O3S: 404.1195; found: 404.1189. 
 
 
Compound 3u: Yield 83 %, colourless solid, mp: 132-133 
o
C; Rf = 0.34 (PE/EA = 
5:1); 
1
H NMR (500 MHz, CDCl3) δ = 10.14 (brs, 1 H), 7.76-7.70 (m, 2 H), 7.63-7.59 
(m, 2 H), 7.24-7.20 (m, 2 H), 7.13-7.08 (m, 1 H), 6.12 (d, J = 2.0 Hz, 1 H), 4.51 (m, 1 
H), 2.62 (s, 3H), 2.37 (s, 3 H), 1.02 (d, J = 7.0 Hz, 6 H) ppm ; 
13
C NMR (125 MHz, 
CDCl3) δ = 199.9 (s), 143.7 (s), 137.3 (s), 132.8 (s), 130.5 (s), 129.6 (d, 2 C), 128.2 
(s), 127.5 (d, 2 C), 127.2 (d), 125.7 (d), 120.1 (s), 119.2 (d), 102.6 (d), 51.9 (d), 26.5 
(q), 21.9 (q, 2 C), 21.6 (q) ppm; IR (reflection): ṽ = 3304, 2993, 1737, 1658, 1590, 
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1542, 1494, 1435, 1392, 1371, 1342, 1305, 1277, 1208, 1184, 1172, 1155, 1131, 1111, 
1086, 1027, 997, 892, 834, 821, 803, 779, 749, 710, 681, 663, 623 cm
-1
; HRMS (EI) 
m/z calcd for C20H22N2O3S: 370.1351; found: 370.1357. 
 
 
Compound 3v: Yield 65 %, colourless solid, mp: 122-124 
o
C; Rf = 0.36 (PE/EA = 
5:1); 
1
H NMR (500 MHz, CDCl3) δ = 10.14 (brs, 1 H), 7.79-7.71 (m, 2 H), 7.62-7.58 
(m, 2 H), 7.23-7.19 (m, 2 H), 7.13-7.08 (m, 1 H), 6.13 (d, J = 3.0 Hz, 1 H), 6.10-6.01 
(m, 1 H), 5.22-5.16 (m, 2 H), 4.50 (m, 1 H), 3.82-3.77 (m, 2 H), 2.36 (s, 3H), 1.02 (d, 
J = 6.5 Hz, 6 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 199.7 (s), 143.7 (s), 137.3 (s), 
133.1 (s), 131.2 (d), 130.5 (s), 129.7 (d, 2 C), 128.3 (s), 127.5 (d, 2 C), 127.3 (d), 
125.2 (d), 119.3 (s), 119.2 (d), 118.9 (t), 102.7 (d), 51.9 (d), 43.2 (t), 21.9 (q, 2 C), 
21.6 (q) ppm; IR (reflection): ṽ = 3354, 2979, 2923, 1738, 1670, 1587, 1544, 1494, 
1438, 1390, 1379 1353, 1307, 1293, 1249, 1210, 1186, 1173, 1163, 1120, 1087, 1065, 
1031, 998, 917, 893, 843, 815, 800, 768, 747, 714, 670, 642, 620 cm
-1
; HRMS (EI) 
m/z calcd for C22H24N2O3S: 396.1508; found: 396.1506. 
 
 
Compound 3w: Yield 73 %, yellow solid, mp: 193-194 
o
C; Rf = 0.44 (PE/EA = 2:1); 
1
H NMR (500 MHz, CD2Cl2) δ = 10.75 (brs, 1 H), 7.87-7.82 (m, 1 H), 7.81-7.74 (m, 
1 H), 7.71-7.63 (m, 2 H), 7.55-7.49 (m, 2 H), 7.23-7.15 (m, 4 H), 7.14-7.08 (m, 1 H), 
7.06-7.01 (m, 2 H), 6.21 (d, J = 2.5 Hz, 1 H), 4.81 (s, 2 H), 2.92 (s, 3H), 2.31 (s, 3 H), 
2.19 (s, 3 H) ppm ; 
13
C NMR (125 MHz, CD2Cl2) δ = 190.0 (s), 143.7 (d), 141.2 (s), 
137.9 (s), 135.5 (s), 133.1 (s), 132.7 (s), 132.3 (s), 129.7 (d, 2 C), 129.3 (d, 2 C), 
128.5 (d, 2C), 128.4 (s), 127.9 (d, 2 C), 126.2 (d), 123.9 (d), 120.5 (s), 119.9 (d), 
119.5 (d), 94.5 (d), 53.8 (t), 37.6 (q), 21.3 (q), 20.8 (q) ppm; IR (reflection): ṽ = 3420, 
3001, 2920, 1737, 1644, 1606, 1590, 1581, 1540, 1514, 1493, 1443, 1410, 1356, 1334, 
46 
 
1299, 1279, 1246, 1180, 1148, 1112, 1061, 1040, 1022, 980, 959, 866, 836, 790, 765, 
733, 686, 664 cm
-1






Compound 3x: Yield 79 %, yellow oil; Rf = 0.62 (PE/EA = 2:1); 
1
H NMR (500 MHz, 
CDCl3) δ = 10.82 (brs, 1 H), 7.88-7.79 (m, 2 H), 7.68-7.64 (m, 1 H), 7.63-7.55 (m, 3 
H), 7.50-7.45 (m, 2 H), 7.19-7.08 (m, 3 H), 6.90-6.85 (m, 2 H), 5.92 (d, J = 2.5 Hz, 1 
H), 3.79 (s, 3 H), 3.49 (t, J = 7.5 Hz, 2 H), 2.32 (s, 3 H), 1.53-1.46 (m, 2 H), 1.35-1.26 
(m, 2 H), 0.81 (t, J = 7.5 Hz, 3 H) ppm ; 
13
C NMR (75 MHz, CDCl3) δ = 190.1 (s), 
161.6 (s), 143.9 (s), 143.7 (d), 135.7 (s), 134.4 (s), 133.3 (s), 130.3 (d, 2 C), 129.6 (d, 
2 C), 128.6 (s), 127.8 (s), 127.6 (d, 2C), 126.2 (d), 123.8 (d), 120.7 (s), 119.2 (d), 
118.7 (d), 114.4 (d, 2 C), 95.0 (d), 55.5 (q), 50.4 (t), 30.1 (t), 21.6 (q), 19.8 (t), 13.6 (q) 
ppm; IR (reflection): ṽ = 3427, 2958, 2932, 2872, 1734, 1645, 1602, 1585, 1571, 1537, 
1510, 1493, 1441, 1422, 1409, 1358, 1321, 1289, 1244, 1172, 1160, 1105, 1090, 1067, 
1031, 982, 951, 871, 830, 802, 745, 671 cm
-1
; HRMS (EI) m/z calcd for C29H30N2O4S: 
502.1926; found: 502.1908. 
 
 
Compound 3y: Yield 65 %, yellow solid, mp: 204-205 
o
C; Rf = 0.34 (PE/EA = 2:1); 
1
H NMR (500 MHz, CD2Cl2) δ = 10.76 (brs, 1 H), 7.86-7.83 (m, 1 H), 7.80-7.75 (m, 
1 H), 7.70-7.66 (m, 1 H), 7.62-7.57 (m, 3 H), 7.22-7.18 (m, 2 H), 7.14-7.09 (m, 1 H), 
7.06-7.02 (m, 2 H), 6.91-6.87 (m, 2 H), 6.22 (d, J = 2.5 Hz, 1 H), 4.81 (s, 2 H), 3.78 (s, 
3 H), 2.92 (s, 3H), 2.20 (s, 3 H) ppm ; 
13
C NMR (125 MHz, CD2Cl2) δ = 189.9 (s), 
161.7 (s), 143.4 (d), 133.1 (s), 137.9 (s), 135.4 (s), 132.7 (s), 130.2 (d, 2 C), 129.3 (d, 
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2 C), 128.5 (s), 128.0 (d, 2C), 127.7 (s), 126.1 (d), 123.8 (d), 120.6 (s), 119.4 (d), 
118.6 (d), 114.4 (d, 2 C), 94.5 (d), 55.4 (q), 53.8 (t), 37.6 (q), 20.8 (q) ppm; IR 
(reflection): ṽ = 3406, 3031, 3001, 2921,2843, 2309, 1909, 1699, 1643, 1605, 1570, 
1541, 1516, 1493, 1442, 1421, 1339, 1287, 1239, 1186, 1147, 1115, 1065, 1036, 976, 
958, 933, 904, 885, 867, 830, 791, 765, 742, 722, 689, 665, 639, 622 cm
-1
; HRMS (EI) 
m/z calcd for C27H26N2O4S: 474.1613; found: 474.1612. 
 
 
Compound 5a: Yield 63 %, yellow solid, mp: 93-95 
o
C; Rf = 0.68 (PE/EA = 5:1); 
1
H 
NMR (300 MHz, CDCl3) δ = 10.01 (s, 1 H), 9.87 (brs, 1 H), 7.56-7.48 (m, 1 H), 
7.44-7.41 (m, 1 H), 7.12-7.07 (m, 1 H), 7.04-7.00 (m, 3 H), 5.13 (d, J = 1.5 Hz, 1 H), 
2.14(s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 193.6 (d), 152.8 (s), 151.3 (s), 
130.8 (s, 2C), 129.4 (s), 129.3 (s), 129.2 (d, 2C), 125.9 (d, 2C), 125.8 (d), 119.8 (d), 
119.3 (s), 78.9 (d), 16.2 (q, 2C) ppm; IR (reflection): ṽ = 3445, 2924, 2817, 1733, 
1670, 1613, 1591, 1551, 1455, 1422, 1354, 1291, 1265, 1232, 1190, 1089, 1045, 787, 
738, 687 cm
-1
; HRMS (EI) m/z calcd for C17H15NO2: 265.1103; found: 265.1116. 
 
 
Compound 5a’: Yield 85 %, colourless soild, mp: 147-148 oC; Rf = 0.30 (CH2Cl2/EA 
= 10:1); 
1
H NMR (500 MHz, CDCl3) δ = 9.91 (s, 1 H), 9.26 (brs, 1 H), 7.55 (d, J = 
7.5 Hz, 1 H), 7.38 (d, J = 7.0 Hz, 1 H), 7.10 (t, J = 7.5 Hz, 1 H), 3.46 (s, 2 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 192.5 (d), 176.5 (s), 143.8 (s), 131.4 (d), 130.0 (d), 
126.6 (s), 122.0 (d), 118.4 (s), 34.7 (t) ppm; IR (reflection): ṽ = 3260, 2924, 2853, 
2730, 2357, 1724, 1710, 1677, 1605, 1460, 1395, 1327, 1305, 1254, 1202, 1160, 106, 
1014, 96, 945, 894, 859, 774, 732, 670, 615 cm
-1
; HRMS (EI) m/z calcd for C9H7NO2: 





Compound 7a: Yield 68 %, colourless solid, mp: 64-65 
o
C; Rf = 0.72 (PE/EA = 5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.01 (s, 1 H), 9.78 (brs, 1 H), 7.76-7.70 (m, 1 H), 
7.50-7.45 (m, 1 H), 7.19-7.09 (m, 1 H), 6.26-6.22 (m, 1 H), 3.22-3.09 (m, 1 H), 
2.13-2.00 (m, 2 H), 1.83-1.57 (m, 6 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 193.7 
(d), 146.3 (s), 133.9 (s), 129.9 (s), 127.6 (d), 127.1 (d), 119.8 (s), 119.2 (d), 97.9 (d), 
38.9 (d), 32.9 (t, 2C), 25.3 (t, 2C) ppm; IR (reflection): ṽ = 3446, 3367, 2954, 2867, 
2812, 2730, 1672, 1607, 1593, 1552, 1489, 1454, 1352, 1320, 1292, 1229, 1177, 1145, 
1062, 1049, 961, 895, 799, 745, 707, 625 cm
-1
; HRMS (EI) m/z calcd for C14H15NO: 
213.1154; found: 213.1138. 
 
 
Compound 7b: Yield 68 %, colourless solid, mp: 66-68 
o
C; Rf = 0.56 (PE/EA = 5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.00 (s, 1 H), 9.85 (brs, 1 H), 7.73-7.66 (m, 1 H), 
7.50-7.44 (m, 1 H), 7.15-7.07 (m, 1 H), 6.15-6.11 (m, 1 H), 1.99-1.89 (m, 1 H), 
0.98-0.90 (m, 2 H), 0.78-0.71 (m, 2 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 193.7 
(d), 144.1 (s), 133.7 (s), 129.9 (s), 127.6 (d), 127.0 (d), 119.6 (s), 119.3 (d), 97.5 (d), 
8.95 (d), 7.78 (t, 2C) ppm; IR (reflection): ṽ = 3444, 3374, 3086, 3057, 3007, 2813, 
2731, 1914, 1784, 1673, 1604, 1593, 1560, 1490, 1453, 1427, 1380, 1341, 1301, 1230, 
1198, 1174, 1143, 1049, 1024, 973, 900, 879, 798, 744, 681, 657 cm
-1
; HRMS (EI) 
m/z calcd for C12H11NO: 185.0841; found: 185.0836. 
 
 
Compound 7c: Yield 65 %, colourless solid, mp: 69-70 
o
C; Rf = 0.66 (PE/EA = 5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.02 (s, 1 H), 9.76 (brs, 1 H), 7.77-7.72 (m, 1 H), 
7.52-7.47 (m, 1 H), 7.17-7.10 (m, 1 H), 6.25-6.21 (m, 1 H), 2.61 (d, J = 7.2 Hz, 2 H), 
2.03-1.89 (m, 1 H), 0.92 (d, J = 6.6 Hz, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
193.7 (d), 141.1 (s), 133.8 (s), 130.1 (s), 127.6 (d), 127.0 (d), 119.8 (s), 119.2 (d), 
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100.4 (d), 37.6 (t), 28.9 (d), 22.5 (q, 2C) ppm; IR (reflection): ṽ = 3342, 2957, 2925, 
2903, 2868, 2813, 2736, 1674, 1608, 1593, 1556, 1490, 1465, 1434, 1383, 1354, 1292, 
1241, 1221, 1200, 1175, 1146, 1063, 1050, 986, 955, 823, 804, 779, 748, 707, 684, 
643 cm
-1
; HRMS (EI) m/z calcd for C13H15NO: 201.1154; found: 201.1161. 
 
 
Compound 7d: Yield 72 %, light yellow oil; Rf = 0.75 (PE/EA = 5:1); 
1
H NMR (300 
MHz, CDCl3) δ = 10.01 (s, 1 H), 9.79 (brs, 1 H), 7.75-7.70 (m, 1 H), 7.49-7.44 (m, 1 
H), 7.15-7.08 (m, 1 H), 6.25-6.20 (m, 1 H), 2.95-2.82 (m, 1 H), 1.71-1.46 (m, 2 H), 
1.35-1.16 (m, 5 H), 0.83 (t, J = 7.2 Hz, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 
193.7 (d), 147.3 (s), 133.7 (s), 129.9 (s), 127.6 (d), 127.1 (d), 119.8 (s), 119.2 (d), 
98.1 (d), 39.2 (t), 33.1 (d), 20.53 (t), 20.51 (q), 14.1 (q) ppm; IR (reflection): ṽ = 3448, 
3373, 3058, 2959, 2930, 2871, 2811, 2731, 1670, 1605, 1593, 1549, 1489, 1454, 1383, 
1350, 1293, 1233, 1192, 1176, 1128, 1049, 966, 879, 800, 745, 696, 661 cm
-1
; HRMS 
(EI) m/z calcd for C14H17NO: 215.1310; found: 215.1313. 
 
 
Compound 7e: Yield 56 %, colourless solid, mp: 68-69 
o
C; Rf = 0.70 (PE/EA = 5:1); 
1
H NMR (500 MHz, CDCl3) δ = 10.01 (s, 1 H), 9.80 (brs, 1 H), 7.76-7.70 (m, 1 H), 
7.50-7.45 (m, 1 H), 7.16-7.09 (m, 1 H), 6.25-6.20 (m, 1 H), 2.72 (d, J = 8.4 Hz, 2 H), 
2.23-2.12 (m, 1 H), 1.79-1.70 (m, 2 H), 1.63-1.44 (m, 4 H), 1.23-1.14 (m, 2 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 193.7 (d), 141.8 (s), 133.8 (s), 130.1 (s), 127.6 (d), 
127.1 (d), 119.8 (s), 119.2 (d), 99.9 (d), 39.9 (d), 34.5 (t), 32.7 (t, 2C), 25.1 (t, 2C) 
ppm; IR (reflection): ṽ = 3372, 3057, 2944, 2861, 2816, 2737, 1903, 1738, 1673, 1607, 
1593, 1553, 1489, 1454, 1382, 1356, 1288, 1229, 1188, 1175, 1135, 1062, 1048, 987, 
956, 902, 798, 779, 743, 704, 671 cm
-1
; HRMS (EI) m/z calcd for C15H17NO: 





Compound 7f: Yield 67 %, light yellow oil; Rf = 0.72 (PE/EA = 5:1); 
1
H NMR (300 
MHz, CDCl3) δ = 10.01 (s, 1 H), 9.79 (brs, 1 H), 7.76-7.71 (m, 1 H), 7.51-7.45 (m, 1 
H), 7.16-7.08 (m, 1 H), 6.25-6.21 (m, 1 H), 2.72 (t, J = 7.5 Hz, 2 H), 1.73-1.60 (m, 2 
H), 1.40-1.17 (m, 6 H), 0.82 (t, J = 6.9 Hz, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ 
= 193.7 (d), 142.3 (s), 133.8 (s), 130.1 (s), 127.6 (d), 127.0 (d), 119.7 (s), 119.2 (d), 
99.4 (d), 31.6 (t), 29.1 (t), 29.0 (t), 28.3 (t), 22.6 (t), 14.1 (q) ppm; IR (reflection): ṽ = 
3446, 3381, 3057, 2954, 2928, 2856, 2731, 1670, 1606, 1593, 1556, 1489, 1454, 1410, 
1351, 1290, 1233, 1196, 1175, 1141, 1109, 1048, 969, 908, 798, 744, 670 cm
-1
; 
HRMS (EI) m/z calcd for C15H19NO: 229.1467; found: 229.1450 
 
 
Compound 7g: Yield 63 %, light yellow solid, mp: 67-68 
o
C; Rf = 0.62 (PE/EA = 5:1); 
1
H NMR (300 MHz, CDCl3) δ = 9.99 (s, 1 H), 9.80 (brs, 1 H), 7.76-7.69 (m, 1 H), 
7.50-7.44 (m, 1 H), 7.26-7.17 (m, 2 H), 7.16-7.07 (m, 4 H), 6.27-6.21 (m, 1 H), 2.74 (t, 
J = 7.5 Hz, 2 H), 2.63 (t, J = 7.5 Hz, 2 H), 2.0 (m, 2 H) ppm; 
13
C NMR (75 MHz, 
CDCl3) δ = 193.7 (d), 141.65 (s), 141.63 (s), 133.8 (s), 130.1 (s), 128.5 (d, 2C), 128.4 
(d, 2C), 127.7 (d), 127.1 (d), 126.0 (d), 119.8 (s), 119.3 (d), 99.6 (d), 35.3 (t), 30.6 (t), 
27.6 (t) ppm; IR (reflection): ṽ = 3364, 3060, 3028, 2954, 2930, 2863, 2818, 2740, 
1670, 1607, 1592, 1556, 1493, 1453, 1440, 1384, 1349, 1325, 1286, 1237, 1206, 1176, 
1158, 1140, 1050, 1028, 1009, 980, 961, 825, 797, 745, 698, 670, 651, 624, 610 cm
-1
; 
HRMS (EI) m/z calcd for C18H17NO: 263.1310; found: 263.1306. 
 
 
Compound 7h: Yield 61 %, yellow solid, mp: 118-120 
o
C; Rf = 0.56 (PE/EA = 5:1); 
1
H NMR (300 MHz, CDCl3) δ = 10.28 (brs, 1 H), 10.06 (s, 1 H), 7.85-7.81 (m, 1 H), 
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7.69-7.63 (m, 2 H), 7.58-7.53 (m, 1 H), 7.43-7.35 (m, 2 H), 7.32-7.26 (m, 1 H), 
7.20-7.14 (m, 1 H), 6.82-6.78 (m, 1 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 193.7 
(d), 139.9 (s), 134.7 (s), 131.6 (s), 130.4 (s), 129.1 (d, 2C), 128.7 (d), 128.3 (d), 127.8 
(d), 125.5 (d, 2C), 120.3 (s), 119.9 (d), 99.5 (d) ppm; IR (reflection): ṽ = 3353, 3052, 
2836, 2811, 2730, 1790, 1679, 1607, 1593, 1547, 1486, 1452, 1384, 1362, 1340, 1306, 
1249, 1226, 1196, 1171, 1063, 1050, 1030, 931, 912, 879, 809, 775, 758, 743, 692, 
673, 621, 610 cm
-1
; HRMS (EI) m/z calcd for C15H11NO: 221.0841; found: 221.0833. 
 
 
Compound 7i: Yield 50 %, yellow solid; mp: 138-139 
o
C; Rf = 0.58 (PE/EA = 5:1); 
1
H NMR (500 MHz, CD2Cl2) δ = 10.18 (brs, 1 H), 10.05 (s, 1 H), 7.84-7.80 (m, 1 H), 
7.62-7.58 (m, 1 H), 7.41-7.35 (m, 2 H), 7.33-7.16 (m, 9 H) ppm; 
13
C NMR (125 MHz, 
CD2Cl2) δ = 193.4 (d), 135.8 (s), 134.4 (s), 133.6 (s), 132.0 (s), 130.2 (d, 2 C), 130.0 
(s), 129.1 (d), 128.7 (d, 2 C), 128.6 (d, 2 C), 128.4 (d, 2 C), 128.1 (d), 126.7 (d), 126.6 
(d), 120.4 (s), 120.0 (d), 114.8 (s) ppm; IR (reflection): ṽ = 2922, 2852, 1674, 1603, 
1461, 1377, 1261, 1026, 954, 801, 743, 698, 664, 612 cm
-1
; HRMS (EI) m/z calcd for 
C21H15NO: 297.1154; found: 297.1144. 
 
 
Compound 7j: Yield 66 %, yellow oil; Rf = 0.54 (PE/EA = 5:1); 
1
H NMR (500 MHz, 
CDCl3) δ = 10.37 (brs, 1 H), 7.82-7.75 (m, 2 H), 7.74-7.70 (m, 1 H), 7.66-7.61 (m, 1 
H), 7.60-7.54 (m, 2 H), 7.11-7.06 (m, 1 H), 6.90-6.85 (m, 2 H), 6.22 (d, J = 2.5 Hz, 1 
H), 3.78 (s, 3 H), 2.95-2.87 (m, 1 H), 1.74-1.60 (m, 1 H), 1.59-1.50 (m, 1 H), 
1.34-1.22 (m, 5 H), 0.84 (t, J = 7.0 Hz, 3 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 
190.8 (s), 161.6 (s), 147.0 (s), 143.2 (d), 135.6 (s), 130.3 (s), 130.2 (d, 2 C), 127.9 (s), 
126.2 (d), 122.9 (d), 120.2 (s), 119.1 (d), 118.6 (d), 114.4 (d, 2 C), 97.9 (d), 55.5 (q), 
39.3 (t), 33.1 (d), 20.6 (t), 20.5 (q), 14.1 (q) ppm; IR (reflection): ṽ = 3430, 3367, 
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2959, 2929, 2871, 1644, 1600, 1570, 1543, 1510, 1491, 1458, 1441, 1422, 1350, 1285, 
1241, 1172, 1102, 1031, 981, 950, 829, 801, 742, 701 cm
-1
; HRMS (EI) m/z calcd for 
C23H25NO2: 347.1885; found: 347.1878. 
 
 
Compound 7k: Yield 27 %; yellow soild, mp: 97-98 
o
C; Rf = 0.44 (PE/EA = 10:1); 
1
H NMR (500 MHz, CDCl3) δ = 10.05 (s, 1 H), 9.91 (brs, 1 H), 7.84-7.79 (m, 1 H), 
7.56-7.51 (m, 1 H), 7.42-7.35 (m, 4 H), 7.29-7.22 (m, 1 H), 7.18-7.11 (m, 1 H), 2.81 (t, 
J = 7.5 Hz, 2 H), 1.69-1.60 (m, 2 H), 1.36-1.25 (m, 2 H), 0.83 (t, J = 7.5 Hz, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 193.8 (d), 138.2 (s), 134.7 (s), 133.2 (s), 129.7 (d, 2 
C), 129.3 (s), 128.6 (d, 2 C), 128.2 (d), 126.3 (d, 2 C), 119.8 (s), 119.5 (d), 114.5 (s), 
32.0 (t), 26.1 (t), 22.6 (t), 13.9 (q) ppm; IR (reflection): ṽ = 3348, 3058, 2954, 2929, 
2869, 2734, 1668, 1601, 1572, 1553, 1495, 1459, 1444, 1422, 1371, 1341, 1225, 1197, 
1088, 1056, 1006, 790, 758, 744, 705, 659, 617 cm
-1
; HRMS (EI) m/z calcd for 






Compound 3g’: Yield 95 %, colourless soild, mp: 142-143 oC; Rf = 0.34 (PE/EA = 
2:1); 
1
H NMR (500 MHz, CDCl3) δ = 9.34 (brs, 1 H), 7.45-7.41 (m, 2 H), 7.37-7.33 
(m, 1 H), 7.16-7.12 (m, 2 H), 6.98-6.93 (m, 2 H), 5.80 (d, J = 2.0 Hz, 1 H), 4.93 (s, 2 
H), 3.43 (t, J = 7.5 Hz, 2 H), 2.32 (s, 3 H), 2.13 (brs, 1 H), 1.50-1.42 (m, 2 H), 
1.32-1.22 (m, 2 H), 0.79 (t, J = 7.5 Hz, 3 H) ppm ; 
13
C NMR (125 MHz, CDCl3) δ = 
143.9 (s), 134.3 (s), 134.0 (s), 132.3 (s), 129.5 (d, 2 C), 127.7 (d, 2C), 127.5 (s), 123.3 
(s), 120.3 (d), 119.9 (d), 119.7 (d), 95.2 (d), 64.0 (t), 50.5 (t), 30.0 (t), 21.6 (q), 19.8 
(t), 13.6 (q) ppm; IR (reflection): ṽ = 3337, 3057, 2961, 2929, 2873, 1737, 1617, 1598, 
1562, 1498, 1437, 1408, 1345, 1302, 1183, 1158, 1118, 1088, 1044, 995, 880, 856, 
808, 745, 722, 711, 688, 666, 636, 608 cm
-1
; HRMS (EI) m/z calcd for C20H24N2O3S: 
372.1508; found: 372.1509. 
 
 
Compound 3g’’: Yield 85 %, colourless soild, mp: 102-103 oC; Rf = 0.73 (PE/EA = 
2:1); 
1
H NMR (300 MHz, CDCl3) δ = 8.90 (brs, 1 H), 7.45-7.34 (m, 3 H), 7.30-7.22 
(m, 1 H), 7.18-7.09 (m, 2 H), 7.00-6.91 (m, 1 H), 5.78 (d, J = 2.4 Hz, 1 H), 3.44 (t, J = 
6.9 Hz, 2 H), 3.32 (s, 1 H), 2.31 (s, 3 H), 1.55-1.40 (m, 2 H), 1.36-1.20 (m, 2 H), 0.80 
(t, J = 7.2 Hz, 3 H) ppm ; 
13
C NMR (75 MHz, CDCl3) δ = 144.1 (s), 134.9 (s), 134.7 
(s), 133.8 (s), 129.6 (d, 2 C), 127.5 (d, 2C), 126.6 (s), 126.0 (d), 121.3 (d), 120.0 (d), 
104.8 (s), 95.3 (d), 81.8 (d), 79.8 (s), 50.3 (t), 30.0 (t), 21.6 (q), 19.8 (t), 13.6 (q) ppm; 
IR (reflection): ṽ = 3324, 2958, 2927, 2868, 1601, 1557, 1492, 1452, 1430, 1407, 
1337, 1298, 1242, 1213, 1160, 1112, 1089, 1070, 1038, 1006, 975, 943, 886, 842, 812, 
778, 741, 707, 681, 644, 617 cm
-1
; HRMS (ESI) m/z calcd for C21H22N2O2S [M+Na]
+
: 
389.1294; found: 389.1295. 
 
[1] L. V. Graux, H. Clavier, G. Buono, ChemCatChem. 2014, 6, 2544-2548. 
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Chapter 3: Gold-Catalyzed Synthesis of Quinolines from 
Propargyl Silyl Ethers and Anthranils through the 
Umpolung of a Gold Carbene Carbon 
3.1 Introduction  
The recent rapid development of gold-catalyzed tandem transformations
[1]
 has 
afforded atom- and step-economical synthetic approaches to complex heterocyclic 
scaffolds that are not easily accessible by traditional methods. Following this principle, 
gold-catalyzed intramolecular nitrene transfers to proximal triple bonds have enabled 












 In addition, gold-catalyzed formal [3+2] annulations of 
nitrenoids with alkynes have attracted attention since these offer more flexible routes 
to aza-heterocyclic frameworks.
[3]
 For instance, Davies and co-workers disclosed a 
gold-catalyzed intermolecular reaction of iminopyridinium ylides and ynamides,
[3a]
 
delivering polysubstituted oxazoles in high efficiency. The gold-catalyzed syntheses 







 et al respectively. Recently, we contributed a 
gold-catalyzed C-H annulation of anthranils with alkynes for the expedient assembly 
of 7-acylindolyl skeletons
[3h]
 by using the potential of anthranil to act as a 
binucleophile (Scheme 1, upper part). It is worth noting that all of the above studies 
rely on -imino gold carbenes as key electrophilic intermediates en route to the 
aza-heterocycles.
[1k]
 If internal alkynes with adjacent methylene moieties are involved 
in these reactions, the presumed -imino gold carbene intermediate is usually 
quenched by a 1,2-hydride shift/deauration sequence that rapidly delivers 
-unsaturated imines.[3g,h] As far as we know, although a related migration process 
has been described by Zhang et al.,
[4]
 gold-catalyzed construction of aza-heterocycles 
triggered by a 1,2-H shift
[2a]
 onto the -imino gold carbene species is no reported. 
 





 and functional materials.
[5e,f]
 In particular, 
2-amino-quinolines exhibit diverse biological activities
[6]
 and have been identified as 
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a beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for 
Alzheimer’s disease therapeutics.[7] But compared to the enormous methods for the 
preparation of quinolines,
[8]
 direct access routes to 2-aminoquinolines from readily 
available substrates are scarce.
[9]
 The prevalent route still focuses on the C2-amination 
of quinolines, which usually requires harsh conditions and specific amination 
reagents.
[10]
 Thus a facile, general, and environmentally benign access to 
2-aminoquinolines is still desirable. In continuation of our previous work on gold 
catalysis,
[3h,11]
 herein we report an unprecedented gold-catalyzed cascade annulation 
of anthranils
[11e]
 and propargylic silyl ethers, which enables the regiospecific and 
convergent synthesis of 2-aminoquinolines and quinoline derivatives under mild 
conditions (Scheme 1, lower part). This reactivity pattern exploits the nucleophilicity 
of the in situ generated N-aryl--unsaturated imine (achieved through Umpolung of 
the electrophilic carbene carbon that reacts in the case of indol formation
[3h] 
). In the 
presence of a propargylic oxygen atom, a Mukaiyama aldol-type reaction of the 
enol/enolether with the electrophilic aldehyde moiety derived from the ring opening 
of the anthranil becomes feasible. 
 
Scheme 1. Upper part: Our previous work on the gold-assisted synthesis of 
7-acylindoles through the generation of a-imino gold carbenes from anthranils. Lower 




3.2 Results and Discussion 
3.2.1 Optimization of the Reaction Conditions 
Firstly the effect of the substituent at the propargylic oxygen in ynamides 2 was 
investigated (Table 1). Only 16% of the product 3aa was obtained from the reaction 
of 1a with 2a bearing a propargylic alcohol with 5 mol% IPrAuCl/AgNTf2 in 
1,2-DCE at 65 
o
C for 3 h (entry 1). The yield was significantly increased to 80% by 
using a ynamide propargylic methyl ether under the same conditions (entry 2). Benzyl 
and phenyl ethers also afforded moderate yields (entries 3, 4). In order to initiate a 
Mukaiyama-type aldol reaction,
[12]
 anthranil was reacted with various propargylic 
silyl ethers (entries 5, 6). The use of tert-butyldimethylsilyl raised the yield to 88% 
(entry 6). Based on these results, the transformation of anthranil 1a and ynamide 
propargyl silyl ether 2a (R=TBS) was selected as a model reaction for optimization of 
the catalysts and solvents (entry 7–13). IPrAuCl/AgNTf2 turned out to be the best 
catalyst system. (ArO)3PAuCl/AgNTf2 (Ar = 2, 4-di-tert-butylphenyl) also performed 
outstandingly, with a 87 % yield (entry 7), while only moderate yields were furnished 
by phosphane ligands. 1,2-DCE gave the best result among the screened solvents. The 
control experiment without a catalyst showed no conversion (entry 14). 
 




Entry catalyst R Solvent Yield %
[b]
 
1 IPrAuCl/AgNTf2 H ClCH2CH2Cl 16 
2 IPrAuCl/AgNTf2 Me ClCH2CH2Cl 80 
3 IPrAuCl/AgNTf2 Bn ClCH2CH2Cl 74 
4 IPrAuCl/AgNTf2 Ph ClCH2CH2Cl 40 
5 IPrAuCl/AgNTf2 TMS
[c]
 ClCH2CH2Cl 86 
6 IPrAuCl/AgNTf2 TBS
[c]
 ClCH2CH2Cl 88 
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7 (ArO)3PAuCl /AgNTf2 TBS ClCH2CH2Cl 87 
8 Ph3PAuCl/AgNTf2 TBS ClCH2CH2Cl 40 
9 JohnPhosAuCl/AgNTf2 TBS ClCH2CH2Cl 61 
10 IPrAuCl/AgNTf2 TBS CHCl3 73 
11 IPrAuCl/AgNTf2 TBS CH2Cl2 
[d]
 70 
12 IPrAuCl/AgNTf2 TBS PhCF3 84 
13 IPrAuCl/AgNTf2 TBS PhMe 80 
14 None    TBS ClCH2CH2Cl 0 
[a] Reaction conditions: 1a (0.24 mmol) and 2 (0.2 mmol) were reacted in 1 ml 
solvent at 65 
o
C for 3 h. [b] Isolated yield. [c] TMS = trimethylsilyl, TBS = 
tert-butyldimethylsilyl, Ar = 2, 4-di-tert-butylphenyl. [d] Sealed tube. 
 
3.2.2 Scope and Limitation 
Under the optimized reaction conditions, we started to survey the scope of the 
reaction with respect to the anthranil. The transformation of differently substituted 
anthranils with ynamide 2a proceeded smoothly to afford various 
3-formyl-2-aminoquinoline derivatives in moderate to excellent yields (Table 2). A 
broad range of functional groups, including ethers (3ba, 3oa, 3ta), esters (3ca), 
acetals (3ga), amines (3ka), bromides (3fa, 3ja), fluorides (3da), trifluoromethyl (3la), 
and unsaturated systems (3ua, 3va), was well compatible under the mild conditions. 
In general, substituents with electron-donating properties at the anthranil led to higher 
yields, while anthranils bearing electron-withdrawing groups usually led moderate 
yields or even disabled the reaction (3sa). This facile access, which allows 
substituents at each position of the 2-aminoquinoline framework, illustrates the great 
generality and flexibility of this approach. A fused quinoline (3ha) that can serve as 
an important substrate in C-H functionalization
[13]
 was smoothly obtained in 72% 
yield. The connectivity was unambiguously determined by X-ray crystal structure 
analysis of 3aa.
[14]
 An isoxazole was examined too, but the corresponding 
2-aminopyridine was not formed, which might result from decomposition of the 








   
3aa, 88 % 3ba, 93 % 3ca, 94 % 
   
3da, 77 % 3ea, 87 % 3fa, 87 % 
   
3ga, 92 % 3ha, 72 % 3ia, 78 % 
   
3ja, 74 % 3ka, 80 % 3la, 68 % 
   
3ma, 71 % 3na, 69 % 3oa, 86 % 
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3pa, 79 % 3qa, 71 % 3ra, 66 % 
  
 
3sa, 0 % 3ta, 53 % 3ua, R = Me, 58 % 
3va, R = MeO, 53 % 
[a] Reaction conditions: 1 (0.24 mmol), 2a (0.2 mmol), and 5 mol% IPrAuCl/AgNTf2 
at 65 
o
C for 3 h in 1 mL dry 1,2-DCE. [b] Yield of isolated product. 
 
Next, we applied a series of ynamide propargyl ethers 2 in the reaction with anthranil 
1a (Table 3). Mesyl (3ac), nosyl (3af), and oxazolidinone (3ad) substituents at the 
ynamide nitrogen were all well tolerated. Various substituents on the sulfonamide 
moiety such as a p-methoxylbenzyl group (3ac) and an ester (3ah) turned out to be 
compatible, delivering good to excellent yields. An N-alkynyl indole provided 
2-(indol-1-yl) quinoline (3ae) in 95% yield. Silyl ethers bearing a secondary carbon in 
the propargylic position gave rise to diversely functionalized ketones (3ai–3an). 




-alkyl substitution patterns still afforded 
moderate yields. Some substituents derived from natural resources, like citronellal 
(3ak) and lily aldehyde (3am), were successfully introduced by this method. An 
electron-deficient perfluorinated aryl substituent gave 68% yield (3ao). An X-ray 
structure analysis of 3aj was conducted to confirm the structural assignment.
[14] 
 









3ac, 84 % 3ad, 81 % 
 
  
3ae, 95 % 3af, 78 % 3ag, 90 % 
 
  
3ah, 85 % 3ai, 66 % 3aj, 71 % 
  




3am, 58 % 3an, 50 % 3ao, 68 % 
[a] Reaction conditions: 1 (0.24 mmol), 2a (0.2 mmol), and 5 mol% IPrAuCl/AgNTf2 
at 65 
o
C for 3 h in 1 mL dry 1,2-DCE. [b] Yield of isolated product. 
 
An extension of the synthesis of other C2-substituted quinolines was possible. The 
less-polarized alkyne 4a (R
5
 = n-propyl) and anthranil 1a provided 5a, albeit in only 
40% yield. A screening of catalysts and solvents was conducted (Table 4), 70% yield 
of 5a could be achieved in TFE/1,2-DCE (1:1) using 5 mol% (ArO)3PAuCl/ AgNTf2 
(Ar=2,4-di-tert-butylphenyl). Alkyl, aryl, and alkenyl groups were all compatible 
under the adjusted conditions (5a-5d). The high regioselectivity can be explained by 
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the inductive effect of the etheral oxygen facilitating the reaction of the distal carbon 
of the triple bond with the oxygen atom.
[16]
 This highly selective synthesis of 









entry variation from standard conditions Yield of 5a 
1 without TFE 40 % 
2 without 1,2-DCE 20 % 
5a, 70 % 3 IPrAuCl as gold catalyst 58 % 
   
5b, 67 % 5c, 66 % 5d, 48 % 
[a] Reaction conditions: 1a (0.4 mmol), 4 (0.2 mmol), 5 mol % (ArO)3PAuCl/AgNTf2 
(Ar = 2, 4-di-tert-butylphenyl) in 1 ml TFE/1,2-DCE (1:1) at 65 
o
C for 12 h. [b] 
Isolated yield. [c] TFE = CF3CH2OH; 1,2-DCE = ClCH2CH2Cl. 
 
3.2.3 Further Applications 
A gram-scale synthesis was carried out with a lower catalyst loading (Scheme 2a), to 
access 3aa in 75% yield. The high potential of the obtained 
3-formyl-2-amino-quinolines for further conversions was proved by deprotection of 
the nosyl group of 3af to the secondary amine 6 (Scheme 2b) and the intramolecular 
aldol cyclization of 3ah to deliver the pyrrolo[2,3-b]dihydroquinoline framework, 
which possesses anti-inflammatory, anticonvulsant and antihypertensive properties
[17] 
(Scheme 2c). In addition, the pyrrolo[2,3-b]quinoline derivative 9 could be easily 
prepared from 3aa in only two steps
[18]






Scheme 2. Gram-scale synthesis and subsequent conversions. 
3.2.4 Mechanistic investigation 
 
Scheme 3. Mechanistic investigation. 
 
Preliminary mechanistic studies were also conducted. The reaction of anthranil and a 
propargylic ester afforded the 1,2-acyloxy migration product
[19]
, which suggests a 
gold carbene intermediate formed through ring opening of the anthranil, which is 
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trapped in a subsequent step by the adjacent acetoxy group (Scheme 3a). The 
cyclization process of the silyl propargyl ether substrate follows a Mukaiyama-type 
process, which was verified by a 
18
O-labelling experiment (Scheme 3b). In contrast, 
the reaction of a phenyl propargyl ether could be promoted by isotope-labeled water 
and 81% 
18
O was found on product 3aa (Scheme 3c), which indicates that instead the 
C-O bond is cleaved rather than the O-Si bond in the upper case (Scheme 3d). 
3.3 Conclusion 
In conclusion, the new reaction allows very interesting ring expansions which has a 
widly range of substates and the excellent tolerance to various functional groups. The 
mechanistic investigation represents two dinct progresses with respect to the 
substituent. 
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3.5 Experimental Section 
General information: Chemicals were purchased from commercial suppliers and 
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used as delivered. The reagents 2, 4 have been prepared according to the literature
[1-3]
. 
Deuterated solvents were bought from Euriso-Top. NMR spectra were, if not 
mentioned otherwise, recorded at room temperature on the following spectrometers: 
Bruker Avance-III-300, Bruker Avance DRX-300, Bruker-Avance DRX-500 and 
Bruker Avance-III-500. Chemical shifts are given in ppm and coupling constants in 
Hz. The following abbreviations were used for 
1
H NMR spectra to indicate the signal 
multiplicity: s (singlet), brs (broad singlet), d (doublet), t (triplet), q (quartet), quint 
(quintet), sext (sextet), sept (septet) and m (multiplet) as well as combinations of them. 
When combinations of multiplicities are given the first character noted refers to the 
biggest coupling constant. All 
13
C NMR spectra were measured with 
1
H-decoupling. 
The multiplicities mentioned in these spectra [s (singlet, quaternary carbon), d 
(doublet, CH-group), t (triplet, CH2-group), q (quartet, CH3-group)] were determined 
by DEPT135 and HSQC spectra. Mass spectra (MS and HRMS) were determined at 
the chemistry department of the University of Heidelberg under the direction of Dr. J. 
Gross. EI
+ 
-spectra were measured on a JOEL JMS-700 spectrometer. For 
ESI
+
-spectra a Bruker ApexQu FT-ICR-MS spectrometer was applied. Infrared 
Spectroscopy (IR) was processed on an FT-IR Bruker (IF528), IR Perkin Elmer (283) 
or FT-IR Bruker Vector 22. The solvent or matrix is denoted in brackets. For the most 
significant bands the wave number ν (cm-1) is given. X-ray crystal structure analyses 
were measured at the chemistry department of the University of Heidelberg under the 
direction of Dr. F. Rominger on a Bruker Smart CCD or Bruker APEX-II CCD 
instrument using Mo-Kα-radiation. Diffraction intensities were corrected for Lorentz 
and polarization effects. An empirical absorption correction was applied using 
SADABS based on the Laue symmetry of reciprocal space. Heavy atom diffractions 
were solved by direct methods and refined against F2 with full matrix least square 
algorithm. Hydrogen atoms were either isotropically refined or calculated. The 
structures were solved and refined by Dr. F. Rominger using the SHELXTL software 
package. Gas Chromatography / Mass Spectrometry (GC/MS) spectra were measured 
on two different hardware systems: 1. HP 5972 Mass Selective Detector, coupled with 
a HP 5890 SERIES II plus gas chromatograph. 2. Agilent 5975C Mass Selective 
Detector, coupled with an Agilent 7890A gas chromatograph. In both cases, as a 
capillary column, an OPTIMA 5 cross-linked Methyl Silicone column (30 m x 0.32 
mm, 0.25 µm) was employed and helium was used as the carrier gas. Gas 
Chromatography (GC) was carried out on a HP 5890 SERIES II plus gas 
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chromatograph. As a capillary column, an OPTIMA 5 cross-linked Methyl Silicone 
column (30 m x 0.32 mm, 0.25 µm) was employed and nitrogen was used as the 
carrier gas. Melting Points were measured in open glass capillaries in a Büchi melting 
point apparatus (according to Dr. Tottoli) and were not corrected. Flash Column 
Chromatography was accomplished using Silica gel 60 (0.04 - 0.063 mm / 230 - 400 
mesh ASTM) purchased from Macherey-Nagel or Aluminium oxide (neutral or basic) 
purchased from Macherey-Nagel. As eluents, mixtures of petroleum ether (PE), ethyl 
acetate (EA), dichloromethane (DCM) and diethylether (Et2O) were used. Analytical 
Thin Layer Chromatography (TLC) was carried out on precoated Macherey-Nagel 
POLYGRAM
®
 SIL G/UV254 or POLYGRAM
®
 ALOX N/UV254 plastic sheets. 
Detection was accomplished using UV-light (254 nm), KMnO4 (in 1.5 M Na2CO3 
(aq.)), molybdatophosphoric acid (5 % in ethanol), vanillin/H2SO4 (in ethanol) or 
anisaldehyde/HOAc (in ethanol). IUPAC names of the compounds described in the 








: A round bottom flask equipped with a magnetic stirrer bar was 
charged with the substituted 2-nitroacylbenzene (3.00 mmol) in EtOAc–MeOH (1:1; 
20 mL). SnCl2 
.
H2O (9.00 mmol) was added and the reaction was stirred at room 
temperature for 24 h. The reaction was quenched by saturated NaHCO3 (20 ml), and 
filtered. The aqueous phase was extracted with EtOAc (3 × 10 mL) and the organic 
portions were combined, washed with H2O (20 mL), saturated aqueous NaCl (20 mL), 
dried over NaSO4, filtered and reduced in vacuo. The residue was purified by column 
chromatography (SiO2, hexanes/EtOAc) to provide the title compound. The 




: A round bottom flask equipped with a magnetic stirrer bar was 
charged with the substituted 2-nitroacylbenzene (1.00 mmol) in conc. HCl ( 3 ml). 
SnCl2 
.
H2O (4 mmol) was added and the reaction was stirred at 10 
o
C for 30 mins. The 
reaction was quenched with saturated NaHCO3 (20 ml), and filtered. The aqueous 
phase was extracted with EtOAc (3 × 10 mL) and the organic portions were combined, 
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washed with H2O (20 mL), saturated aqueous NaCl (20 mL), dried over NaSO4, 
filtered and reduced in vacuo. The residue was purified by column chromatography 
(SiO2, hexanes/EtOAc) to provide the title compound. The characterization data of 
unknown compounds has been listed in part 3. 
 
Experimental Procedure 2: Gold-catalyzed transformation of anthranils with 
ynamide propargylic ethers  
 
A round bottom flask equipped with a magnetic stirrer bar was charged with IPrAuCl 
(5 mol%, 6.2 mg), AgNTf2 (5 mol%, 4 mg), and solvent (1 ml). The mixture was 
stirred for 5 minutes at room temperature. Then the ynamide propargylic ethers (0.2 
mmol) and anthranil (0.24 mmol) were added. The reaction was heated at 65 
o
C for 3 
h. After cooling to room temperature, the solvent was reduced in vacuo, and the 
residue was purified by column chromatography (SiO2, hexanes/EtOAc) to provide 
the title compound. The characterization data of the products are listed in part 3.  
 
Gram-scale reaction: A round bottom flask equipped with a magnetic stirrer bar was 
charged with IPrAuCl (1 mol%, 31 mg), AgNTf2 (1 mol%, 20 mg), and solvent (20 
ml). The mixture was stirred for 10 minutes at room temperature. Then the ynamide 
propargylic ethers (5 mmol, 1.76 g) and anthranil (6 mmol, 0.71 g) were added. The 
reaction was heated at 65 
o
C for 3 h. After cooling to room temperature, the solvent 
was reduced in vacuo, and the residue was purified by column chromatography (SiO2, 
hexanes/EtOAc = 8:1) to provide the product in 75 % yield (1.28 g). 
 
Experimental Procedure 3: Gold-catalyzed transformation of non-polarized 
propargylic ethers with anthranils 
 
A round bottom flask equipped with a magnetic stirrer bar was charged with 
(ArO)3PAuCl (5 mol%, 8.8 mg) (Ar = 2, 4- di-tert-butylphenyl), AgNTf2 (5 mol%, 4 
mg) in 1 ml TFE/1,2-DCE co-solvent (ratio 1:1). The mixture was stirred for 5 
minutes at room temperature. Then the anthranil (0.4 mmol) and the alkyne (0.2 mmol) 
were added. The reaction was stirred at 65 
o
C for 12 h. After cooling to room 
temperature, the solvent was reduced in vacuo, and the residue was purified by 
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column chromatography (SiO2, hexanes/EtOAc) to provide the title compound. The 
characterization data of the products has been listed in part 3. 
 
Experimental Procedure 4: Removal of the nosyl group of 3af 
 
To the solution of 3af (0.2 mmol) and K2CO3 (0.6 mmol) in MeCN (1 ml) PhSH (0.4 
mmol) was added. The reaction was stirred at room temperature until complete 
consumption of the starting material, monitored by TLC (about 1 h). The reaction was 
washed with H2O (15 mL), extracted with EtOAc (3 × 5 mL) and the organic portions 
were combined, dried over NaSO4, filtered and reduced in vacuo. The residue was 
purified by column chromatography (SiO2, hexanes/EtOAc) to provide the title 
compound 6. The characterization data of the obtained product is listed in part 3. 
 
Experiment Procedure 5: The synthesis of 7 from 3ah 
 
The mixture of 3ah (0.2 mmol), MeCN (1 ml) and Et3N (0.4 mmol) was stirred 48 h 
at room temperature. The mixture was washed with H2O (10 mL), and extracted with 
EtOAc (3 × 5 mL). The organic portions were combined and washed with saturated 
aqueous NaCl (10 mL), dried over NaSO4, filtered and reduced in vacuo. The residue 
was purified by column chromatography (SiO2, hexane/EtOAc) to provide the title 
compound 7. The characterization data of the product is listed in part 3. 
 
Experimental Procedure 6: The synthesis of 9 from 3aa 
 
To a mixture of 3aa (0.5 mmol), K2CO3 (1 mmol) in MeOH (2 ml) was added the 
Bestman-Ohira reagent and the reaction was stirred for 12 h at room temperature to 
afford the product 8. Then, the compound 8 was heated at 80 
o
C for 24 h catalyzed by 
10 mol% AuBr3 in 1 ml DCE under argon protection. The mixture was washed with 
H2O (10 mL), and extracted with EtOAc (3 × 5 mL). The organic portions were 
combined and washed with saturated aqueous NaCl (10 mL), dried over NaSO4, 
filtered and reduced in vacuo. The residue was purified by column chromatography 
(SiO2, hexane/EtOAc) to provide the product 9. The characterization of product has 







Conditions according to procedure 3. The result was monitored by GC/MS 
without isolation.  
 













































The operation was the same as procedure 2, in addition 5 equiv. H2
18
O were 
added to the reaction mixture before heating. The result was detected by NMR and 
GC/MS without isolation.  
 
 
























H NMR (300 MHz, 
CDCl3) δ = 9.09 (s, 1 H), 7.67-7.60 (m, 1 H), 7.18-7.08 (m, 2 H) ppm; 
13
C NMR (75 
MHz, CDCl3) δ = 158.9 (J = 245.4 Hz, s), 154.5 (J = 10.8 Hz, d), 154.3 (s), 124.2 (J = 
31.2 Hz, d), 117.8 (J = 9.3 Hz, d), 117.4 (J = 11.5 Hz, s), 100.8 (J = 24.9Hz, d) ppm; 
IR (ATR): ṽ = 3127, 1651, 1575, 1552, 1524, 1469, 1410, 1358, 1326, 1270, 1227, 
1155, 1131, 1114, 955, 922, 885, 851, 812, 742 cm
-1
; HRMS (EI) m/z calcd for 
C7H4FNO: 137.0277; found: 137.0276. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 8.83 (s, 1 H), 7.41-7.38 (m, 1 H), 6.88-6.84 (m, 1 H), 6.36 (s, 1 H), 3.04 (s, 
6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 157.9 (s), 153.0 (d), 151.4 (s), 119.8 (d), 
118.7 (d), 114.1 (s), 87.4 (d), 40.6 (q, 2 C) ppm; IR (ATR): ṽ = 3446, 3092, 2919, 
2854, 2821, 2489, 2359, 2215, 2071, 1910, 1868, 1646, 1574, 1509, 1483, 1443, 1396, 
1356, 1303, 1261, 1225, 1151, 1114, 1063, 958, 917, 849, 793, 735, 715, 639 cm
-1
; 
HRMS (EI) m/z calcd for C9H10N2O: 162.0793; found: 162.0785. 
 
 
Compound 1l: Yield 78 %, light yellow oil; 
1
H NMR (500 MHz, CDCl3) δ = 9.26 (s, 
1 H), 8.01 (s, 1 H), 7.74 (d, J = 9.0 Hz, 1 H), 7.17 (d, J = 9.0 Hz, 1 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 155.6 (d), 154.8 (s), 133.0 (J = 32.1 Hz, s), 123.3 (J = 271 Hz, 
s), 121.7 (d), 120.3 (J = 2.5 Hz, d), 118.5 (s), 114.2 (J = 5 Hz, d) ppm; IR (ATR): ṽ = 
3142, 3122, 2928, 2362, 1914, 1754, 1651, 1627, 1568, 1521, 1464, 1417, 1389, 1347, 
1285, 1255, 1240, 1191, 1155, 1105, 936, 925, 884, 827, 787, 746, 661 cm
-1
; HRMS 









H NMR (500 MHz, 
CDCl3) δ = 9.22 (s, 1 H), 7.51 (d, J = 9.0 Hz, 1 H), 7.34 (d, J = 7.0 Hz, 1 H), 6.97 (dd, 
J = 7.0 Hz and 9.0 Hz, 1 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 156.0 (d), 154.7 
(s), 130.0 (d), 124.8 (d), 121.3 (s), 119.4 (s), 118.5 (d) ppm; IR (ATR): ṽ = 3120, 
2925, 2854, 1750, 1635, 1610, 1581, 1552, 1512, 1463, 1385, 1318, 1248, 1212, 1155, 
1120, 1024, 978, 922, 879, 830, 775, 741, 678, 622 cm
-1
; HRMS (EI) m/z calcd for 
C7H4ClNO: 152.9981; found: 152.9987. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 6.68 (s, 1 H), 6.48 (s, 1 H), 3.94 (s, 3 H), 3.90 (s, 3 H), 2.68 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 162.5 (s), 155.24 (s), 155.2 (s), 148.8 (s), 111.0 (s), 
94.4 (d), 91.1 (d), 56.2 (q), 55.9 (q), 11.7 (q) ppm; IR (ATR): ṽ = 3082, 3009, 2970, 
2841, 1737, 1656, 1583, 1533, 1502, 1465, 1451, 1434, 1376, 1317, 1243, 1224, 1204, 
1173, 1072, 1030, 1008, 978, 841, 820, 737, 724 cm
-1
; HRMS (EI) m/z calcd for 
C10H11NO3: 193.0739; found: 193.0735. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.58 (s, 1 H), 8.84 (s, 1 H), 8.03-8.00 (m, 1 H), 7.86-7.74 (m, 2 H), 
7.67-7.57 (m, 1 H), 7.36 (d, J = 8.1 Hz, 2 H), 7.21 (d, J = 7.8 Hz, 2 H), 3.32 (s, 3 H), 
2.41 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 188.9 (d), 153.0 (s), 148.5 (s), 
144.4 (s), 138.6 (d), 132.32 (s), 132.31 (d), 129.5 (d, 2 C), 129.4 (d), 128.7 (d), 128.6 
(d, 2 C), 127.8 (d), 127.7 (s), 126.6 (s), 36.7 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2968, 
2926, 2883, 1717, 1688, 1615, 1584, 1494, 1459, 1409, 1386, 1372, 1345, 1304, 1294, 
1266, 1185, 1159, 1115, 1087, 1049, 1016, 1005, 970, 940, 920, 890, 869, 817, 806, 
792, 779, 759, 751, 706, 670, 622 cm
-1
; HRMS (EI) m/z calcd for C18H16N2O3S: 
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340.0882; found: 340.0854. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.57 (s, 1 H), 8.71 (s, 1 H), 7.73-7.66 (m, 1 H), 7.46-7.31 (m, 3 H), 
7.25-7.16 (m, 3 H), 3.95 (s, 3 H), 3.29 (s, 3 H), 2.41 (s, 3 H) ppm; 
13
C NMR (75 MHz, 
CDCl3) δ = 189.2 (d), 158.7 (s), 151.0 (s), 144.7 (s), 144.2 (s), 137.0 (d), 132.4 (s), 
130.0 (d), 129.4 (d, 2 C), 128.6 (d, 2 C), 127.9 (s), 127.7 (s), 125.5 (d), 106.2 (d), 55.8 
(q), 36.7 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3086, 3056, 2998, 2966, 2948, 2935, 2875, 
1698, 1620, 1589, 1500, 1451, 1423, 1394, 1375, 1352, 1342, 1307, 1263, 1226, 1186, 
1158, 1138, 1117, 1087, 1036, 1025, 958, 943, 904, 864, 834, 819, 801, 783, 772, 730, 
666, 625, 611 cm
-1




Compound 3ca: Yield 94 %, colorless oil; 
1
H NMR (300 MHz, CDCl3) δ = 10.56 (s, 1 
H), 8.78 (s, 1 H), 7.86-7.80 (m, 1 H), 7.73-7.69 (m, 1 H), 7.56-7.50 (m, 1 H), 7.34 (d, 
J = 8.4 Hz, 2 H), 7.21 (d, J = 8.1 Hz, 2 H), 3.30 (s, 3 H), 2.41 (s, 3 H), 2.38 (s, 3 H) 
ppm; 
13
C NMR (75 MHz, CDCl3) δ = 188.6 (d), 169.3 (s), 152.9 (s), 149.4 (s), 146.4 
(s), 144.5 (s), 138.2 (d), 132.2 (s), 130.2 (d), 129.5 (d, 2 C), 128.6 (d, 2 C), 128.0 (s), 
127.7 (d), 126.9 (s), 119.8 (d), 36.6 (q), 21.6 (q), 21.1 (q) ppm; IR (ATR): ṽ = 3066, 
2944, 2874, 2256, 1766, 1698, 1622, 1592, 1571, 1497, 1449, 1419, 1370, 1353, 1306, 
1260, 1241, 1188, 1150, 1120, 1088, 1046, 1012, 969, 934, 898, 841, 813, 785, 774, 
734, 706, 682, 658, 625 cm
-1










H NMR (500 MHz, 
CDCl3) δ = 10.56 (s, 1 H), 8.76 (s, 1 H), 7.85-7.80 (m, 1 H), 7.64-7.57 (m, 1 H), 
7.57-7.50 (m, 1 H), 7.33 (d, J = 8.5 Hz, 2 H), 7.21 (d, J = 8.0 Hz, 2 H), 3.30 (s, 3 H), 
2.41 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 188.6 (d), 161.0 (J = 249.6 Hz, s), 
152.5 (J = 3 Hz, s), 145.6 (s), 144.5 (s), 137.9 (J = 5.5 Hz, d), 132.1 (s), 131.2 (J = 8.3 
Hz, d), 129.5 (d, 2 C), 128.6 (d, 2 C), 128.1 (s), 127.3 (J = 10.5 Hz, s), 122.6 (J = 25.7 
Hz, d), 112.3 (J = 21.7 Hz, d), 36.6 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3082, 2884, 
1692, 1626, 1588, 1569, 1498, 1464, 1419, 1386, 1372, 1346, 1306, 1294, 1262, 1214, 
1187, 1163, 1151, 1134, 1120, 1087, 1051, 1018, 1005, 966, 944, 897, 875, 838, 817, 
804, 786, 772, 738, 722, 665, 623 cm
-1
; HRMS (EI) m/z calcd for C18H15FN2O3S: 
358.0787; found: 358.0797. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.54 (s, 1 H), 8.73 (s, 1 H), 7.98-7.94 (m, 1 H), 7.79-7.66 (m, 2 H), 7.32 
(d, J = 8.4 Hz, 2 H), 7.20 (d, J = 8.1 Hz, 2 H), 3.30 (s, 3 H), 2.41 (s, 3 H) ppm; 
13
C 
NMR (75 MHz, CDCl3) δ = 188.4 (d), 153.2 (s), 146.8 (s), 144.5 (s), 137.6 (d), 133.6 
(s), 133.2 (d), 132.1 (s), 130.2 (d), 129.5 (d, 2 C), 128.5 (d, 2 C), 128.3 (s), 127.8 (d), 
127.2 (s), 36.6 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3069, 2883, 1693, 1609, 1581, 1486, 
1465, 1413, 1384, 1369, 1349, 1296, 1249, 1178, 1160, 1122, 1076, 1044, 1003, 937, 
885, 832, 814, 801, 786, 770, 729, 707, 685, 656, 624 cm
-1
; HRMS (EI) m/z calcd for 
C18H15ClN2O3S: 374.0492; found: 374.0496. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.54 (s, 1 H), 8.72 (s, 1 H), 8.17-8.10 (m, 1 H), 7.86-7.78 (m, 1 H), 
7.74-7.64 (m, 1 H), 7.32 (d, J = 8.4 Hz, 2 H), 7.20 (d, J = 8.1 Hz, 2 H), 3.30 (s, 3 H), 
2.41 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 188.3 (d), 153.2 (s), 147.0 (s), 
144.5 (s), 137.5 (d), 135.7 (d), 132.1 (s), 131.2 (d), 130.3 (d), 129.5 (d, 2 C), 128.5 (d, 
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2 C), 128.3 (s), 127.7 (s), 121.6 (s), 36.6 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3067, 2962, 
2927, 2883, 1692, 1581, 1482, 1464, 1411, 1384, 1368, 1348, 1294, 1249, 1178, 1160, 
1122, 1085, 1061, 1042, 938, 927, 885, 831, 814, 785, 768, 706, 677, 647, 624 cm
-1
; 
HRMS (EI) m/z calcd for C18H15BrN2O3S: 417.9987; found: 418.9989. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.51 (s, 1 H), 8.57 (s, 1 H), 7.35 (d, J = 8.4 Hz, 2 H), 7.20 (d, J = 8.4 Hz, 
2 H), 7.15 (s, 1 H), 7.05 (s, 1 H), 6.13 (s, 2 H), 3.25 (s, 3 H), 2.40 (s, 3 H) ppm; 
13
C 
NMR (75 MHz, CDCl3) δ = 189.2 (d), 153.3 (s), 151.8 (s), 149.0 (s), 147.7 (s), 144.2 
(s), 136.5 (d), 132.5 (s), 129.4 (d, 2 C), 128.6 (d, 2 C), 125.8 (s), 123.9 (s), 105.2 (d), 
103.8 (d), 102.5 (t), 36.7 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3063, 2919, 2872, 2782, 
1693, 1643, 1613, 1589, 1490, 1463, 1394, 1369, 1349, 1307, 1283, 1260, 1234, 1187, 
1163, 1136, 1088, 1037, 945, 908, 846, 816, 771, 740, 707, 697, 684, 662, 626 cm
-1
; 
HRMS (EI) m/z calcd for C19H16N2O5S: 384.0780; found: 384.0766. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.67 (s, 1 H), 8.82 (s, 1 H), 8.64-8.57 (m, 1 H), 7.95-7.77 (m, 3 H), 
7.77-7.68 (m, 1 H), 7.65-7.56 (m, 1 H), 7.40 (d, J = 8.4 Hz, 2 H), 7.18 (d, J = 8.1 Hz, 
2 H), 3.42 (s, 3 H), 2.38 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 189.2 (d), 
152.7 (s), 147.6 (s), 144.2 (s), 137.6 (d), 134.7 (s), 132.4 (s), 130.4 (s), 129.7 (d), 
129.4 (d, 2 C), 129.1 (d), 128.7 (d, 2 C), 128.0 (d), 127.8 (s), 127.3 (d), 125.4 (d), 
125.2 (s), 125.0 (d), 37.1 (q), 21.6 (q) ppm; IR (ATR): ṽ = 2948, 2879, 1693, 1586, 
1509, 1486, 1444, 1405, 1372, 1344, 1309, 1291, 1264, 1230, 1181, 1159, 1132, 1088, 
1046, 996, 939, 898, 876, 856, 819, 802, 794, 759, 729, 715, 686, 667, 620 cm
-1
; 








H NMR (300 MHz, 
CDCl3) δ = 10.60 (s, 1 H), 8.85 (s, 1 H), 8.08-8.01 (m, 2 H), 7.94-7.87 (m, 1 H), 7.69 
(d, J = 8.4 Hz, 2 H), 7.54 (d, J = 8.4 Hz, 2 H), 7.40 (d, J = 8.4 Hz, 2 H), 7.22 (d, J = 
8.4 Hz, 2 H), 3.35 (s, 3 H), 2.41 (s, 3 H), 1.39 (s, 9 H) ppm; 
13
C NMR (75 MHz, 
CDCl3) δ = 188.9 (d), 153.5 (s), 151.9 (s), 149.0 (s), 144.9 (s), 144.4 (s), 138.3 (d), 
136.5 (s), 132.4 (s), 129.8 (d), 129.5 (d, 2 C), 128.6 (d, 2 C), 127.41 (s), 127.37 (d), 
127.23 (d, 2 C), 126.1 (d, 2 C), 125.8 (d), 125.6 (s), 36.7 (q), 34.7 (s), 31.3 (q, 3 C), 
21.7 (q) ppm; IR (ATR): ṽ = 2965, 2872, 1693, 1620, 1587, 1490, 1462, 1430, 1411, 
1371, 1349, 1309, 1269, 1242, 1181, 1156, 1119, 1087, 1049, 972, 936, 890, 809, 765, 
736, 727, 706, 677, 657, 632, 620 cm
-1
; HRMS (EI) m/z calcd for C28H28N2O3S: 
472.1821; found: 472.1811. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.53 (s, 1 H), 8.79 (s, 1 H), 8.03 (s, 1 H), 7.90-7.82 (m, 1 H), 7.73-7.65 
(m, 1 H), 7.33 (d, J = 8.1 Hz, 2 H), 7.20 (d, J = 8.1 Hz, 2 H), 3.29 (s, 3 H), 2.42 (s, 3 
H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 188.3 (d), 153.9 (s), 148.8 (s), 144.6 (s), 
138.5 (d), 132.1 (s), 131.4 (d), 131.0 (d), 130.5 (d), 129.6 (d, 2 C), 128.5 (d, 2 C), 
127.9 (s), 127.1 (s), 125.2 (s), 36.6 (q), 21.7 (q) ppm; IR (ATR): ṽ = 3084, 3063, 2936, 
2877, 1698, 1605, 1585, 1561, 1482, 1429, 1406, 1385, 1373, 1353, 1304, 1251, 1188, 
1158, 1122, 1089, 1046, 934, 895, 873, 819, 808, 780, 757, 724, 708, 674, 655, 631, 
619 cm
-1
; HRMS (EI) m/z calcd for C18H15BrN2O3S: 417.9987; found: 417.9995. 
 
 
Compound 3ka: Yield 80 %, colourless oil, 
1
H NMR (500 MHz, CDCl3) δ = 10.47 (s, 
1 H), 8.59 (s, 1 H), 7.77-7.73 (m, 1 H), 7.46-7.42 (m, 2 H), 7.24-7.20 (m, 2 H), 
80 
 
7.17-7.13 (m, 1 H), 6.76-6.74 (m, 1 H), 3.26 (s, 3 H), 3.12 (s, 6 H), 2.41 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 189.2 (d), 154.1 (s), 153.1 (s), 150.9 (s), 144.0 (s), 
137.8 (d), 132.9 (s), 130.5 (d), 129.4 (d, 2 C), 128.7 (d, 2 C), 123.7 (s), 119.0 (s), 
116.8 (d), 105.2 (d), 40.3 (q, 2 C), 36.8 (q), 21.6 (q) ppm; IR (ATR): ṽ = 2925, 2876, 
1682, 1621, 1585, 1553, 1505, 1449, 1432, 1389, 1360, 1345, 1257, 1233, 1189, 1157, 
1126, 1087, 1047, 967, 926, 895, 830, 807, 775, 760, 727, 707, 696, 666, 645, 618 
cm
-1
; HRMS (ESI) m/z calcd for C20H21N3O3S [M+Na]
+
: 406.1196; found: 406.1198. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 10.57 (s, 1 H), 8.89 (s, 1 H), 8.17-8.12 (m, 2 H), 7.82-7.77 (m, 1 H), 
7.36-7.31 (m, 2 H), 7.26-7.21 (m, 2 H), 3.28 (s, 3 H), 2.43 (s, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 188.1 (d), 154.1 (s), 147.5 (s), 144.8 (s), 138.4 (d), 133.6 (J = 
32.7 Hz, s), 131.9 (s), 130.6 (d), 129.6 (d, 2 C), 129.2 (s), 128.5 (d, 2 C), 127.9 (s), 
126.3 (J = 4.1 Hz, d), 123.5 (J = 271.2 Hz, s), 123.3 (J = 3.1 Hz, d), 36.5 (q), 21.7 (q) 
ppm; IR (ATR): ṽ = 3057, 2873, 1692, 1618, 1586, 1569, 1497, 1457, 1420, 1375, 
1365, 1350, 1304, 1259, 1233, 1197, 1185, 1162, 1139, 1114, 1089, 1039, 1029, 967, 
909, 884, 837, 814, 798, 780, 748, 696, 672, 628 cm
-1
; HRMS (EI) m/z calcd for 
C19H15F3N2O3S: 408.0755; found: 408.0749. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 10.63 (s, 1 H), 8.79 (s, 1 H), 7.84-7.81 (m, 1 H), 7.63-7.60 (m, 1 H), 
7.52-7.47 (m, 1 H), 7.35 (d, J = 8.5 Hz, 2 H), 7.20 (d, J = 8.5 Hz, 2 H), 3.31 (s, 3 H), 
2.40 (s, 3 H), 2.38 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 189.3 (d), 152.0 (s), 
147.4 (s), 144.2 (s), 138.8 (d), 137.1 (s), 132.4 (d), 132.2 (s), 129.2 (d, 2 C), 128.7 (d, 
2 C), 127.7 (d), 127.3 (d), 127.2 (s), 126.6 (s), 36.9 (q), 21.6 (q), 17.3 (q) ppm; IR 
(ATR): ṽ = 2920, 2872, 1693, 1613, 1589, 1492, 1468, 1421, 1402, 1373, 1348, 1307, 
1248, 1180, 1158, 1136, 1089, 1064, 1028, 940, 898, 843, 819, 803, 778, 759, 737, 
710, 671, 623 cm
-1










H NMR (300 MHz, 
CDCl3) δ = 10.60 (s, 1 H), 8.84 (s, 1 H), 7.95-7.83 (m, 2 H), 7.58-7.49 (m, 1 H), 7.40 
(d, J = 8.1 Hz, 2 H), 7.22 (d, J = 8.1 Hz, 2 H), 3.34 (s, 3 H), 2.41 (s, 3 H) ppm; 
13
C 
NMR (75 MHz, CDCl3) δ = 188.5 (d), 153.5 (s), 144.6 (s), 144.5 (s), 139.1 (d), 133.4 
(s), 132.2 (d), 132.1 (s), 129.4 (d, 2 C), 128.6 (d, 2 C), 128.3 (d), 128.2 (s), 127.8 (d), 
127.7 (s), 36.8 (q), 21.6 (q) ppm; IR (ATR): ṽ = 2881, 1698, 1609, 1592, 1485, 1447, 
1425, 1407, 1386, 1369, 1345, 1308, 1261, 1179, 1159, 1122, 1088, 1034, 1010, 963, 
934, 912, 899, 816, 806, 774, 758, 738, 707, 676, 636, 622 cm
-1
; HRMS (EI) m/z 
calcd for C18H15ClN2O3S: 374.0492; found: 374.0494. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.57 (s, 1 H), 8.77 (s, 1 H), 7.58-7.40 (m, 4 H), 7.25-7.19 (m, 2 H), 
7.17-7.12 (m, 1 H), 3.91 (s, 3 H), 3.34 (s, 3 H), 2.41 (s, 3 H) ppm; 
13
C NMR (75 MHz, 
CDCl3) δ = 189.0 (d), 155.2 (s), 151.9 (s), 144.1 (s), 140.4 (s), 138.6 (d), 132.9 (s), 
129.4 (d, 2 C), 128.8 (d, 2 C), 128.1 (d), 127.9 (s), 127.6 (s), 121.2 (d), 111.8 (d), 56.6 
(q), 37.0 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3066, 2955, 1697, 1612, 1593, 1571, 1495, 
1471, 1420, 1389, 1374, 1345, 1306, 1273, 1259, 1207, 1176, 1157, 1093, 1038, 1007, 
964, 932, 898, 842, 816, 806, 758, 741, 716, 705, 671, 620 cm
-1
; HRMS (EI) m/z 
calcd for C19H18N2O4S: 370.0987; found: 370.0961. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.56 (s, 1 H), 9.15 (s, 1 H), 7.90-7.82 (m, 1 H), 7.81-7.73 (m, 1 H), 
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7.66-7.56 (m, 1 H), 7.32 (d, J = 8.4 Hz, 2 H), 7.20 (d, J = 8.1 Hz, 2 H), 3.31 (s, 3 H), 
2.41 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 188.2 (d), 153.6 (s), 149.1 (s), 
144.6 (s), 138.5 (d), 132.4 (d), 132.1 (s), 131.4 (d), 129.5 (d, 2 C), 128.5 (d, 2 C), 
128.4 (d), 128.3 (s), 126.4 (s), 123.6 (s), 36.6 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2871, 
2254, 1696, 1604, 1584, 1549, 1484, 1451, 1418, 1378, 1346, 1306, 1265, 1208, 1183, 
1156, 1116, 1086, 1040, 939, 916, 894, 814, 766, 757, 733, 705, 667, 616 cm
-1
; 
HRMS (EI) m/z calcd for C18H15BrN2O3S: 417.9987; found: 417.9941. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.75 (s, 1 H), 8.25-8.18 (m, 1 H), 7.81-7.70 (m, 2 H), 7.68-7.59 (m, 1 H), 
7.42 (d, J = 8.4 Hz, 2 H), 7.22 (d, J = 8.1 Hz, 2 H), 3.28 (s, 3 H), 3.06 (s, 3 H), 2.42 (s, 
3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 192.1 (d), 153.8 (s), 150.2 (s), 147.3 (s), 
144.2 (s), 132.7 (s), 131.6 (d), 129.4 (d), 129.3 (d, 2 C), 128.8 (d, 2 C), 127.6 (d and s, 
2 C), 126.0 (s), 125.4 (d), 37.1 (q), 21.6 (q), 14.9 (q) ppm; IR (ATR): ṽ = 3067, 3033, 
2944, 2927, 2871, 1920, 1733, 1699, 1614, 1598, 1565, 1500, 1446, 1418, 1386, 1354, 
1291, 1239, 1187, 1163, 1113, 1089, 1019, 967, 913, 882, 814, 765, 734, 706, 691, 
671, 619 cm
-1
; HRMS (EI) m/z calcd for C19H18N2O3S: 354.1038; found: 354.1048. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.32 (s, 1 H), 7.92-7.86 (m, 1 H), 7.80-7.72 (m, 1 H), 7.64-7.46 (m, 7 H), 
7.40-7.32 (m, 2 H), 7.31-7.24 (m, 2 H), 3.33 (s, 3 H), 2.45 (s, 3 H) ppm; 
13
C NMR (75 
MHz, CDCl3) δ = 190.7 (d), 152.2 (s), 151.8 (s), 147.6 (s), 144.1 (s), 134.2 (s), 133.7 
(s), 131.6 (d), 129.7 (d, 2 C), 129.4 (d, 2 C), 128.9 (d), 128.8 (d), 128.7 (d, 2 C), 128.4 
(d, 2 C), 127.6 (d), 127.4 (d), 126.8 (s), 126.5 (s), 36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ 
= 1699, 1610, 1598, 1567, 1550, 1488, 1441, 1423, 1387, 1348, 1308, 1287, 1236, 
1193, 1163, 1151, 1117, 1086, 1071, 1052, 1026, 999, 952, 922, 878, 847, 800, 784, 
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770, 701, 667, 638, 621 cm
-1








H NMR (300 MHz, 
CDCl3) δ = 10.71 (s, 1 H), 7.44 (d, J = 8.4 Hz, 2 H), 7.34 (s, 1 H), 7.23 (d, J = 8.1 Hz, 
2 H), 7.07 (s, 1 H), 4.06 (s, 3 H), 3.99 (s, 3 H), 3.26 (s, 3 H), 301 (s, 3 H), 2.43 (s, 3 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 192.3 (d), 154.2 (s), 152.8 (s), 150.5 (s), 147.9 
(s), 145.0 (s), 144.0 (s), 133.0 (s), 129.3 (d, 2 C), 128.8 (d, 2 C), 124.4 (s), 123.1 (s), 
107.8 (d), 102.8 (d), 56.4 (q), 56.2 (q), 37.1 (q), 21.6 (q), 15.2 (q) ppm; IR (ATR): ṽ = 
2949, 1692, 1618, 1597, 1556, 1504, 1472, 1431, 1411, 1345, 1311, 1272, 1252, 1216, 
1188, 1164, 1140, 1101, 1086, 1061, 1026, 1003, 955, 910, 861, 831, 821, 805, 741, 
708, 672, 648 cm
-1








H NMR (500 MHz, 
CDCl3) δ = 10.69 (s, 1 H), 8.40-8.35 (m, 1 H), 7.95 (d, J = 16.5 Hz, 1 H), 7.84-7.74 
(m, 2 H), 7.62-7.58 (m, 1 H), 7.55 (d, J = 8.0 Hz, 2 H), 7.48 (d, J = 8.0 Hz, 2 H), 
7.27-7.22 (m, 4 H), 6.83 (d, J = 16.5 Hz, 1 H), 3.31 (s, 3 H), 2.44 (s, 3 H), 2.41 (s, 3 
H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 191.2 (d), 153.3 (s), 149.7 (s), 148.3 (s), 
144.1 (s), 139.7 (d), 139.1 (s), 133.6 (s), 133.0 (s), 131.7 (d), 129.6 (d, 2 C), 129.4 (d, 
2 C), 129.1 (d), 128.8 (d, 2 C), 127.5 (d), 127.4 (d), 127.2 (d, 2 C), 126.0 (s), 124.5 (s), 
122.0 (d), 37.0 (q), 21.7 (q), 21.4 (q) ppm; IR (ATR): ṽ = 2963, 2926, 2863, 191, 
1687, 1631, 1607, 1566, 1536, 1511, 1493, 1445, 1416, 1384, 1340, 1304, 1234, 1184, 
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1157, 1115, 1086, 1014, 972, 937, 898, 855, 811, 780, 733, 706, 667, 619 cm
-1
; 
HRMS (EI) m/z calcd for C27H24N2O3S: 456.1508; found: 456.1518. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.48 (s, 1 H), 8.20-8.13 (m, 1 H), 7.68 (d, J = 16.5 Hz, 1 H), 7.63-7.50 
(m, 2 H), 7.43-7.34 (m, 3 H), 7.27 (d, J = 8.4 Hz, 2 H), 7.03 (d, J = 8.1 Hz, 2 H), 6.75 
(d, J = 8.7 Hz,2 H), 6.60 (d, J = 16.5 Hz, 1 H), 3.65 (s, 3 H), 3.09 (s, 3 H), 2.22 (s, 3 
H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 191.3 (d), 160.4 (s), 153.3 (s), 149.8 (s), 
148.3 (s), 144.1 (s), 139.6 (d), 133.1 (s), 131.7 (d), 129.4 (d, 2 C), 129.2 (s), 129.1 (d), 
128.75 (d, 2 C), 128.69 (d, 2 C), 127.5 (d), 127.4 (d), 126.0 (s), 124.4 (s), 120.6 (d), 
114.4 (d, 2 C), 55.5 (q), 37.0 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2969, 1686, 1602, 1566, 
1537, 1512, 1493, 1462, 1421, 1385, 1340, 1306, 1251, 1177, 1158, 1113, 1087, 1029, 
1014, 973, 940, 899, 853, 828, 813, 800, 786, 766, 732, 705, 670, 620 cm
-1
; HRMS 
(EI) m/z calcd for C27H24N2O4S: 472.1457; found: 472.1466. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.45 (s, 1 H), 8.65 (s, 1 H), 7.92-7.81 (m, 2 H), 7.80-7.71 (m, 1 H), 
7.60-7.52 (m, 1 H), 7.50-7.43 (m, 2 H), 7.27-7.19 (m, 4 H), 7.16-7.03 (m, 3 H), 4.93 
(s, 2 H), 2.42 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 189.0 (d), 151.5 (s), 
148.6 (s), 144.4 (s), 138.5 (d), 135.4 (s), 134.1 (s), 132.3 (d), 129.6 (d, 2 C), 129.5 (d), 
129.0 (d, 2 C), 128.7 (d), 128.6 (s), 128.5 (d, 2 C), 128.4 (d, 2 C), 127.9 (d, 2 C), 
126.7 (s), 52.8 (t), 21.7 (q) ppm; IR (ATR): ṽ = 3089, 2873, 1741, 1693, 1618, 1586, 
1570, 1497, 1457, 1420, 1375, 1365, 1348, 1304, 1294, 1259, 1233, 1197, 1185, 1162, 





; HRMS (EI) m/z calcd for C24H20N2O3S: 416.1195; found: 416.1226. 
 
 




H NMR (300 MHz, 
CDCl3) δ = 10.26 (s, 1 H), 8.66 (s, 1 H), 8.14-8.08 (m, 1 H), 7.98-7.83 (m, 2 H), 
7.68-7.58 (m, 1 H), 7.18-7.10 (m, 2 H), 6.70-6.63 (m, 2 H), 5.09 (s, 2 H), 3.68 (s, 3 H), 
3.14 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 189.1 (d), 159.4 (s), 152.1 (s), 
148.9 (s), 139.0 (d), 132.6 (d), 130.5 (d, 2 C), 129.6 (d), 128.8 (d), 128.3 (s), 128.2 (d), 
127.1 (s), 126.8 (s), 114.1 (d, 2 C), 55.1 (q), 53.6 (t), 37.2 (q) ppm; IR (ATR): ṽ = 
3050, 3013, 2902, 2836, 1693, 1614, 1580, 1513, 1494, 1456, 1421, 1389, 1374, 1345, 
1324, 1305, 1263, 1243, 1192, 1154, 1108, 1053, 1033, 1007, 959, 944, 917, 890, 849, 
811, 791, 770, 744, 725, 649, 620 cm
-1
; HRMS (EI) m/z calcd for C19H18N2O4S: 
370.0987; found: 370.0991. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 10.09 (s, 1 H), 8.73 (s, 1 H), 8.00-7.88 (m, 2 H), 7.84-7.75 (m, 1 H), 
7.60-7.52 (m, 1 H), 4.65 (t, J = 7.5 Hz, 2 H), 4.52 (t, J = 7.5 Hz, 2 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 187.1 (d), 157.4 (s), 148.6 (s), 148.0 (s), 139.9 (d), 132.6 (d), 
129.4 (d), 128.2 (d), 126.9 (d), 126.0 (s), 123.3 (s), 63.4 (t), 44.9 (t) ppm; IR (ATR): ṽ 
= 2910, 1745, 1686, 1618, 1590, 1497, 1468, 1425, 1384, 1340, 1298, 1266, 1248, 
1211, 1197, 1155, 1144, 1133, 1102, 1030, 1002, 967, 913, 864, 819, 784, 768, 752, 
735, 699, 644, 622 cm
-1










H NMR (300 MHz, 
d
6
-DMSO) δ = 9.94 (s, 1 H), 9.27 (s, 1 H), 8.86 (s, 1 H), 8.43-8.30 (m, 2 H), 8.18-8.12 
(m, 1 H), 8.09-8.01 (m, 1 H), 7.87-7.81 (m, 1 H), 7.62-7.56 (m, 1 H), 7.36-7.28 (m, 2 
H), 2.55 (s, 3 H) ppm; 
13
C NMR (125 MHz, d
6
-DMSO) δ = 193.9 (s), 189.2 (d), 148.7 
(s), 148.5 (s), 143.6 (d), 138.2 (d), 137.8 (s), 134.3 (d), 130.5 (d), 128.8 (d, 2 C), 
127.2 (s), 126.5 (s), 124.8 (s), 124.6 (d), 123.7 (d), 122.3 (d), 118.9 (s), 112.5 (d), 
28.0 (q) ppm; IR (ATR): ṽ = 3108, 3053, 2884, 1691, 1645, 1617, 1584, 1526, 1496, 
1451, 1432, 1402, 1375, 1332, 1295, 1263, 1232, 1197, 1160, 1118, 1101, 1029, 1015, 
964, 927, 914, 857, 822, 785, 751, 739, 716, 703, 656, 642, 623 cm
-1
; HRMS (EI) m/z 
calcd for C20H14N2O2: 314.1055; found: 314.1057. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 10.64 (s, 1 H), 8.91 (s, 1 H), 8.29 (d, J = 9.0 Hz, 2 H), 8.08-8.03 (m, 1 H), 
7.87-7.78 (m, 2 H), 7.75 (d, J = 9.0 Hz, 2 H), 7.71-7.66 (m, 1 H), 3.82 (d, J = 7.5 Hz, 
2 H), 1.49-1.40 (m, 2 H), 1.37-1.28 (m, 2 H), 0.85 (t, J = 7.5 Hz, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 188.7 (d), 151.2 (s), 150.4 (s), 148.7 (s), 142.6 (s), 139.2 (d), 
132.9 (d), 129.7 (d, 2 C), 129.6 (d), 128.7 (s), 128.6 (d), 128.5 (d), 126.9 (s), 123.9 (d, 
2 C), 49.7 (t), 30.2 (t), 20.0 (t), 13.5 (q) ppm; IR (ATR): ṽ = 3112, 3061, 2933, 2875, 
1693, 1618, 1583, 1529, 1496, 1461, 1447, 1423, 1349, 1311, 1256, 1229, 1196, 1167, 
1158, 1105, 1086, 1066, 1037, 1010, 970, 920, 901, 871, 856, 796, 757, 735, 683, 648, 
620 cm
-1
; HRMS (EI) m/z calcd for C20H19N2O5S: 413.1045; found: 413.1044. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 10.52 (s, 1 H), 8.57 (s, 1 H), 7.80-7.75 (m, 2 H), 7.68-7.63 (m, 1 H), 
7.48-7.42 (m, 3 H), 7.30-7.25 (m, 2 H), 7.13-7.06 (m, 5 H), 2.27 (s, 3 H) ppm; 
13
C 
NMR (125 MHz, CDCl3) δ = 189.2 (d), 152.9 (s), 148.8 (s), 144.1 (s), 139.9 (d), 
139.7 (s), 135.6 (s), 132.7 (d), 129.5 (d), 129.4 (d, 2 C), 129.3 (d, 2 C), 129.04 (d), 
129.02 (d, 2 C), 128.9 (d, 2 C), 128.4 (d), 128.2 (d), 127.0 (s), 126.9 (s), 21.7 (q) ppm; 
87 
 
IR (ATR): ṽ = 3066, 2968, 2926, 2869, 1738, 1694, 1617, 1585, 1493, 1455, 1420, 
1354, 1261, 1214, 1185, 1163, 1104, 1090, 1030, 966, 936, 910, 813, 796, 756, 696, 
675, 627, 612 cm
-1








H NMR (500 MHz, 
CDCl3) δ = 10.75 (s, 1 H), 8.87 (s, 1 H), 8.04-7.98 (m, 1 H), 7.82-7.74 (m, 2 H), 
7.66-7.60 (m, 1 H), 7.37 (d, J = 8.5 Hz, 2 H), 7.22 (d, J = 8.5 Hz, 2 H), 4.64 (s, 2 H), 
4.04 (q, J = 7.0 Hz, 2 H), 2.42 (s, 3 H), 1.11 (t, J = 7.0 Hz, 3 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 189.7 (d), 168.0 (s), 151.9 (s), 148.3 (s), 144.7 (s), 138.6 (d), 133.4 
(s), 132.2 (d), 129.7 (d, 2 C), 129.5 (d), 128.6 (d), 128.5 (s), 128.2 (d, 2 C), 127.9 (d), 
126.9 (s), 61.6 (t), 50.2 (t), 21.7 (q), 14.0 (q) ppm; IR (ATR): ṽ = 2968, 2926, 1751, 
1732, 1690, 1618, 1587, 1496, 1458, 1423, 1374, 1346, 1308, 1270, 1196, 1162, 1119, 
1089, 1029, 965, 935, 919, 884, 808, 783, 759, 740, 706, 675, 624 cm
-1
; HRMS (EI) 
m/z calcd for C21H20N2O5S: 412.1093; found: 412.1097. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 8.53 (s, 1 H), 7.95-7.91 (m, 1 H), 7.82-7.78 (m, 1 H), 7.76-7.71 (m, 1 H), 
7.61-7.56 (m, 1 H), 7.35 (d, J = 8.0 Hz, 2 H), 7.18 (d, J = 8.0 Hz, 2 H), 3.33 (s, 3 H), 
2.83 (s, 3 H), 2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 199.2 (s), 150.2 (s), 
147.3 (s), 144.1 (s), 138.8 (d), 133.1 (s), 132.8 (s), 131.4 (d), 129.4 (d, 2 C), 128.6 (d), 
128.5 (d), 128.4 (d, 2 C), 127.5 (d), 126.5 (s), 36.5 (q), 29.6 (q), 21.6 (q) ppm; IR 
(ATR): ṽ = 3062, 2942, 2874, 1737, 1694, 1619, 1586, 1531, 1492, 1456, 1427, 1402, 
1376, 1349, 1264, 1202, 1159, 1130, 1088, 1020, 962, 922, 848, 814, 793, 761, 738, 
707, 685, 660, 620 cm
-1





Compound 3aj: Yield 71 %, colorless oil, 
1
H NMR (300 MHz, CDCl3) δ = 8.45 (s, 1 
H), 7.94-7.87 (m, 1 H), 7.83-7.77 (m, 1 H), 7.76-7.67 (m, 1 H), 7.62-7.54 (m, 1 H), 
7.37 (d, J = 8.4 Hz, 2 H), 7.18 (d, J = 8.1 Hz, 2 H), 3.32 (s, 3 H), 3.12 (d, J = 6.9 Hz, 
2 H), 2.38 (s, 3 H), 2.33-2.19 (m, 1 H), 1.00 (t, J = 6.9 Hz, 6 H) ppm; 
13
C NMR (75 
MHz, CDCl3) δ = 201.9 (s), 150.2 (s), 147.1 (s), 144.0 (s), 138.5 (d), 133.7 (s), 133.1 
(s), 131.2 (d), 129.3 (d, 2 C), 128.47 (d, 3 C), 128.45 (d), 127.5 (d), 126.6 (s), 50.6 (t), 
36.7 (q), 25.2 (d), 22.7 (q, 2 C), 21.6 (q) ppm; IR (reflection): ṽ = 3063, 2959, 2931, 
2872, 1690, 1618, 1584, 1564, 1490, 1456, 1424, 1401, 1376, 1353, 1306, 1263, 1186, 
1159, 1121, 1087, 1057, 985, 920, 865, 812, 778, 760, 706, 676, 639, 609 cm
-1
; 
HRMS (EI) m/z calcd for C22H24N2O3S: 396.1508; found: 396.1500. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 8.45 (s, 1 H), 7.94-7.90 (m, 1 H), 7.83-7.78 (m, 1 H), 7.75-7.70 (m, 1 H), 
7.62-7.56 (m, 1 H), 7.38 (d, J = 8.0 Hz, 2 H), 7.19 (d, J = 8.0 Hz, 2 H), 3.32 (s, 3 H), 
3.19 (t, J = 7.0 Hz, 2 H), 2.40 (s, 3 H), 1.85-1.75 (m, 2 H), 1.02 (t, J = 7 Hz, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 202.3 (s), 150.1 (s), 147.1 (s), 144.0 (s), 138.5 (d), 
133.5 (s), 133.0 (s), 131.2 (d), 129.3 (d, 2 C), 128.5 (d), 128.47 (d, 2 C), 128.45 (d), 
127.5 (d), 126.6 (s), 43.6 (t), 36.7 (q), 21.6 (q), 18.0 (t), 13.9 (q) ppm; IR (ATR): ṽ = 
3057, 2981, 2956, 2928, 2872, 1738, 1690, 1618, 1586, 1567, 1491, 1454, 1421, 1400, 
1377, 1342, 1305, 1290, 1258, 1186, 1157, 1125, 1086, 1060, 991, 944, 917, 900, 838, 
816, 796, 768, 742, 707, 673, 642, 615 cm
-1
; HRMS (EI) m/z calcd for C21H22N2O3S: 





Compound 3al: Yield 52 %, colorless oil, 
1
H NMR (500 MHz, CDCl3) δ = 8.45 (s, 1 
H), 7.95-7.90 (m, 1 H), 7.82-7.78 (m, 1 H), 7.75-7.70 (m, 1 H), 7.61-7.56 (m, 1 H), 
7.36 (d, J = 8.0 Hz, 2 H), 7.18 (d, J = 8.5 Hz, 2 H), 5.07-5.01 (m, 1 H), 3.31-3.23 (m, 
4 H), 3.09-3.01 (m, 1 H), 2.39 (s, 3 H), 2.14-2.05 (m, 1 H), 2.03-1.94 (m, 2 H), 1.61 (s, 
3 H), 1.56 (s, 3 H), 1.46-1.36 (m, 1 H), 1.30-1.21 (m, 1 H), 0.97 (d, J = 6.5 Hz, 3 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 202.1 (s), 150.2 (s), 147.1 (s), 144.0 (s), 138.7 
(d), 133.7 (s), 132.9 (s), 131.5 (s), 131.2 (d), 129.3 (d, 2 C), 128.5 (d, 4 C), 127.5 (d), 
126.6 (s), 124.4 (d), 49.2 (t), 37.1 (t), 36.7 (q), 29.5 (q), 25.7 (d), 25.5 (t), 21.6 (q), 
19.8 (q), 17.7 (q) ppm; IR (reflection): ṽ = 3063, 2959, 2925, 2873, 2855, 1918, 1692, 
1618, 1585, 1566, 1491, 1454, 1427, 1402, 1376, 1355, 1307, 1264, 1188, 1161, 1123, 
1088, 1060, 1019, 996, 921, 846, 814, 793, 778, 760, 706, 678, 611 cm
-1
; HRMS (EI) 
m/z calcd for C27H32N2O3S: 464.2134; found: 464.2145. 
 
 
Compound 3am: Yield 58 %, colorless oil; 
1
H NMR (300 MHz, CDCl3) δ = 8.22 (s, 1 
H), 7.85-7.80 (m, 1 H), 7.77-7.65 (m, 2 H), 7.57-7.51 (m, 1 H), 7.38-7.32 (m, 2 H), 
7.20-7.05 (m, 6 H), 4.18-4.09 (m, 1 H), 3.30 (s, 3 H), 3.10-3.00 (m, 1 H), 2.81-2.71 
(m, 1 H), 2.38 (s, 3 H), 1.33 (d, J = 6.6 Hz, 3 H), 1.15 (s, 9 H) ppm; 
13
C NMR (75 
MHz, CDCl3) δ = 206.2 (s), 149.9 (s), 148.8 (s), 147.0 (s), 144.0 (s), 139.6 (d), 136.6 
(s), 133.0 (s), 132.8 (s), 131.1 (d), 129.3 (d, 2 C), 128.8 (d, 2 C), 128.48 (s), 128.47 (d, 
2 C), 128.4 (d), 127.3 (d), 126.5 (s), 125.0 (d, 2 C), 46.1 (d), 40.1(t), 36.7 (q), 34.2 (s), 
31.2 (q, 3 C), 21.6 (q), 17.0 (q) ppm; IR (reflection): ṽ = 3059, 3026, 2963, 2870, 
1800, 1692, 1618, 1585, 1563, 1510, 1491, 1460, 1424, 1401, 1376, 1354, 1306, 1267, 
1187, 1159, 1120, 1088, 1053, 969, 921, 814, 797, 777, 760, 736, 706, 678, 638, 609 
cm
-1





Compound 3an: Yield 50 %, colorless oil; 
1
H NMR (500 MHz, CDCl3) δ = 8.45 (s, 1 
H), 7.95-7.91 (m, 1 H), 7.81-7.77 (m, 1 H), 7.75-7.70 (m, 1 H), 7.62-7.56 (m, 1 H), 
7.40 (d, J = 8.5 Hz, 2 H), 7.20 (d, J = 8.5 Hz, 2 H), 3.77-3.71 (m, 1 H), 3.30 (s, 3 H), 
2.41 (s, 3 H), 1.87-1.76 (m, 2 H), 1.59-1.44 (m, 2 H), 1.36-1.23 (m, 4 H), 0.94 (t, J = 
7.5 Hz, 3 H), 0.86 (t, J = 7.0 Hz, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 205.4 
(s), 150.2 (s), 147.1 (s), 143.9 (s), 139.5 (d), 133.5 (s), 133.1 (s), 131.2 (d), 129.3 (d, 2 
C), 128.7 (d, 2 C), 128.5 (d), 128.4 (d), 127.5 (d), 126.8 (s), 50.4 (d), 37.1 (q), 30.0 (t), 
29.3 (t), 23.7 (t), 22.9 (t), 21.6 (q), 14.0 (q), 11.4 (q) ppm; IR (reflection): ṽ = 3063, 
2959, 2931, 2872, 1691, 1618, 1597, 1584, 1564, 1491, 1457, 1424, 1401, 1376, 1354, 
1307, 1264, 1186, 1160, 1121, 1088, 1057, 1018, 985, 962, 920, 865, 812, 778, 760, 
706, 677, 693, 609 cm
-1








H NMR (500 MHz, 
CDCl3) δ = 8.84 (s, 1 H), 8.05-8.02 (m, 1 H), 7.87-7.84 (m, 1 H), 7.84-7.78 (m, 1 H), 
7.67-7.63 (m, 1 H), 7.23 (d, J = 8.0 Hz, 2 H), 7.16 (d, J = 8.5 Hz, 2 H), 3.09 (s, 3 H), 
2.38 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 183.0 (s), 150.3 (s), 147.9 (s), 
145.6 (dm, Jf = 253.7 Hz, s, 2 C), 144.5 (s), 143.1 (dm, Jf = 255.0 Hz, s), 141.3 (d), 
137.7 (dm, Jf = 231.6 Hz, s, 2 C), 132.4 (d), 131.9 (s), 130.8 (s), 129.5 (d, 2 C), 129.1 
(d), 128.6 (d), 128.3 (d, 2C), 127.8 (d), 126.5 (s), 114.7(s), 35.8 (q), 21.6 (q) ppm; IR 
(ATR): ṽ = 3422, 3336, 3065, 2947, 2930, 1680, 1652, 1618, 1586, 1523, 1498, 1457, 
1427, 1404, 1377, 1353, 1310, 1266, 1194, 1160, 1131, 1106, 1088, 1056, 994, 921, 
860, 815, 792, 781, 759, 737, 706, 672, 615 cm
-1





: 529.0616; found: 529.0621.  
 
 




H NMR (300 MHz,CDCl3) δ 
= 10.37 (s, 1 H), 8.58 (s, 1 H), 8.11-8.03 (m, 1 H), 7.94-7.87 (m, 1 H), 7.85-7.76 (m, 1 
H), 7.60-7.50 (m, 1 H), 3.37-3.26 (m, 2 H), 1.91-1.73 (m, 2 H), 1.05 (t, J = 7.2 Hz, 3 
H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 191.1 (d), 162.2 (s), 149.3 (s), 142.1 (d), 
132.6 (d), 129.1 (d), 128.9 (d), 127.6 (s), 126.9 (d), 126.1 (s), 38.2 (t), 23.6 (t), 14.2 (q) 
ppm; IR (ATR): ṽ = 2957, 2930, 2899, 2873, 2741, 1694, 1619, 1597, 1558, 1491, 
1467, 1455, 1428, 1415, 1375, 1341, 1217, 1185, 1154, 1110, 961, 916, 869, 842,784, 
762, 751 cm
-1
; HRMS (EI) m/z calcd for C13H13NO: 199.0997; found: 199.0992. 
 
 




H NMR (500 MHz,CDCl3) 
δ = 10.38 (s, 1 H), 8.61 (s, 1 H), 8.14-8.06 (m, 1 H), 7.98-7.92 (m, 1 H), 7.88-7.82 (m, 
1 H), 7.63-7.56 (m, 1 H), 3.05 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 191.3 (d), 
158.3 (s), 149.2 (s), 142.5 (d), 132.7 (d), 129.0 (d), 128.7 (d), 128.0 (s), 127.0 (d), 
126.1 (s), 23.9 (q) ppm; IR (ATR): ṽ = 2926, 2853, 2755, 1698, 1647, 1619, 1593, 
1560, 1492, 1421, 1372, 1340, 1282, 1253, 1232, 1157, 1111, 1032, 1006, 970, 929, 
904, 876, 811, 788, 759, 670, 625 cm
-1
; HRMS (EI) m/z calcd for C11H9NO: 
171.0684; found: 171.0680. 
 
 




H NMR (500 MHz,CDCl3) 
δ = 10.17 (s, 1 H), 8.84 (s, 1 H), 8.25-8.19 (m, 1 H), 8.03-7.98 (m, 1 H), 7.90-7.84 (m, 
1 H), 7.72-7.66 (m, 2 H), 7.65-7.60 (m, 1 H), 7.59-7.50 (m, 3 H) ppm; 
13
C NMR (75 
MHz, CDCl3) δ = 191.5 (d), 160.3 (s), 149.5 (s), 138.3 (d), 137.7 (s), 132.7 (d), 130.3 
(d, 2 C), 129.6 (d), 129.51 (d), 129.49 (d), 128.8 (d, 2 C), 127.7 (s), 127.6 (d), 126.4 (s) 
ppm; IR (ATR): ṽ = 3054, 2864, 1692, 1615, 1584, 1555, 1486, 1455, 1444, 1423, 
92 
 
1371, 1270, 1200, 1157, 1123, 1076, 1038, 1019, 1009, 964, 934, 916, 868, 822, 796, 
774, 753, 711, 679, 614 cm
-1








H NMR (500 MHz,CDCl3) 
δ = 10.40 (s, 1 H), 8.58 (s, 1 H), 8.12-8.05 (m, 1 H), 7.93-7.88 (m, 1 H), 7.85-7.78 (m, 
1 H), 7.58-7.52 (m, 1 H), 7.51-7.44 (m, 1 H), 7.19-7.09 (m, 1 H), 2.10-2.03 (m, 3 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 191.4 (d), 155.1 (s), 149.5 (s), 142.3 (d), 137.3 
(d), 132.7 (d), 129.2 (d), 129.0 (d), 127.1 (d), 126.9 (d), 126.6 (s), 126.2 (s), 19.0 (q) 
ppm; IR (ATR): ṽ = 2911, 1771, 1694, 1652, 1617, 1588, 1553, 1491, 1426, 1403, 
1370, 1326, 1249, 1186, 1153, 1108, 1019, 959, 911, 871, 854, 779, 756, 697, 634, 
615 cm
-1
; HRMS (EI) m/z calcd for C13H11NO: 197.0841; found: 197.0842. 
 
 
Compound 6: Yield 71 %, colorless oil;
 1
H NMR (300 MHz, CDCl3): δ = 9.95 (s, 1 
H), 8.18 (s, 1 H), 7.99 (brs, 1 H), 7.71-7.58 (m, 3 H), 7.23-7.14 (m, 1 H), 3.70-3.60 
(m, 2 H), 1.77-1.63 (m, 2 H), 1.56-1.41 (m, 2 H), 0.99 (t, J = 7.2 Hz, 3 H) ppm; 
13
C 
NMR (75 MHz, CDCl3) δ = 193.1 (d), 154.9 (s), 151.3 (s), 148.6 (d), 133.5 (d), 129.2 
(d), 126.5 (d), 122.3 (d), 121.8 (s), 117.4 (s), 40.4 (t), 31.5 (t), 20.4 (t), 13.9 (q) ppm; 
IR (reflection): ṽ = 3364, 3057, 2957, 2929, 2871, 2860, 2724, 1673, 1622, 1604, 
1571, 1538, 1467, 1399, 1374, 1355, 1323, 1271, 1222, 1162, 1143, 1124, 1077, 952, 
915, 856, 754, 728 cm
-1




Compound 7: Yield 95 %, colorless oil; 
1
H NMR (300 MHz, CDCl3) δ = 8.13-8.04 
(m, 2 H), 7.83-7.73 (m, 2 H), 7.54-7.40 (m, 2 H), 7.27-7.11 (m, 3 H), 5.15 (s, 1 H), 
4.98-4.93 (m, 1 H), 4.19-4.04 (m, 2 H), 3.99-3.85 (m, 1 H), 2.24 (s, 3 H), 1.15 (t, J = 
93 
 
7.2 Hz, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 169.7 (s), 153.6 (s), 147.9 (s), 
144.6 (s), 135.6 (s), 134.6 (d), 130.1 (d), 129.1 (d, 2 C), 129.0 (d, 2 C), 128.2 (d), 
128.1 (d), 125.2 (s), 124.8 (d), 124.3 (s), 71.6 (d), 70.3 (d), 62.2 (t), 21.6 (q), 14.0 (q) 
ppm; IR (reflection): ṽ = 3486, 3066, 2983, 2927, 2254, 1748, 1633, 1597, 1584, 1511, 
1494, 1470, 1413, 1354, 1322, 1198, 1169, 1121, 1094, 1054, 1024, 960, 915, 865, 
831, 813, 798, 757, 731, 703, 666, 621 cm
-1
; HRMS (EI) m/z calcd for C21H20N2O5S: 
412.1093; found: 412.1080. 
 
 




H NMR (300 MHz, CDCl3) 
δ = 8.40 (s, 1 H), 7.89-7.76 (m, 4 H), 7.74-7.66 (m, 1 H), 7.60-7.52 (m, 1 H), 
7.36-7.28 (m, 2 H), 3.47 (s, 1 H), 3.26 (s, 3 H), 2.46 (s, 3 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 153.9 (s), 145.9 (s), 143.7 (s), 143.1 (d), 135.0 (s), 130.7 (d), 129.2 
(d, 2 C), 129.0 (d, 2 C), 128.8 (d), 127.7 (d), 127.2 (d), 126.6 (s), 116.6 (s), 83.4 (d), 
79.4 (s), 37.2 (q), 21.7 (q) ppm; IR (reflection): ṽ = 3266, 2925, 1618, 1599, 1586, 
1564, 1489, 1458, 1445, 1422, 1401, 1370, 1348, 1302, 1264, 1186, 1162, 1152, 1121, 
1088, 1048, 958, 917, 864, 808, 793, 778, 753, 706, 692, 664, 631, 619 cm
-1
; HRMS 
(EI) m/z calcd for C19H16N2O2S: 336.0932; found: 336.0918. 
 
 




H NMR (300 MHz, CDCl3) 
δ = 8.71 (s, 1 H), 8.12-8.07 (m, 2 H), 8.03-7.92 (m, 3 H), 7.74-7.66 (m, 1 H), 
7.53-7.46 (m, 1 H), 7.31-7.24 (m, 2 H), 4.01 (s, 3 H), 2.36 (s, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 148.9 (s), 145.6 (s), 143.7 (s), 140.2 (s), 137.8 (d), 129.8 (d, 2 
C), 129.2 (d), 128.6 (d), 128.1 (d), 127.7 (d), 126.7 (d, 2 C), 125.3 (s), 124.4 (d), 
117.3 (s), 113.4 (s), 32.2 (q), 21.6 (q) ppm; IR (reflection): ṽ = 3121, 3068, 2952, 
2924, 2855, 1620, 1596, 1572, 1528, 1500, 1478, 1433, 1389, 1363, 1337, 1301, 1290, 
1261, 1177, 1137, 1120, 1083, 1052, 1021, 938, 903, 871, 843, 813, 787, 768, 737, 
706, 669, 648 cm
-1






Compound 10: Yield 67 %, yellow oil; 
1
H NMR (300 MHz, CDCl3) δ = 9.65 (s, 1 H), 
7.94-7.70 (m, 3 H), 7.50-7.40 (m, 1 H), 7.37-7.27 (m, 2 H), 7.21-7.10 (m, 1 H), 
6.85-6.76 (m, 1 H), 5.46-5.30 (m, 2 H), 3.22 (s, 3 H), 2.44 (s, 3 H), 1.75 (s, 3 H) ppm; 
13
C NMR (100 MHz, CDCl3) δ = 190.6 (d), 168.2 (s), 150.2 (s), 144.6 (s), 135.0 (d), 
134.7 (s), 129.5 (d, 3 C), 128.4 (d), 127.7 (d, 2 C), 126.1 (s), 124.2 (d), 119.6 (d, 2 C), 
112.5 (t), 36.3 (q), 21.6 (q), 20.0 (q) ppm; IR (reflection): ṽ = 3267, 3066, 3031, 2926, 
2855, 2750, 1761, 1687, 1665, 1625, 1592, 1524, 1495, 1453, 1401, 1358, 1320, 1275, 
1203, 1170, 1120, 1091, 1063, 1021, 971, 923, 816, 777, 706, 671, 610 cm
-1
; HRMS 
(ESI) m/z calcd for [C20H20N2O5S+H]
+
: 401.1166; found: 401.1165. 
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X-Ray Crystal Structure Analyses 
The crystallographic data (CCDC) can be obtained free of charge from the 
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
 
 











































Chapter 4: Counteranion-Directed Divergent [4+2] 
Annulation of Benzofurazans with Ynamides by Gold and 
Platinum Catalysis: Switchable Access to Quinoxaline 
N-Oxides/ Quinoxalines  
4.1 Introduction 
Quinoxaline N-oxides and quinoxalines are of great significance owning to their 
important biological properties, including antiinflammatory, antimicrobial and 
antitumoral activities. This created increasing attentions from the synthetic 
community.
[1]
 The condensation of o-phenylenediamine with aldehydes/ketones is the 
prevalent entry to quinoxalines, despite regioselectivity frustration.
[2]
 Various 
oxidation approaches toward quinoxaline N-oxides from the corresponding 
quinoxalines also exist.
[3]
 However, the specific synthesis of quinoxaline 
mono-N-oxide is still a challenge due to easy over-oxidations, low regioselectivity 
between both nitrogen atoms and limited tolerance of functional groups. Moreover, 
these linear synthetic strategies are usually accompanied with low atom-economy and 





 remains highly 
desirable. 
 
Catalytic alkyne activation by π acids, especially gold and platinum, had immense 
impact on synthetic chemistry, greatly promoting the facile and flexible construction 
of intricate heterocyclic scaffolds.
[5]
 In recent years, -imino gold carbene-mediated 
intramolecular transfer of nitrene to alkynes enabled novel and atom-economical 
accesses to diverse aza-heterocycles.
[6-11]
 For instance, our group contributed 
gold-catalyzed formal [3+2] and [4+2] cycloadditions of alkynes with anthranils 
toward the 7-acylindole and 2-aminoquinoline skeleton respectively.
[10]
 A concise 
route to 2-aminopyroles through gold-catalyzed [3+2] annulation of ynamides with 
isoxazoles as nitrene equivalent was reported by Ye and co-workers.
[11a]
 Divergent to 
gold catalysis, -imino platinum carbenoids turned out to be more oxophilic giving 





In most gold and platinum-catalyzed transformations, the counteranion is generally 
considered as an accelerating factor and the counteranion effect on the reaction 
selectivity or the catalyst structure is less focused.
[13]
 Herein we presented 
Au/Pt-catalyzed counteranion-directed selective syntheses of quinoxaline N-oxides 
and quinoxalines. Benzofurazan was selected as a new nucleophilic ―nitrenoid‖ as 
potential -imino metal carbenoid precursor. Despite its commercial availability and 
wide existence in medical molecules,
[14]
 the chemistry of this compound is rare. In 
contrast to isoxazole as reactant, both gold and platinum carbenes, generated from the 
reaction of ynamide with benzofurazan, triggered the same [4+2] annulation without a 
chemoselective divergence. Nevertheless, the choice of the counteranion had the 
crucial influence on switching access to different products. While the deoxidized 
product quinoxaline resulted from the bulky NTf2
-
 anion, chloride as counterion led to 
quinoxaline mono-N-oxide as the major product (Scheme 1, b). Further, 
counteranion-induced alternative cyclization processes were indicated by mechanistic 
investigations. 
 
Scheme 1. Switchable access to aza-heterocyclic compounds. 
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4.2 Results and Discussion 
4.2.1 Optimization of the Reaction Conditions 
We initially surveyed the reaction of 2 equiv. benzofurazan 1a and ynamide 2a (R = 
Me) with 10 mol % PtCl2 in PhMe at 80 
o
C for 24 h (Table 1, entry 1). The products 
3a and 4a were obtained in 30 % and 13 % respectively. Both solid state molecular 
structures were determined by single-crystal X-ray diffraction.
[15a]
 In order to increase 
the selectivity, various ligands and anions were examined (entry 2-9). PtCl2 in 
combination with highly hindered phosphite ligand L4 gave the best result with 80 % 
yield of 3a and 12 % yield of 4a (entry 8), whereas PtI2 delivered low yield and 
selectivity (entry 9). To our delight, the transformation of benzofurazan 1a with 
ynamide 2b (R = Bn) specifically produced 3a in 83 % yield with L4 as ligand (entry 
10). Taking advantage of AuCl/L4 or AuCl3 also afforded the excellent selectivity, 
albeit in lower yield (entry 11, 13). The yield of 3a could be raised to 79 % by AuCl 
without any ligand (entry 12). In contrast, 10 mol% AgNTf2 as additive reversed the 
product selectivity, favoring the quinoxaline product. Under these conditions 1,2-DCE 
performed better in yield than toluene (entry 14). Based on this result, we chose the 
reaction of 4 equiv. benzofurazan 1a and ynamide 2a in 1,2-DCE as model system to 
optimize the catalyst (entry 15-22). Among gold and platinum catalysts, 
L1AuCl/AgNTf2 showed higher catalytic activity and selectivity, delivering 4a in 
67 % yield (entry 18). Besides of NTf2
-
, the other bulky anion SbF6
-
 also offered good 
selectivity of 4a although with moderate yield (entry 19). The control experiment 
demonstrated the catalytic capacity of gold and platinum (entry 23). Moreover, the 
absence of silver salt has a slightly negative impact on the selectivity (entry 24). 
Finally, PtCl2/L4 qualified for the syntheses of quinoxaline N-oxides, while 
quinoxalines were favorably prepared with the L1AuCl/AgNTf2 catalyst system.  
 








Entry 10 mol% Catalyst R Additive Yield of 3 Yield of 4 
1
[a]
 PtCl2 Me — 30 % 13 % 
2
[a]
 Pt(COD)Cl2 Me — 40 % 23 % 
3
[a]
 PtCl2 Me 1 atm. CO 45 % 28 % 
4
[a]
 PtCl2 Me 10 mol% P(C6F5)3 38 % 25 % 
5
[a]
 PtCl2 Me 10 mol% L1 50 % 13 % 
6
[a]
 PtCl2 Me 10 mol% L2 55 % 15 % 
7
[a]
 PtCl2 Me 10 mol% L3 70 %  18 % 
8
[a]
 PtCl2 Me 10 mol% L4 80 % 12 % 
9
[a]
 PtI2 Me 10 mol% L4 35 % 10 % 
10
[a]
 PtCl2 Bn 10 mol% L4 83 % < 5 % 
11
[a]
 AuCl Bn 10 mol% L4 48 % < 5 % 
12
[a]
 AuCl Bn — 79 % 13 % 
13
[a]
 AuCl3 Bn — 50 % <5 % 
14
[a]











 IPrAuCl Me 10 mol% AgNTf2 12 % 43 % 
16
[b]
 tBuXPhosAuCl Me 10 mol% AgNTf2 10 % 54 % 
17
[b]
 L4AuCl Me 10 mol% AgNTf2 < 5 % 51 % 
18
[b]
 L1AuCl Me 10 mol% AgNTf2 < 5 %  67 % 
19
[b]
 L1AuCl Me 10 mol% AgSbF6 8 % 43 % 
20
[b]
 PtCl2 Me 20 mol% AgNTf2 < 5 % 41 % 
21
[b]
 Pt(COD)Cl2 Me 20 mol% AgNTf2 < 5 % 38 % 
22
[b]





 AgNTf2 Me — < 5 % 23 % 
24
[b]
 L1AuNTf2 Me — 12 % 51 % 
[a] 1a (0.2 mmol) and 2 (0.1 mmol) in toluene at 80 
o
C for 24 h. [b] 1a (0.4 mmol) 
and 2 (0.1 mmol) in 1,2-DCE at 80 
o
C for 24 h. [c] isolated yield.  
 
4.2.2 Scope and Limitation 
Under the optimized reaction conditions, we began to evaluate the scope of ynamides 
(Table 2). First the treatment of diverse ynamides with benzofurazan 1a was 
conducted under condition A. A broad set of protecting groups and substituents at the 
R
2
-position were checked (3a-f). Ms, Bs and the easily removable nosyl group were 
well tolerated. Benzyl substituted ynamides provided higher yield than methyl. Then, 
our attention was turned to variations on the aryl moiety of the ynamide. A wide range 
of functional groups, including trifluoromethyl (3i), fluoride (3h, 3s), bromide (3l, 3n), 
ester (3m) and methoxyl moieties (3o, 3q), were all compatible, delivering the 
corresponding functionalized quinoxaline N-oxides in good to excellent yields. 
Naphthyl, heterocyclic and even alkenyl substituted ynamides also proceeded 
smoothly (3r, 3t-v). Subsequently, the generality of ynamides was also examined 
under condition B (4a-m). A range of substituted quinoxalines was also successfully 
prepared in moderate to good yields with fine tolerance of functional groups. 
 




Condition A (PtCl2/L4):  
   
3a, PG = Ts, R = Me, 80 % 3g, R = 4-Me, 70 %  
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3b, PG = Ts, R = Bn, 83 % 3h, R = 4-F, 78 % 3m, R = 4-COOMe, 54 % 
3c, PG = Ms, R = Me, 70 % 3i, R = 4-CF3, 50 % 3n,  R = 4-Br, 70 % 
3d, PG = Ms, R = PMB, 95 % 3j, R = 4-tBu, 78 % 3o,  R = 4-MeO, 50 % 
3e, PG = Bs, R = PMB, 80 %  3k, R = 3-Cl, 59 % 3p,  R = 4-Ph, 65 % 
3f, PG = Ns, R = n-Bu, 94 % 3l, R = 2-Br, 42 %  
   
3q, 63 % 3r, 97 % 3s, 70 % 
   
3t, 50 % 3u, 74 % 3v, 33 % 
 
Condition B (L1AuCl/AgNTf2): 
   
4a,  R = H, 67 % 
4b,  R = 4-Me, 70 % 
4c,  R = 4-MeO, 63 % 
4d,  R = 4-F, 51 % 
4e,  R = 4-CF3, 49 % 
4f,  R = 4-tBu, 71 % 
4g,  R = 3-Cl, 53 % 
4h,  R =3-Me, 50 % 
4i, 69 % 4j, 58 % 
   
4k, 57 % 4l, 62 % 4m, 53 % 
[a] Condition A: 1a (0.2mmol), 2 (0.1 mmol), and 10 mol% PtCl2/L4 at 80 
o
C for 24 h 
in toluene. Condition B: 1a (0.4 mmol), 2 (0.1 mmol), and 10 mol% L1AuCl/AgNTf2 
at 80 
o




In addition to benzofurazan, a variety of substituted derivatives were also explored to 
suit the reaction with ynamides under condition A and B (Table 3). Gratifyingly, 
methoxy (3x, 3ab-c, 4p-q), bromide (3y, 4o) and amide (3aa) were all tolerated 
delivering versatile scaffolds for further decoration. For common approaches to 
quinoxalines, the control of regioselectivity remains a challenge.
[2, 4d-e]
 Hence, a few 
attempts were made on the regiospecific synthesis of quinoxalines N-oxides and 
quinoxalines following this method. In the case of 3ab and 4p, the conjugative effect 
of the -methoxy group enhances the nucleophilicity of the adjacent nitrogen which 
induces good regioselectivity. An analogous substituent effect attributes to the 
formation of product 3aa. An excellent regioselectivity was obtained by the reaction 
of -substituted benzofurazans, in which one of the nitrogen was shielded by an 
additional substituent (3ac-d, 4q-r). To underline the correct structural assignments 









Condition A (PtCl2/L4): 
   
3w, 90 %
 
3x, 86 % 3y, 75 %
[d]
 





isomeric ratio: 2:1 3aa, 96 %
[d]
 










 (C8:C5 > 20:1) 3ad, 76 %
[d]




Condition B (L1AuCl/AgNTf2): 
   
4n, 65 % 4o, 51 %
[d]
 










(C5:C8 = 8:1) 
4r, 61 %
[d]







[a] Condition A: 1 (0.2 mmol), 2 (0.1 mmol), and 10 mol% PtCl2/L4 at 80 
o
C for 24 h 
in toluene. Condition B: 1 (0.4 mmol), 2 (0.1 mmol), and 10 mol% L1AuCl/AgNTf2 
at 80 
o
C for 24 h in 1,2-DCE. [b] Isolated yields. [c] Isomeric ratios were determined 
by 
1




4.2.3 Further Applications 
Quinoxaline N-oxides are considered as significant intermediates in organic synthesis. 
By taking the advantage of N-oxides as directing group, the further decoration could 
be facilely accomplished by direct C-H functionalization (Scheme 2).
[16]
 As example, 
the quinoxaline N-oxide 3b was suitable for iridium-catalyzed selective C8-amination 
(3b-1). The iodinated product 3b-2 was also prepared from 3a with 
N-iodosuccinimide via a similar strategy. 
 
 
Scheme 2. C-H functionalization of quinoxaline N-oxide. 
4.2.3 Mechanistic Investigation 
 
Scheme 3. Mechanistic investigation. 
 
Preliminary mechanistic investigations on the counteranion-mediated selectivity 
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switch were investigated next. The treatment of quinoxaline N-oxide and ynamide 
with L1AuCL/AgNTf2 offered the quinoxaline accompanied by oxidized by-products 
(Scheme 3, a). However, under the same condition only few oxidized by-products 
were observed for the transformation of benzofurazan with the same ynamide 
(Scheme 3, b). This result suggests that the quinoxaline is not formed by the 
deoxidization of its corresponding quinoxaline N-oxide. On the basis of above studies, 
a probable reaction mechanism is shown in Scheme 4. The benzofurazan initially 
reacts with the metal-activated ynamide to generate a -imino metal carbene A/A’ 
with the in-situ formation of a nitrosyl group. Then, the resulting carbene intermediate 
can follow different pathways. In the case of a chloride ion, the metal carbene A is 
attacked by the nitrosyl group furnishing metal-ligated cyclized intermediate B, which 
subsequently produces quinoxaline N-oxide after metal elimination (path a). On the 
other hand, when the bulky ion NTf2
-
 is involved, due to the higher electrophilicity of 
exposed metal core a [2+2] cycloaddition of nitrosyl group and metal carbene A’ is 
preferred.
[17]
 The quinoxaline is generated by a metathesis process losing the metallic 
oxide, which might decompose to regenerate the active metal catalyst (path b).  
 
Scheme 4. Plausible mechanism. 
4.3 Summary  
In summary, we described gold and platinum-catalyzed counteranion-controlled 
divergent [4+2] cycloaddition of benzofurazans and ynamides. The tunable protocol 
provided convenient and regioselective syntheses of quinoxaline mono-N-oxides and 
quinoxalines from common starting materials. A wide range of functional groups were 
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well tolerated. Mechanistic studies disclosed the counteranion effect on the selectivity 
of the products via alternative cyclization pathways.  
4.4 References  
[1]  a) E. Glazer, L. Chappel, J. Med. Chem. 1982, 25, 766-769; b) J. P. Dirlam, J. E. 
Presslitz, B. J. Williams, J. Med. Chem. 1983, 26, 1122-1126; c) A. Carta, P. 
Corona, M. Loriga, Curr Med Chem. 2005, 12, 2259-2272; d) D. P. Singh, S. K. 
Deivedi, S. R. Hashim, R. G. Singhal, Pharmaceuticals 2010, 3, 2416-2425; e) G. 
Liu, C. H. Botting, K. M. Evans, J. A. G. Walton, G. Xu, A. M. Z. Slawin, N. J. 
Westwood, ChemMedChem 2010, 5, 41-45; f) O. I. El-Sabbagh, M. E. El-Sadek, 
S. M. Lashine, S.H.Yassin, S. M. El-Nabtity, Med. Chem. Res. 2009, 18, 782-797; 
g) M. González, H. Cerecetto, Expert Opin. Ther. Pat. 2012, 22, 1289-1302.  
[2]  For selected instances, see: a) T. Shepherd, D. M. Smith, J. Chem. Soc., Perkin 
Trans. 1, 1987, 501-505; b) W. Wang, Y. Shen, X. Meng, M. Zhao, Y. Chen, B. 
Chen, Org. Lett. 2011, 13, 4514-4517; c) S. Shi, T. Wang, W. Yang, M. Rudolph, 
A. S. K. Hashmi, Chem. Eur. J. 2013, 19, 6576-6580; d) Y. Chen, K. Li, M. 
Zhao,Y. Li, B. Chen, Tetrahedron Lett. 2013, 54, 1627-1630; e) Y. H. Cho, K. H. 
Kim, C. H. Cheon, J. Org. Chem. 2014, 79, 901-907; f) S. K. Guchhait, G. 
Priyadarshani, N. M. Gulghane, RSC Adv. 2016, 6, 56056-56063; g) J. Shen, X. 
Wang, X. Lin, Z. Yang, G. Cheng, X. Cui, Org. Lett. 2016, 18, 1378-1381. 
[3]  a) J. A. Bull, J. J. Mousseau, G. Pelletier, A. B. Charette, Chem. Rev. 2012, 112, 
2642-2713; b) M. Carmeli, S. Rozen, J. Org. Chem. 2006, 71, 5761-5765; c) C. 
E. Mixan, R. G. Pews, J. Org. Chem. 1977, 42, 1869-1871; d) H. S. Kim, Y. 
Kurasawa, A. Takada, J. Heterocyclic Chem. 1989, 26, 871-873. 
[4]  For recent instances, see: a) F. Chen, X. Huang, X. Li, T. Shen, M. Zou, N. Jiao, 
Angew. Chem. Int. Ed. 2014, 53, 10495-10499; Angew. Chem. 2014, 126, 
10663-10667; b) T. Chen, X. Chen, J. Wei, D. Lin, Y. Xie, W. Zeng, Org. Lett. 
2016, 18, 2078-2081; c) H. Ma, D. Li, W. Yu, Org. Lett. 2016, 18, 868-871; d) D. 
Leifert, A. Studer, Angew. Chem. Int. Ed. 2016, 55, 11660-11663; Angew. Chem. 
2016, 128, 11832-11835; e) X. Sun, W. Wang, Y. Li, J. Ma, S. Yu, Org. Lett. 
2016, 18, 4638-4641. 
[5]  a) A. Fürstner, P. W. Davies, Angew. Chem. Int. Ed. 2007, 46, 3410-3449; Angew. 
Chem. 2007, 119, 3478-3519; b) E. Jiménez-Núñez, A. M. Echavarren, Chem. 
108 
 
Commun. 2007, 333-346; c) A. Fürstner, Chem. Soc. Rev. 2009, 38, 3208-3221; d) 
S. M. A. Sohel, R.-S. Liu, Chem. Soc. Rev. 2009, 38, 2269-2281; e) A. Corma, A. 
Leyva-Pérez, M. J. Sabater, Chem. Rev. 2011, 111, 1657-1712; f) M. Rudolph, A. 
S. K. Hashmi, Chem. Soc. Rev. 2012, 41, 2448-2462; g) A. S. K. Hashmi, F. D. 
Toste, Eds., Wiley-VCH: Weinheim, 2012; h) A. Fürstner, Acc. Chem. Res. 2014, 
47, 925-938; i) R. Dorel, A. M. Echavarren, Chem. Rev. 2015, 115, 9028-9072; j) 
D. Pflästerer, A. S. K. Hashmi, Chem. Soc. Rev. 2016, 45, 1331-1367. 
[6]  a) P. W. Davies, A. Cremonesi, L. Dumitrescu, Angew. Chem. Int. Ed. 2011, 50, 
8931-8935; Angew. Chem. 2011, 123, 9093-9097; b) M. Garzón, P. W. Davies, 
Org. Lett. 2014, 16, 4850-4853; c) E. Chatzopoulou, P. W. Davies, Chem. 
Commun. 2013, 49, 8617-8619; d) A. D. Gillie, R. J. Redd and P. W. Davies, Adv. 
Synth. Catal. 2016, 358, 226-239; e) P. W. Davies, M. Garzón, Asian J. Org. 
Chem. 2015, 4, 694-708. 
[7]  a) S. K. Pawar, R. L. Sahani, R.-S. Liu, Chem. Eur. J. 2015, 21, 10843-10850; b) 
R. L. Sahani, R.-S. Liu, Angew. Chem. Int. Ed. 2017, 56, 1026-1030; Angew. 
Chem. 2017, 129, 1046-1050; c) R. L. Sahani, R.-S. Liu, Angew. Chem. Int. Ed. 
2017, 56, doi: 10.1002/anie.201707423. 
[8]  a) L. Zhu, Y. Yu, Z. Mao, X. Huang, Org. Lett. 2015, 17, 30-33; b) Y. Wu, L. 
Zhu, Y. Yu, X. Luo, X. Huang, J. Org. Chem. 2015, 80, 11407-11416; c) Y. Yu, G. 
Chen, L. Zhu, Y. Liao, Y. Wu, X. Huang, J. Org. Chem. 2016, 81, 8142-8154. 
[9]  a) M. Chen, N. Sun, H. Chen, Y. Liu, Chem. Commun. 2016, 52, 6324-6327; b) J. 
González, J. Santamaría, Á. L. Suárez-Sobrino, A. Ballesterosa, Adv. Synth. 
Catal. 2016, 358, 1398-1403. 
[10] a) H. Jin, L. Huang, J. Xie, M. Rudolph, F. Rominger, A. S. K. Hashmi, Angew. 
Chem. Int. Ed. 2016, 55, 794-797; Angew. Chem. 2016, 128, 804-808; b) H. Jin, 
B. Tian, X. Song, J. Xie, M. Rudolph, F. Rominger, A. S. K. Hashmi, Angew. 
Chem. Int. Ed. 2016, 55, 12688-12692; Angew. Chem. 2016, 128, 12880-12884. 
[11] a) A.-H. Zhou, Q. He, C. Shu, Y.-F. Yu, S. Liu, T. Zhao, W. Zhang, X. Lu, L.-W. 
Ye, Chem. Sci. 2015, 6, 1265-1271; b) C. Shu, Y.-H. Wang, B. Zhou, X.-L. Li, 
Y.-F. Ping, X. Lu, L.-W. Ye, J. Am. Chem. Soc. 2015, 137, 9567-9570; c) C. Shu, 
Y.-H. Wang, C.-H. Shen, P.-P. Ruan, X. Lu, L.-W. Ye, Org. Lett. 2016, 18, 
3254-3257. 
[12] W.-B. Shen, X.-Y. Xiao, Q. Sun, B. Zhou, X.-Q. Zhu, J.-Z. Yan, X. Lu, L.-W. Ye, 
Angew. Chem. Int. Ed. 2017, 56, 605-609; Angew. Chem. 2017, 129, 620-624. 
109 
 
[13] a) M. Jia, M. Bandini, ACS Catal. 2015, 5, 1638-1652; b) B. Ranieri, I. Escofet, 
A. M. Echavarren, Org. Biomol. Chem. 2015, 13, 7103-7118; c) G. Lemière, V. 
Gandon, N. Agenet, J.-P. Goddard, A. de Kozak, C. Aubert, L. Fensterbank, M. 
Malacria, Angew. Chem. Int. Ed. 2006, 45, 7596-7599; Angew. Chem. 2006, 118, 
7758-7761; d) Y. Xia, A. S. Dudnik, V. Gevorgyan, Y. Li, J. Am. Chem. Soc. 
2008, 130, 6940-6941; e) W. Li, Y. Li, J. Zhang, Chem. Eur. J. 2010, 16, 
6447-6450; f) P. W. Davies, N. Martin, Org. Lett. 2009, 11, 2293-2296; g) A. S. 
K. Hashmi, T. Lauterbach, P. Nösel, M. H. Vilhelmsen, M. Rudolph, F. Rominger, 
Chem. Eur. J. 2013, 19, 1058-1065. 
[14] a) J. L. Rogers, L. Bayeh, T. H. Scheuermann, J. Longgood, J. Key, J. Naidoo, L. 
Melito, C. Shokri, D. E. Frantz, R. K. Bruick, K. H. Gardner, J. B. MacMillan, U. 
K. Tambar, J. Med. Chem. 2013, 56, 1739-1747; b) E. A. Chugunova, N. I. 
Akylbekov, A. D. Voloshina, N. V. Kulik, V. V. Zobov, V. M. Babaev, N. V. 
Gavrilov, A. R. Burilov, Synth. Commun. 2016, 46, 1560-1565; c) Z. Zhang, O. 
Obianyo, E. Dall, Y. Du, H. Fu, X. Liu, S. S. Kang, M. Song, S.-P. Yu, C. Cabrele, 
M. Schubert, X. Li, J.-Z. Wang, H. Brandstetter, K. Ye, Nat. Commun. 2017, 8, 
14740-14757. 
[15] CCDC 1570450 (3a), 1536744 (4a) ,CCDC 1570451 (3ab), 1536745 (4p), and 
1536746 (4r) contain the supplementary crystallographic data. These data can be 
obtained free of charge from the cambridge crystallographic data centre. 
[16] For selected instances, see: a) H. Hwang, J. Kim, J. Jeong, S. Chang, J. Am. 
Chem. Soc. 2014, 136, 10770-10776; b) X. Zhang, Z. Qi, X. Li, Angew. Chem. 
Int. Ed. 2014, 53, 10794-10798; Angew. Chem. 2014, 126, 10970-10974; c) J. 
Jeong, P. Patel, H. Hwang, S. Chang, Org. Lett. 2014, 16, 4598-4601; d) K. Shin, 
S. W. Park, S. Chang, J. Am. Chem. Soc. 2015, 137, 8584-8592; e) Y. Wang, L. 
Zhang, Synthesis 2015, 47, 289-305; f) D. Kalsi, R. A. Laskar, N. Barsu, J. R. 
Premkumar, B. Sundararaju, Org. Lett. 2016, 18, 4198-4201. 
[17] a) V. V. Pagar, A. M. Jadhav, R.-S. Liu, J. Am. Chem. Soc. 2011, 133, 





4.5 Experimental Section  
General information: Chemicals were purchased from commercial suppliers and 
used as delivered. The benzofurazan is bought from SigmaAldrich. Substrates 1 and 2 
were prepared according to related literatures.
[1-5]
 Deuterated solvents were bought 
from Euriso-Top. NMR spectra were, if not mentioned otherwise, recorded at room 
temperature on the following spectrometers: Bruker Avance-III-300, Bruker Avance 
DRX-300, Bruker-Avance DRX-500 and Bruker Avance-III-500. Chemical shifts are 
given in ppm and coupling constants in Hz. The following abbreviations were used 
for 
1
H NMR spectra to indicate the signal multiplicity: s (singlet), brs (broad singlet), 
d (doublet), t (triplet), q (quartet), quint (quintet), sext (sextet), sept (septet) and m 
(multiplet) as well as combinations of them. When combinations of multiplicities are 
given the first character noted refers to the biggest coupling constant. All 
13
C NMR 
spectra were measured with 
1
H-decoupling. The multiplicities mentioned in these 
spectra [s (singlet, quaternary carbon), d (doublet, CH-group), t (triplet, CH2-group), q 
(quartet, CH3-group)] were determined by DEPT135 and HSQC spectra. Mass spectra 
(MS and HRMS) were determined at the chemistry department of the University of 
Heidelberg under the direction of Dr. J. Gross. EI
+ 
-spectra were measured on a JOEL 
JMS-700 spectrometer. For ESI
+
-spectra a Bruker ApexQu FT-ICR-MS spectrometer 
was applied. Infrared Spectroscopy (IR) was processed on an FT-IR Bruker (IF528), 
IR Perkin Elmer (283) or FT-IR Bruker Vector 22. The solvent or matrix is denoted in 
brackets. For the most significant bands the wave number ν (cm-1) is given. X-ray 
crystal structure analyses were measured at the chemistry department of the 
University of Heidelberg under the direction of Dr. F. Rominger on a Bruker Smart 
CCD or Bruker APEX-II CCD instrument using Mo-Kα-radiation. Diffraction 
intensities were corrected for Lorentz and polarization effects. An empirical 
absorption correction was applied using SADABS based on the Laue symmetry of 
reciprocal space. Heavy atom diffractions were solved by direct methods and refined 
against F2 with full matrix least square algorithm. Hydrogen atoms were either 
isotropically refined or calculated. The structures were solved and refined by Dr. F. 
Rominger using the SHELXTL software package. Gas Chromatography / Mass 
Spectrometry (GC/MS) spectra were measured on two different hardware systems: 1. 
HP 5972 Mass Selective Detector, coupled with a HP 5890 SERIES II plus gas 
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chromatograph. 2. Agilent 5975C Mass Selective Detector, coupled with an Agilent 
7890A gas chromatograph. In both cases, as a capillary column, an OPTIMA 5 
cross-linked Methyl Silicone column (30 m x 0.32 mm, 0.25 µm) was employed and 
helium was used as the carrier gas. Gas Chromatography (GC) was carried out on a 
HP 5890 SERIES II plus gas chromatograph. As a capillary column, an OPTIMA 5 
cross-linked Methyl Silicone column (30 m x 0.32 mm, 0.25 µm) was employed and 
nitrogen was used as the carrier gas. Melting Points were measured in open glass 
capillaries in a Büchi melting point apparatus (according to Dr. Tottoli) and were not 
corrected. Flash Column Chromatography was accomplished using Silica gel 60 (0.04 
- 0.063 mm / 230 - 400 mesh ASTM) purchased from Macherey-Nagel or Aluminium 
oxide (neutral or basic) purchased from Macherey-Nagel. As eluents, mixtures of 
petroleum ether (PE), ethyl acetate (EA), dichloromethane (DCM) and diethylether 
(Et2O) were used. Analytical Thin Layer Chromatography (TLC) was carried out on 
precoated Macherey-Nagel POLYGRAM
®
 SIL G/UV254 or POLYGRAM
®
 ALOX 
N/UV254 plastic sheets. Detection was accomplished using UV-light (254 nm), 
KMnO4 (in 1.5 M Na2CO3 (aq.)), molybdatophosphoric acid (5 % in ethanol), 
vanillin/H2SO4 (in ethanol) or anisaldehyde/HOAc (in ethanol). IUPAC names of the 







A round bottom flask equipped with a magnetic stirrer bar was added 10 mol% PtCl2 
(2.6 mg), 10 mol% L4 (9.2 mg), 1 (0.2 mmol), 2 (0.1 mmol) and toluene (1 ml). The 
reaction was heated at 70 
o
C for 24 h. After cooling to room temperature, the solvent 
was reduced in vacuo, and the residue was purified by column chromatography (SiO2, 
hexanes/EtOAc) to provide the title compound. The characterization data of the 





A round bottom flask equipped with a magnetic stirrer bar was charged with L1AuCl 
(10 mol%, 6.5 mg), AgNTf2 (10 mol%, 4 mg), and 1,2-DCE (1 ml). The mixture was 
stirred for 5 minutes at room temperature. Then the benzofurazan 1 (0.4 mmol) were 
added. The ynamides 2 (0.1 mmol) dissolved in 1 ml 1,2-DCE was dropwisely added 
into above mixture over 10 h at 70 
o
C by syringe pump. The reaction continued to 
heat for 12 h. After cooling to room temperature, the solvent was reduced in vacuo, 
and the residue was purified by column chromatography (SiO2, hexanes/EtOAc) to 
provide the title compound.  
 
 
A round bottom flask equipped with a magnetic stirrer bar was charged with 
[Cp*IrCl2]2 (2 mol%, 3.2 mg), AgNTf2 (8 mol%, 3.2 mg), quinoxaline N-oxide (0.1 
mmol), TsN3 (0.15 mmol) and 1,2-dichloroethane (0.5 ml). The mixture heated at 50 
o
C for 12 h. After cooling to room temperature, the solvent was reduced in vacuo, and 
the residue was purified by column chromatography (SiO2, hexanes/EtOAc) to 
provide the title compound.  
 
 
A round bottom flask equipped with a magnetic stirrer bar was charged with 
[Cp*RhCl2]2 (4 mol%, 2.5 mg), AgNTf2 (16 mol%, 6.4 mg), quinoxaline N-oxide (0.1 
mmol), NIS (0.15 mmol) and 1,2-dichloroethane (0.5 ml) under nitrogen atmosphere. 
The mixture was heated at 50 
o
C for 12 h. After cooling to room temperature, the 
solvent was reduced in vacuo, and the residue was purified by column 




A round bottom flask equipped with a magnetic stirrer bar was charged with L1AuCl 
(10 mol%, 6.5 mg), AgNTf2 (10 mol%, 4 mg), and 1,2-DCE (1 ml). The mixture was 
stirred for 5 minutes at room temperature. Then the ynamide (0.1 mmol) and 
quinoxaline N-oxide (0.1 mmol) were added. The mixture was heated for 1 h. After 
cooling to room temperature, the solvent was reduced in vacuo, and the residue was 









H NMR (500 MHz, CDCl3) δ = 8.64-8.58 (m, 1 H), 8.01-7.95 (m, 1 H), 
7.87-7.82 (m, 1 H), 7.82-7.56 (m, 1 H), 7.74-7.67 (m, 4 H), 7.63-7.53 (m, 3 H), 
7.35-7.30 (m, 2 H), 2.94 (s, 3 H), 2.49 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
151.1 (s), 144.1 (s), 142.0 (s), 140.8 (s), 136.8 (s), 135.1 (s), 131.8 (d), 130.6 (d), 
130.4 (d), 129.8 (d), 129.5 (d), 129.4 (d), 129.0 (s), 128.9 (d), 128.6 (d), 119.5 (d), 
36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ = 3064, 2957, 1717, 1597, 1575, 1537, 1497, 
1481, 1453, 1397, 1344, 1297, 1237, 1162, 1117, 1084, 1032, 1018, 995, 902, 867, 
814, 767, 728, 699, 666, 618 cm
-1











H NMR (500 MHz, CDCl3) δ = 8.47-8.42 (m, 1 H), 7.98-7.94 (m, 1 H), 
7.79-7.72 (m, 1 H), 7.70-7.64 (m, 1 H), 7.45-7.35 (m, 3 H), 7.35-7.29 (m, 2 H), 
7.22-7.15 (m, 2 H), 7.14-7.07 (m, 1 H), 7.05-6.93 (m, 4 H), 6.78-6.67 (m, 2 H), 4.48 
(s, 2 H), 2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 149.6 (s), 144.3 (s), 
142.7 (s), 141.9 (s), 136.8 (s), 135.3 (s), 134.0 (s), 131.8 (d), 130.7 (d), 130.6 (d), 
129.8 (d), 129.5 (d), 129.4 (d), 129.0 (d), 128.9 (s), 128.5 (d), 128.2 (d), 128.1 (d), 
119.6 (d), 53.7 (t), 21.7 (q) ppm; IR (ATR): ṽ = 3067, 2931, 1911, 1599, 1578, 1530, 
1495, 1479, 1454, 1402, 1375, 1344, 1300, 1225, 1184, 1152, 1117, 1088, 1049, 1019, 
993, 963, 915, 892, 866, 810, 769, 722, 700, 677, 663, 653, 630, 617 cm
-1
; HRMS 
(ESI) m/z calcd for [M+H]
+
: 482.1533; found: 482.1532 
 
 




H NMR (500 MHz, CDCl3) δ = 8.53-8.47 (m, 1 H), 7.99-7.94 (m, 1 H), 7.79-7.73 (m, 
1 H), 7.72-7.66 (m, 1 H), 7.63-7.57 (m, 2 H), 7.52-7.40 (m, 3 H), 3.12 (s, 3 H), 2.90 (s, 
3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 151.3 (s), 141.9 (s), 139.8 (s), 136.9 (s), 
131.9 (d), 130.6 (d), 130.2 (d), 130.0 (d), 129.5 (d), 128.7 (d), 128.5 (s), 119.6 (d), 
39.5 (q), 37.0 (q) ppm; IR (ATR): ṽ = 2959, 2903, 2867, 1716, 1600, 1578, 1509, 
1484, 1454, 1394, 1362, 1346, 1300, 1240, 1202, 1187, 1161, 1131, 1108, 1084, 1017, 
1004, 896, 875, 831, 810, 788, 773, 758, 731, 717, 704, 675, 660, 635, 624, 615 cm
-1
; 
HRMS (ESI) m/z calcd for [M+H]
+









H NMR (500 MHz, CDCl3) δ = 8.49-8.44 (m, 1 H), 8.01-7.95 (m, 1 H), 
7.79-7.73 (m, 1 H), 7.71-7.65 (m, 1 H), 7.42-7.36 (m, 3 H), 7.35-7.28 (m, 2 H), 6.88 
(d, J = 8.5 Hz, 2 H), 6.64 (d, J = 8.5 Hz, 2 H), 4.41 (s, 2 H), 3.67 (s, 3 H), 2.89 (s, 3 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 159.6 (s), 150.4 (s), 141.9 (s), 140.9 (s), 136.8 
(s), 131.9 (d), 130.8 (d), 130.6 (d), 130.5 (d), 129.8 (d), 129.6 (d), 128.5 (s), 128.4 (d), 
126.2 (s), 119.6 (d), 114.1 (d), 55.3 (q), 53.8 (t), 41.4 (q) ppm; IR (ATR): ṽ = 2933, 
2837, 1723, 1612, 1576, 1513, 1483, 1454, 1402, 1337, 1247, 1177, 1150, 1112, 1028, 
953, 893, 865, 808, 784, 765, 722, 698, 665, 651, 620 cm
-1
; HRMS (ESI) m/z calcd 
for [M+H]
+
: 436.1326; found: 436.1323. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.49-8.45 (m, 1 H), 7.96-7.92 (m, 1 H), 7.81-7.75 (m, 
1 H), 7.73-7.67 (m, 1 H), 7.56-7.51 (m, 2 H), 7.45-7.39 (m, 3 H), 7.39-7.33 (m, 2 H), 
7.13-7.02 (m, 2 H), 6.66 (d, J = 8.5 Hz, 2 H), 6.64 (d, J = 9.0 Hz, 2 H), 4.40 (s, 2 H), 
3.65 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 159.6 (s), 149.5 (s), 142.5 (s), 
141.9 (s), 137.6 (s), 136.9 (s), 131.95 (d), 131.92 (d), 131.0 (d), 130.8 (d), 130.5 (d), 
130.4 (d), 129.5 (d), 129.4 (d), 128.7 (s), 128.4 (s), 128.2 (d), 125.6 (s), 119.7 (d), 
113.9 (d), 55.2 (q), 53.6 (t) ppm; IR (ATR): ṽ = 3064, 2934, 2836, 1738, 1612, 1573, 
1513, 1500, 1482, 1452, 1401, 1390, 1349, 1293, 1279, 1247, 1162, 1087, 1068, 1009, 
963, 894, 865, 822, 803, 782, 754, 737, 698, 670, 633 cm
-1
; HRMS (ESI) m/z calcd 
for [M+H]
+
: 576.0587; found: 576.0597. 
 
 






H NMR (500 MHz, CDCl3) δ = 8.54-8.50 (m, 1 H), 8.31 (d, J = 8.5 Hz, 2 H), 8.04 (d, 
J = 9.0 Hz, 2 H), 7.86-7.82 (m, 1 H), 7.81-7.76 (m, 1 H), 7.75-7.69 (m, 1 H), 
7.65-7.60 (m, 2 H), 7.54-7.46 (m, 3 H), 3.20 (t, J = 7. 5 Hz, 2 H), 1.11-1.02 (m, 2 H), 
0.96-0.86 (m, 2 H), 0.60 (t, J = 7.5 Hz, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
150.3 (s), 149.2 (s), 145.1 (s), 141.9 (s), 141.6 (s), 137.1 (s), 132.2 (d), 131.0 (d), 
130.4 (d), 130.2 (d), 130.1 (d), 129.4 (d), 128.7 (d), 128.5 (s), 123.8 (d), 119.7 (d), 
50.4 (t), 29.7 (t), 19.8 (t), 13.5 (q) ppm; IR (ATR): ṽ = 3109, 2959, 2930, 2911, 2872, 
2850, 1736, 1606, 1575, 1524, 1499, 1480, 1463, 1446, 1404, 1347, 1312, 1293, 1240, 
1227, 1160, 1130, 1110, 1077, 1034, 1024, 978, 949, 884, 859, 778, 769, 746, 734, 
719, 700, 683, 666, 636 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+








H NMR (500 MHz, CDCl3) δ = 8.52-8.47 (m, 1 H), 7.87-7.83 (m, 1 H), 7.74-7.69 (m, 
1 H), 7.69-7.61 (m, 3 H), 7.52 (d, J = 8.0 Hz, 2 H), 7.30 (d, J = 8.0 Hz, 2 H), 7.23 (d, 
J = 8.0 Hz, 2 H), 2.84 (s, 3 H), 2.39 (s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
151.2 (s), 144.0 (s), 141.9 (s), 140.8 (s), 140.0 (s), 136.9 (s), 135.3 (s), 131.6 (d), 
130.4 (d), 130.2 (d), 129.4 (d), 129.3 (d), 129.2 (d), 128.9 (d), 125.8 (s), 119.5 (d), 
35.8 (q), 20.6 (q) ppm; IR (ATR): ṽ = 2934, 1738, 1595, 1576, 1510, 1485, 1460, 
1425, 1395, 1355, 1329, 1296, 1232, 1186, 1161, 1115, 1085, 1019, 987, 898, 866, 
816, 784, 767, 733, 716, 703, 675, 646, 616 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 
420.1376; found: 420.1379. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.52-8.47 (m, 1 H), 7.87-7.84 (m, 1 H), 7.77-7.72 (m, 
1 H), 7.71-7.66 (m, 1 H), 7.66-7.59 (m, 4 H), 7.27-7.22 (m, 2 H), 7.22-7.15 (m, 2 H), 
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2.86 (s, 3 H), 2.40 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 163.4 (J = 249 Hz, 
s), 151.1 (s), 144.2 (s), 142.0 (s), 140.0 (s), 136.9 (s), 134.9 (s), 132.6 (J = 8.7 Hz, d), 
131.9 (d), 130.7 (d), 129.5 (d), 129.4 (d), 129.0 (d), 124.8 (J = 3.8 Hz, s), 119.5 (d), 
115.8 (J = 21.8 Hz, d), 36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2926, 1600, 1577, 1535, 
1510, 1483, 1451, 1428, 1395, 1345, 1295, 1231, 1186, 1161, 1117, 1084, 1019, 1003, 
903, 874, 834, 812, 771, 732, 706, 666, 643, 616 cm
-1
; HRMS (ESI) m/z calcd for 
[M+H]
+
: 424.1126; found: 424.1125. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.53-8.48 (m, 1 H), 7.91-7.87 (m, 1 H), 
7.80-7.68 (m, 6 H), 7.50 (d, J = 8.0 Hz, 2 H), 7.21 (d, J = 8.0 Hz, 2 H), 2.91 (s, 3 H), 
2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 150.7 (s), 144.4 (s), 142.3 (s), 
139.7 (s), 136.8 (s), 134.5 (s), 132.9 (J = 1.3 Hz, s), 132.2 (d), 131.6 (J = 31.8 Hz, s), 
131.1 (d), 130.8 (d), 129.6 (d), 129.4 (d), 128.8 (d), 128.5 (J = 283 Hz, s), 125.4 (J = 
3.7 Hz, d), 119.5 (d), 36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ = 3066, 2363, 1664, 1617, 
1597, 1574, 1518, 1484, 1450, 1408, 1397, 1352, 1321, 1236, 1187, 1164, 1124, 1091, 
1075, 1063, 1019, 990, 901, 871, 827, 816, 770, 741, 732, 698, 674, 656, 646, 622 
cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 474.1094; found: 474.1093. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.52-8.47 (m, 1 H), 7.88-7.84 (m, 1 H), 
7.75-7.69 (m, 1 H), 7.69-7.60 (m, 3 H), 7.59-7.54 (m, 2 H), 7.53-7.48 (m, 2 H), 
7.25-7.20 (m, 2 H), 2.83 (s, 3 H), 2.38 (s, 3 H), 1.32 (s, 9 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 152.9 (s), 151.2 (s), 144.0 (s), 141.8 (s), 140.7 (s), 136.9 (s), 135.3 
(s), 131.6 (d), 130.4 (d), 130.0 (d), 129.4 (d), 129.3 (d), 129.0 (d), 125.7 (s), 125.5 (d), 
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119.5 (d), 36.9 (q), 34.9 (s), 31.3 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2958, 1734, 1599, 
1577, 1540, 1509, 1484, 1453, 1393, 1362, 1346, 1300, 1240, 1202, 1187, 1160, 1131, 
1108, 1084, 1016, 1003, 896, 875, 831, 810, 788, 773, 758, 730, 717, 704, 675, 660, 
635, 624, 615 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 462.1846; found: 462.1846. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.52-8.48 (m, 1 H), 7.89-7.85 (m, 1 H), 7.78-7.73 (m, 
1 H), 7.73-7.67 (m, 1 H), 7.62-7.56 (m, 3 H), 7.55-7.50 (m, 1 H), 7.45-7.40 (m, 2 H), 
7.26-7.21 (m, 2 H), 2.89 (s, 3 H), 2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
150.9 (s), 144.2 (s), 142.1 (s), 139.7 (s), 136.9 (s), 134.7 (s), 134.3 (s), 132.1 (d), 
130.8 (d), 130.7 (s), 130.4 (d), 130.0 (d), 129.9 (d), 129.6 (d), 129.4 (d), 128.9 (d), 
128.8 (d), 119.5 (d), 37.0 (q), 21.7 (q) ppm; IR (ATR): ṽ = 3068, 2929, 1724, 1597, 
1576, 1534, 1490, 1450, 1397, 1346, 1292, 1263, 1236, 1187, 1161, 1117, 1085, 999, 
873, 806, 774, 752, 728, 691, 667, 617 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 
440.0830; found: 440.0827. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.55-8.50 (m, 1 H), 7.92-7.88 (m, 1 H), 
7.81-7.74 (m, 1 H), 7.73-7.59 (m, 5 H), 7.53-7.47 (m, 1 H), 7.39-7.33 (m, 1 H), 
7.26-7.22 (m, 2 H), 2.94 (s, 3 H), 2.40 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
151.1 (s), 144.2 (s), 142.5 (s), 140.8 (s), 136.8 (s), 134.8 (s), 133.3 (d), 132.6 (d), 
132.1 (d), 131.3 (d), 130.9 (s), 130.6 (d), 129.6 (d), 129.4 (d), 129.0 (d), 127.9 (d), 
123.8 (s), 119.6 (d), 37.0 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2923, 2854, 1713, 1661, 
1596, 1575, 1536, 1492, 1466, 1449, 1399, 1353, 1333, 1303, 1260, 1236, 1157, 1119, 
1084, 1047, 1019, 1001, 966, 867, 812, 762, 719, 704, 665, 615 cm
-1
; HRMS (ESI) 
m/z calcd for [M+H]
+








H NMR (500 MHz, CDCl3) δ = 8.52-8.47 (m, 1 H), 8.17-8.13 (m, 2 H), 
8.01-7.96 (m, 1 H), 7.81-7.77 (m, 1 H), 7.75-7.66 (m, 3 H), 3.89 (s, 3 H), 3.15 (s, 3 H), 
2.91 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 166.5 (s), 150.9 (s), 142.1 (s), 
139.2 (s), 136.9 (s), 133.1 (s), 132.3 (d), 131.3 (s), 130.8 (d), 130.5 (d), 129.8 (d), 
129.6 (d), 119.5 (d), 52.4 (q), 39.2 (q), 37.1 (q) ppm; IR (ATR): ṽ = 2931, 1720, 1611, 
1578, 1537, 1511, 1484, 1452, 1435, 1395, 1340, 1276, 1193, 1157, 1110, 1085, 1021, 
1005, 963, 907, 878, 853, 825, 799, 767, 747, 723, 701, 666, 651, 620 cm
-1
; HRMS 
(ESI) m/z calcd for [M+H]
+
: 338.0962; found: 338.0959. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.51-8.46 (m, 1 H), 7.98-7.94 (m, 1 H), 
7.80-7.75 (m, 1 H), 7.73-7.68 (m, 1 H), 7.62 (d, J = 8.5 Hz, 2 H), 7.51 (d, J = 8.5 Hz, 
2 H), 3.19 (s, 3 H), 2.91 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 151.0 (s), 
142.0 (s), 139.0 (s), 136.9 (s), 132.2 (d), 132.0 (d), 131.9 (d), 130.8 (d), 129.5 (d), 
127.3 (s), 124.6 (s), 119.5 (d), 39.3 (q), 37.1 (q) ppm; IR (ATR): ṽ = 2930, 1717, 
1578, 1537, 1495, 1481, 1454, 1405, 1390, 1338, 1294, 1242, 1200, 1156, 1115, 1085, 
1070, 1014, 1002, 963, 904, 871, 822, 798, 766, 748, 728, 707, 665, 651, 620 cm
-1
; 
HRMS (ESI) m/z calcd for [M+H]
+
: 408.0012; found: 408.0010. 
 
  




H NMR (500 MHz, CDCl3) δ = 8.52-8.48 (m, 1 H), 7.96-7.92 (m, 1 H), 
120 
 
7.77-7.72 (m, 1 H), 7.71-7.65 (m, 1 H), 7.61 (d, J = 8.5 Hz, 2 H), 7.00 (d, J = 9.0 Hz, 
2 H), 3.81 (s, 3 H), 3.20 (s, 3 H), 2.88 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
160.8 (s), 151.4 (s), 141.6 (s), 139.5 (s), 136.9 (s), 131.8 (d), 131.7 (d), 130.5 (d), 
129.4 (d), 120.1 (s), 119.5 (d), 114.2 (d), 55.4 (q), 39.7 (q), 36.9 (q) ppm; IR (ATR): ṽ 
= 2932, 2840, 1716, 1607, 1578, 1483, 1455, 1396, 1337, 1303, 1291, 1250, 1178, 
1155, 1113, 1085, 1023, 1001, 964, 906, 873, 831, 804, 767, 747, 667, 645, 631, 616 
cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 360.1013; found: 360.1012. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.54-8.49 (m, 1 H), 7.99-7.93 (m, 1 H), 
7.79-7.74 (m, 1 H), 7.73-7.66 (m, 5 H), 7.62-7.57 (m, 2 H), 7.43-7.37 (m, 2 H), 
7.34-7.28 (m, 1 H), 3.18 (s, 3 H), 2.93 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
151.3 (s), 142.7 (s), 141.9 (s), 140.3 (s), 139.6 (s), 137.0 (s), 132.0 (d), 130.7 (d), 
130.6 (d), 129.5 (d), 128.9 (d), 127.9 (d), 127.3 (d), 127.27 (d), 127.22 (s), 119.6 (d), 
39.6 (q), 37.1 (q) ppm; IR (ATR): ṽ = 2926, 1725, 1602, 1579, 1519, 1483, 1450, 
1397, 1335, 1299, 1236, 1200, 1157, 1144, 1114, 1084, 1027, 1005, 965, 909, 875, 
837, 765, 747, 731, 695, 663, 649, 637, 620 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 
406.1220; found: 406.1221. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.51-8.47 (m, 1 H), 7.86-7.82 (m, 1 H), 
7.74-7.63 (m, 4 H), 7.27-7.23 (m, 2 H), 7.17-7.10 (m, 2 H), 6.99-6.96 (m, 1 H), 
4.31-4.21 (m, 4 H), 2.87 (s, 3 H), 2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
151.2 (s), 145.0 (s), 144.0 (s), 143.6 (s), 141.8 (s), 140.2 (s), 136.9 (s), 135.4 (s), 
131.6 (d), 130.4 (d), 129.4 (d), 129.3 (d), 128.9 (d), 123.8 (d), 121.5 (s), 119.6 (d), 
119.5 (d), 117.6 (d), 37.0 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2975, 2872, 1717, 1599, 
121 
 
1577, 1540, 1508, 1483, 1459, 1448, 1430, 1398, 1367, 1343, 1304, 1281, 1249, 1186, 
1158, 1139, 1126, 1116, 1087, 1062, 1003, 937, 915, 885, 836, 810, 767, 748, 720, 
705, 687, 663, 618 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+








H NMR (500 MHz, CDCl3) δ = 8.50-8.45 (m, 1 H), 8.01-7.98 (m, 1 H), 7.79-7.71 (m, 
2 H), 7.71-7.64 (m, 1 H), 7.64-7.58 (m, 2 H), 7.48-7.41 (m, 1 H), 7.19-7.13 (m, 1 H), 
7.12-7.04 (m, 4 H), 6.96-6.90 (m, 2 H), 4.47 (s, 2 H), 3.87 (s, 3 H), 2.88 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 158.9 (s), 150.5 (s), 141.8 (s), 141.0 (s), 136.9 (s), 
135.1 (s), 134.4 (s), 131.9 (d), 130.6 (d), 130.4 (d), 130.3 (d), 129.6 (d), 129.5 (d), 
128.7 (d), 128.4 (d), 128.3 (s), 127.8 (d), 126.8 (d), 123.4 (s), 119.5 (d), 119.1 (d), 
105.8 (d), 55.4 (q), 54.1 (t), 41.3 (q) ppm; IR (ATR): ṽ = 3034, 2929, 1738, 1632, 
1650, 1573, 1492, 1479, 1451, 1411, 1342, 1287, 1272, 1209, 1155, 1140, 1110, 1060, 
1022, 950, 919, 895, 856, 835, 810, 772, 758, 740, 721, 697, 680, 668, 644, 628 cm
-1
; 
HRMS (ESI) m/z calcd for [M+H]
+
: 486.1482; found: 486.1480. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.50-8.45 (m, 1 H), 7.94-7.89 (m, 1 H), 
7.79-7.73 (m, 1 H), 7.71-7.65 (m, 1 H), 7.52 (d, J = 8.5 Hz, 2 H), 7.45-7.38 (m, 1 H), 
7.21 (d, J = 8.0 Hz, 2 H), 7.14-7.07 (m, 2 H), 7.06-6.91 (m, 4 H), 6.87-6.81 (m, 2 H), 
4.64 (d, J = 8.5 Hz, 1 H), 4.41 (d, J = 9.0 Hz, 1 H), 2.40 (s, 3 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 161.3 (J = 251 Hz, s), 150.1 (s), 144.3 (s), 142.2 (s), 139.2 (s), 
136.7 (s), 135.1 (s), 134.0 (s), 132.1 (d), 131.8 (J = 2.7 Hz, d), 131.7 (J = 8.7 Hz, d), 
130.7 (d), 129.6 (d), 129.5 (d), 129.4 (d), 129.0 (d), 128.5 (d), 128.2 (d), 123.8 (J = 
3.7 Hz, d), 119.7 (d), 117.5 (J = 15 Hz, s), 115.5 (J = 21.6 Hz, d), 54.0 (q), 21.7 (q) 
122 
 
ppm; IR (ATR): ṽ = 3065, 2927, 1734, 1618, 1598, 1577, 1533, 1498, 1481, 1455, 
1404, 1354, 1304, 1264, 1230, 1186, 1162, 1118, 1089, 1028, 965, 916, 872, 814, 759, 
731, 701, 664, 651, 626 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+








H NMR (500 MHz, CD2Cl2) δ = 8.73-8.71 (m, 1 H), 8.52-8.48 (m, 1 H), 7.28-7.61 
(m, 6 H), 7.33-7.26 (m, 3 H), 3.11 (s, 3 H), 2.42 (s, 3 H) ppm; 
13
C NMR (125 MHz, 
CDCl3) δ = 149.2 (s), 144.4 (s), 138.9 (s), 135.8 (s), 135.1 (s), 134.4 (s), 132.9 (d), 
131.03 (d), 131.00 (d), 130.9 (d), 129.4 (d), 129.3 (d), 128.9 (d), 128.4 (s), 127.1 (d), 
119.3 (d), 37.0 (q), 21.7 (q) ppm; IR (ATR): ṽ = 3077, 2909, 1738, 1597, 1583, 1524, 
1504, 1482, 1451, 1415, 1393, 1363, 1344, 1333, 1304, 1281, 1244, 1223, 1185, 1166, 
1114, 1088, 1075, 1046, 1017, 956, 903, 863, 841, 812, 781, 759, 747, 719, 704, 668, 
651, 617 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 412.0784; found: 412.0790. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.47-8.42 (m, 1 H), 7.90-7.85 (m, 1 H), 7.82-7.78 (m, 
1 H), 7.76-7.70 (m, 1 H), 7.68-7.61 (m, 3 H), 7.33-7.29 (m, 1 H), 7.28-7.24 (m, 1 H), 
7.23-7.18 (m, 2 H), 7.10-7.05 (m, 1 H), 7.02-6.96 (m, 2 H), 6.79-6.72 (m, 2 H), 2.38 
(s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 150.9 (s), 144.0 (s), 141.3 (s), 138.2 
(s), 136.7 (s), 136.6 (s), 136.2 (s), 131.7 (d), 130.4 (d), 129.8 (d), 129.4 (d), 128.9 (d), 
128.8 (d), 128.7 (d), 128.5 (d), 128.1 (d), 127.4 (s), 125.0 (d), 119.4 (d), 21.7 (q) ppm; 
IR (ATR): ṽ = 3104, 2959, 2925, 1734, 1596, 1578, 1522, 1484, 1451, 1428, 1346, 
1308, 1280, 1237, 1211, 1186, 1165, 1138, 1111, 1089, 1056, 1017, 949, 908, 846, 
811, 767, 717, 694, 680, 661, 634, 619, 610 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 




Compound 3v: Yield 33 %, Rf = 0.12 (PE/EA = 4:1), colorless oil; 
1
H NMR (500 
MHz, CDCl3) δ = 8.86-8.80 (m, 1 H), 8.51-8.45 (m, 1 H), 7.96-7.91 (m, 1 H), 
7.74-7.67 (m, 2 H), 7.51-7.46 (m, 2 H), 7.37-7.25 (m, 4 H), 7.07 (d, J = 8.5 Hz, 2 H), 
6.58 (d, J = 8.5 Hz, 2 H), 4.84 (s, 2 H), 3.55 (s, 3 H), 3.15 (s, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 159.6 (s), 150.5 (s), 139.9 (d), 138.7 (s), 137.5 (s), 137.3 (s), 
131.0 (d), 130.97 (s), 130.95 (d), 130.8 (d), 129.4 (d), 129.3 (d), 128.8 (d), 127.9 (d), 
126.0 (s), 119.0 (d), 115.8 (d), 114.1 (d), 55.1 (q), 54.8 (t), 38.7 (q) ppm; IR (ATR): ṽ 
= 2955, 1612, 1576, 1513, 1441, 1409, 1396, 1342, 1248, 1177, 1154, 1113, 1032, 
965, 947, 901, 864, 813, 756, 689, 652, 627 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 
462.1482; found: 462.1480. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.21 (s, 1 H), 7.73 (s, 1 H), 7.40-7.33 (m, 3 H), 
7.32-7.25 (m, 2 H), 6.85 (d, J = 8.5 Hz, 2 H), 6.62 (d, J = 8.5 Hz, 2 H), 4.38 (s, 2 H), 
3.67 (s, 3 H), 2.91 (s, 3 H), 2.43 (s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 159.5 
(s), 149.3 (s), 142.7 (s), 141.8 (s), 140.7 (s), 140.3 (s), 135.1 (s), 130.8 (d), 130.5 (d), 
129.5 (d), 128.8 (d), 128.7 (s), 128.2 (d), 126.3 (s), 118.6 (d), 114.0 (d), 55.3 (q), 53.8 
(t), 41.1 (q), 20.6 (q), 20.2 (q) ppm; IR (ATR): ṽ = 2994, 2919, 2835, 1698, 1613, 
1570, 1513, 1484, 1462, 1423, 1399, 1353, 1337, 1320, 1267, 1248, 1231, 1150, 1097, 
1075, 1026, 1011, 976, 952, 937, 888, 865, 854, 827, 776, 767, 755, 744, 691, 678, 
666, 651, 622 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+









H NMR (500 MHz, CDCl3) δ = 7.79 (s, 1 H), 7.39-7.33 (m, 3 H), 7.30-7.22 (m, 3 H), 
6.85 (d, J = 9.0 Hz, 2 H), 6.63 (d, J = 8.5 Hz, 2 H), 4.40 (s, 2 H), 4.02 (s, 3 H), 3.98 (s, 
3 H), 3.68 (s, 3 H), 2.90 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 159.5 (s), 
154.2 (s), 153.7 (s), 148.0 (s), 139.7 (s), 139.0 (s), 132.6 (s), 130.8 (d), 130.5 (d), 
129.4 (d), 128.8 (s), 128.2 (d), 126.3 (s), 114.0 (d), 107.3 (d), 98.0 (d), 56.8 (q), 56.7 
(q), 55.3 (q), 53.7 (t), 41.0 (q) ppm; IR (ATR): ṽ = 2942, 2836, 1716, 1613, 1581, 
1499, 1456, 1434, 1387, 1322, 1285, 1237, 1212, 1174, 1150, 1112, 1069, 1028, 1001, 
955, 903, 831, 771, 748, 701, 669, 654, 612 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 
496.1537; found: 496.1536. 
 
 
Compound 3y: Rf = 0.24 (PE/EA = 4:1), total yield 75 % (mixture ratio = 5:4), 
yellow soild; 
1
H NMR (500 MHz, CDCl3) δ = 8.64 (s, 0.41 H), 8.36-8.30 (m, 0.52 H), 
8.18 (s, 0.50 H), 7.84 (s, 1 H), 7.77-7.71 (m, 0.56 H), 7.44-7.37 (m, 3 H), 7.37-7.27 
(m, 2 H), 6.91-6.84 (m, 2 H), 6.69-6.60 (m, 2 H), 4.44-4.33 (m, 2 H), 3.71-3.62 (m, 3 
H), 2.91-2.80 (m, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 159.6 (s), 151.5 (s), 
150.7 (s), 142.5 (s), 141.3 (s), 141.0 (s), 140.6 (s), 137.3 (s), 135.8 (s), 135.6 (d), 
133.8 (d), 131.7 (d), 130.84 (d), 130.80 (d), 130.7 (d), 130.43 (d), 130.41 (d), 130.0 
(d), 128.7 (s), 128.48 (d), 128.47 (d), 128.1 (s), 128.0 (s), 126.4 (s), 126.1 (s), 125.0 
(s), 122.3 (d), 121.1 (d), 114.1 (d), 114.0 (d), 55.3 (q), 53.7 (t), 41.6 (q), 41.5 (q) ppm; 
IR (ATR): ṽ = 2933, 1612, 1567, 1513, 1476, 1459, 1401, 1340, 1247, 1216, 1178, 
1150, 1117, 1028, 954, 912, 874, 822, 779, 757, 723, 697, 662, 639 cm
-1
; HRMS (ESI) 
m/z calcd for [M+H]
+




Compound 3z: Rf = 0.14 (PE/EA = 4:1), total yield 84 % (mixture ratio = 2:1), 
yellow soild; 
1
H NMR (500 MHz, CDCl3) δ = 8.56 (s, 0.33 H), 8.44-8.40 (m, 0.65 H), 
8.04 (s, 0.69 H), 8.00-7.96 (m, 0.36 H), 7.94-7.86 (m, 1 H), 7.47-7.41 (m, 2 H), 
7.40-7.27 (m, 4 H), 7.22-7.15 (m, 2 H), 7.14-7.08 (m, 1 H), 7.06-6.92 (m, 4 H), 
6.77-6.70 (m, 2 H), 6.61-6.50 (m, 2 H), 4.49 (s, 2 H), 3.84-3.74 (m, 6 H), 2.41-2.35 
(m, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 161.5 (s), 161.4 (s), 157.76 (s), 
157.71 (s), 149.4 (s), 148.7 (s), 144.2 (s), 142.7 (s), 142.6 (s), 142.3 (s), 142.2 (s), 
141.7 (s), 140.8 (s), 136.8 (s), 135.4 (s), 135.39 (s), 135.37 (s), 134.1 (s), 134.0 (d), 
133.1 (d), 131.7 (d), 131.6 (d), 130.7 (d), 130.6 (d), 129.9 (d), 129.8 (d), 129.4 (d), 
129.23 (d), 129.21 (d), 129.17 (s), 129.12 (s), 129.08 (d), 128.8 (d), 128.6 (d), 128.5 
(d), 128.2 (d), 128.1 (d), 128.0 (d), 121.3 (s), 121.1 (s), 118.8 (d), 118.7 (d), 105.22 
(d), 105.20 (d), 99.2 (d), 99.1 (d), 55.7 (q), 55.6 (q), 55.5 (q), 53.8 (t), 53.7 (t), 21.7 (q) 
ppm; IR (ATR): ṽ = 2938, 1678, 1608, 1578, 1511, 1496, 1461, 1411, 1347, 1302, 
1265, 1209, 1185, 1160, 1120, 1090, 1028, 965, 938, 867, 807, 779, 762, 732, 698, 
663, 624 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 618.2057; found: 618.2055. 
 
 
Compound 3aa: Rf = 0.5 (pure EA), total yield 96 % (C7: C6 = 5:1), colourless soild; 
1
H NMR (500 MHz, CDCl3) δ = 8.85-8.80 (m, 0.17 H), 8.45-8.40 (m, 0.84 H), 
8.26-8.21 (m, 0.85 H), 8.09-8.03 (m, 1 H), 7.99-7.94 (m, 0.18 H), 7.42-7.24 (m, 5 H), 
6.91-6.82 (m, 2 H), 6.67-6.60 (m, 2 H),4.43-4.35 (m, 2 H), 4.00-3.88 (m, 2 H), 3.67 (s, 
3 H), 2.95-2.85 (m, 3 H), 2.68-2.59 (m, 2 H), 2.24-2.12 (m, 2 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 175.0 (s), 159.7 (s), 150.9 (s), 149.0 (s), 142.6 (s), 142.4 (s), 142.2 
(s), 139.9 (s), 138.7 (s), 136.8 (s), 133.2 (s), 130.85 (d), 130.81 (d), 130.5 (d), 130.4 
(d), 130.0 (d), 129.7 (d), 128.5 (s), 128.4 (s), 128.3 (d), 128.2 (d), 126.2 (s), 126.1 (s), 
125.3 (d), 123.1 (d), 120.1 (d), 116.7 (d), 114.1 (d), 114.0 (d), 105.9 (d), 55.3 (q), 53.8 
126 
 
(t), 53.7 (t), 48.8 (t), 48.7 (t), 41.5 (q), 41.1 (q), 33.0 (t), 32.9 (t), 17.9 (t), 17.7 (t) ppm; 
IR (ATR): ṽ = 2960, 1703, 1612, 1578, 1513, 1471, 1379, 1332, 1276, 1248, 1214, 
1178, 1150, 1123, 1028, 954, 868, 825, 779, 756, 731, 699, 669, 625 cm
-1
; HRMS 
(ESI) m/z calcd for [M+H]
+
: 503.1748; found: 503.1744. 
 
 
Compound 3ab: Rf = 0.08 (PE/EA = 4:1), total yield 97 % (C7: C6 = 7:1), colourless 
soild; 
1
H NMR (500 MHz, CDCl3) δ = 8.38-8.33 (m, 0.89 H), 7.89-7.85 (m, 0.12 H), 
7.80-7.78 (m, 0.10 H), 7.40-7.21 (m, 7 H), 6.91-6.82 (m, 2 H), 6.77-6.59 (m, 2 H), 
4.40 (s, 2 H), 3.95-3.87 (m, 3 H), 3.68 (s, 3 H), 2.93-2.83 (m, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 162.4 (s), 159.6 (s), 150.6 (s), 143.9 (s), 139.2 (s), 132.0 (s), 
130.8 (d), 130.6 (d), 129.6 (d), 128.6 (s), 128.3 (d), 126.3 (s), 123.1 (d), 120.8 (d), 
114.0 (d), 107.4 (d), 56.1 (q), 55.3 (q), 53.7 (t), 41.4 (q) ppm; IR (ATR): ṽ = 2966, 
2930, 1611, 1581, 1514, 1470, 1414, 1380, 1350, 1336, 1316, 1257, 1216, 1178, 1147, 
1105, 1047, 1024, 956, 866, 850, 828, 771, 754, 738, 720, 699, 659, 634, 620 cm
-1
; 
HRMS (ESI) m/z calcd for [M+H]
+
: 450.1482; found: 450.1481. 
 
 




H NMR (500 MHz, CDCl3) δ = 7.64-7.56 (m, 1 H), 7.54-7.48 (m, 1 H), 
7.45-7.39 (m, 2 H), 7.39-7.33 (m, 1 H), 7.32-7.25 (m, 2 H), 7.21-7.16 (m, 2 H), 
7.13-7.08 (m, 1 H), 7.04-6.98 (m, 3 H), 6.98-6.90 (m, 2 H), 6.74-6.67 (m, 2 H), 4.44 
(s, 2 H), 3.89 (s, 3 H), 2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 153.5 (s), 
149.3 (s), 144.7 (s), 144.2 (s), 144.1 (s), 135.5 (s), 134.1 (s), 131.3 (d), 130.7 (d), 
129.8 (d), 129.6 (s), 129.3 (d), 129.04 (d), 129.02 (d), 128.9 (s), 128.4 (d), 128.1 (d), 
127.9 (d), 121.7 (d), 110.8 (d), 57.1 (q), 53.4 (t), 21.7 (q) ppm; IR (ATR): ṽ = 3062, 
2930, 1716, 1595, 1500, 1455, 1364, 1334, 1266, 1236, 1168, 1087, 1035, 1023, 972, 
944, 869, 843, 813, 770, 737, 697, 665 cm
-1





512.1639; found: 512.1636. 
 
 




H NMR (500 MHz, CDCl3) δ = 7.58 (s, 1 H), 7.38-7.32 (m, 3 H), 7.26-7.16 (m, 3 
H), 6.89 (d, J = 8.5 Hz, 2 H), 6.66 (d, J = 8.5 Hz, 2 H), 4.40 (s, 2 H), 3.68 (s, 3 H), 
2.91 (s, 3 H), 2.85 (s, 3 H), 2.43 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 159.5 
(s), 149.6 (s), 144.0 (s), 141.7 (s), 141.1 (s), 135.4 (d), 134.8 (s), 133.1 (s), 130.8 (d), 
130.4 (d), 129.4 (d), 129.0 (s), 128.4 (d), 127.1 (d), 126.4 (s), 114.0 (d), 55.3 (q), 53.6 
(t), 41.1 (q), 24.2 (q), 21.3 (q) ppm; IR (ATR): ṽ = 2932, 2838, 1714, 1612, 1581, 
1513, 1461, 1342, 1284, 1248, 1152, 1113, 1075, 1031, 947, 926, 839, 765, 699, 656, 
640, 618 cm
-1
; HRMS (ESI) m/z calcd for [M+H]
+
: 464.1639; found: 464.1639. 
 
 




H NMR (500 MHz, CDCl3) δ = 12.4 (s, 1 H), 7.80-7.76 (m, 1 H), 7.70-7.65 (m, 
2 H), 7.62-7.55 (m, 1 H), 7.55-7.50 (m, 1 H), 7.45-7.40 (m, 1 H), 7.37-7.30 (m, 4 H), 
7.20-7.11 (m, 5 H), 7.06-7.00 (m, 2 H), 6.94-6.86 (m, 2 H), 6.73-6.66 (m, 2 H), 4.41 
(s, 2 H), 2.38 (s, 3 H), 2.28 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 149.4 (s), 
144.6 (s), 144.2 (s), 143.5 (s), 142.9 (s), 136.2 (s), 134.9 (s), 133.7 (s), 133.1 (s), 
131.9 (d), 130.4 (d), 129.8 (d), 129.7 (d), 129.4 (d), 128.9 (d), 128.5 (d), 128.3 (d), 
128.2 (d), 128.0 (s), 127.4 (d), 126.4 (s), 123.6 (d), 118.2 (d), 53.5 (t), 21.7 (q), 21.6 
(q) ppm; IR (ATR): ṽ = 1580, 1532, 1496, 1446, 1410, 1345, 1292, 1185, 1162, 1122, 
1088, 1023, 957, 889, 855, 811, 756, 726, 698, 659 cm
-1
; HRMS (ESI) m/z calcd for 
[M+Na]
+








H NMR (500 MHz, CDCl3) δ = 8.33-8.27 (m, 1 H), 7.94-7.88 (m, 1 H), 
7.42-7.36 (m, 3 H), 7.35-7.28 (m, 3 H), 7.21-7.16 (m, 2 H), 7.15-7.10 (m, 1 H), 
7.06-6.92 (m, 4 H), 6.75-6.69 (m, 2 H), 4.45 (s, 2 H), 2.38 (s, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 149.2 (s), 145.4 (d), 144.3 (s), 143.4 (s), 142.5 (s), 135.6 (s), 
135.2 (s), 133.9 (s), 132.1 (d), 130.7 (d), 130.6 (d), 129.8 (d), 129.4 (d), 129.3 (d), 
128.9 (d), 128.8 (s), 128.5 (d), 128.3 (d), 128.2 (d), 80.6 (s), 53.5 (t), 21.7 (q) ppm; IR 
(ATR): ṽ = 1596, 1548, 1522, 1497, 1475, 1446, 1417, 1387, 1337, 1266, 1185, 1160, 
1088, 1025, 968, 907, 862, 804, 772, 756, 722, 696, 664, 629 cm
-1
; HRMS (ESI) m/z 
calcd for [M+Na]
+
: 630.0319; found: 630.0328. 
 
 




H NMR (300 MHz, CDCl3) δ = 8.11-8.05 (m, 1 H), 7.96-7.90 (m, 2 H), 
7.85-7.79 (m, 1 H), 7.72-7.60 (m, 4 H), 7.51-7.41 (m, 3 H), 7.25-7.19 (m, 2 H), 2.99 
(s, 3 H), 2.37 (s, 3 H) ppm; 
13
C NMR (75 MHz, CDCl3) δ = 153.2 (s), 148.2 (s), 143.9 
(s), 141.6 (s), 140.1 (s), 137.4 (s), 135.0 (s), 130.4 (d), 130.1 (d), 129.4 (d), 129.3 (d), 
129.2 (d), 129.0 (d), 128.6 (d), 128.3 (d), 36.8 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3058, 
3043, 3028, 1597, 1546, 1488, 1468, 1444, 1395, 1351, 1304, 1224, 1185, 1160, 1087, 
1067, 1032, 1003, 995, 917, 851, 815, 771, 745, 694, 670, 640, 612 cm
-1
; HRMS (EI) 
m/z calcd for C22H19N3O2S: 389.1198; found: 389.1167. 
 
 






H NMR (500 MHz, CDCl3) δ = 8.07-8.04 (m, 1 H), 7.86-7.82 (m, 2 H), 
7.81-7.78 (m, 1 H), 7.70-7.60 (m, 4 H), 7.28-7.20 (m, 4 H), 2.98 (s, 3 H), 2.37 (s, 6 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 152.0 (s), 147.1 (s), 142.8 (s), 140.5 (s), 138.8 
(s), 138.5 (s), 133.9 (s), 133.4 (s), 129.3 (d), 128.9 (d), 128.3 (d), 128.2 (d), 128.1 (d), 
128.08 (d), 128.07 (d), 127.9 (d), 35.8 (q), 20.6 (q), 20.4 (q) ppm; IR (ATR): ṽ = 3055, 
2961, 1693, 1598, 1453, 1392, 1353, 1304, 1259, 1224, 1183, 1162, 1088, 1069, 1024, 
998, 916, 853, 825, 814, 802, 769, 751, 705, 676, 648, 629, 611 cm
-1
; HRMS (EI) m/z 
calcd for C23H21N3O2S: 403.1354; found: 403.1329. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.07-8.03 (m, 1 H), 7.99-7.93 (m, 2 H), 7.81-7.76 (m, 
1 H), 7.72-7.61 (m, 4 H), 7.27-7.22 (m, 2 H), 7.03-6.97 (m, 2 H), 3.83 (s, 3 H), 3.00 (s, 
3 H), 2.40 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 160.8 (s), 152.5 (s), 148.1 
(s), 143.9 (s), 141.6 (s), 139.8 (s), 135.0 (s), 130.8 (d), 130.4 (d), 129.8 (d), 129.6 (s), 
129.3 (d), 129.1 (d), 128.2 (d), 114.2 (d), 55.4 (q), 36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ 
= 2962, 2934, 1611, 1579, 1516, 1484, 1465, 1420, 1392, 1348, 1293, 1255, 1224, 
1172, 1159, 1111, 1087, 1072, 1031, 995, 915, 853, 830, 812, 802, 774, 755, 706, 674, 
646, 624, 611 cm
-1
; HRMS (ESI) m/z calcd for [C23H21N3O3S+H]
+








H NMR (500 MHz, CDCl3) δ = 8.07-8.04 (m, 1 H), 7.98-7.93 (m, 2 H), 7.81-7.77 (m, 
1 H), 7.72-7.63 (m, 2 H), 7.59 (d, J = 8.0 Hz, 2 H), 7.22 (d, J = 8.0 Hz, 2 H), 
7.16-7.11 (m, 2 H), 3.01 (s, 3 H), 2.37 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
163.6 (J = 248.2 Hz, s), 152.2 (s), 148.0 (s), 144.1 (s), 141.5 (s), 140.1 (s), 134.6 (s), 
130 
 
133.5 (J = 3.4 Hz, s), 131.4 (J = 8.5 Hz, d), 130.6 (d), 130.3 (d), 129.3 (d), 129.1 (d), 
129.0 (d), 128.4 (d), 115.7 (J = 21 Hz, d), 36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ = 3067, 
1914, 1693, 1598, 1510, 1482, 1396, 1347, 1303, 1217, 1156, 1131, 1105, 1085, 1001, 
918, 866, 841, 808, 772, 752, 719, 705, 679, 650, 624 cm
-1
; HRMS (EI) m/z calcd for 
C22H18FN3O2S: 407.1104; found: 407.1098. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.11-8.08 (m, 1 H), 8.07-8.02 (m, 2 H), 
7.85-7.82 (m, 1 H), 7.76-7.68 (m, 4 H), 7.50 (d, J = 8.0 Hz, 2 H), 7.21 (d, J = 8.0 Hz, 
2 H), 3.07 (s, 3 H), 2.38 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 152.1 (s), 
147.9 (s), 144.2 (s), 141.5 (s), 141.1 (J = 1.0 Hz, s), 140.4 (s), 134.3 (s), 131.1 (J = 
31.8 Hz, s), 130.8 (d), 130.7 (d), 129.7 (d), 129.4 (d), 129.3 (d), 128.8 (d), 128.4 (d), 
126.3 (J = 273.2 Hz, s), 125.5 (J = 3.8 Hz, d), 36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ = 
1598, 1471, 1395, 1345, 1323, 1292, 1245, 1228, 1165, 1118, 1075, 1019, 998, 952, 
919, 861, 846, 817, 805, 774, 758, 732, 708, 701, 672, 648, 630, 617 cm
-1
; HRMS 
(ESI) m/z calcd for [C23H18F3N3O2S+Na]
+
: 480.0964; found: 480.0985. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.07-8.03 (m, 1 H), 7.88 (d, J = 8.5 Hz, 2 H), 
7.82-7.78 (m, 1 H), 7.68-7.59 (m, 4 H), 7.48 (d, J = 8.5 Hz, 2 H), 7.22 (d, J = 8.5 Hz, 
2 H), 2.98 (s, 3 H), 2.36 (s, 3 H), 1.31 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
153.0 (s), 152.6 (s), 148.1 (s), 143.9 (s), 141.6 (s), 139.9 (s), 135.1 (s), 134.4 (s), 
130.3 (d), 129.9 (d), 129.3 (d), 129.2 (d), 129.1 (d), 128.9 (d), 128.3 (d), 125.7 (d), 
36.9 (q), 34.8 (s), 31.4 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2961, 2870, 1739, 1694, 1599, 
1481, 1463, 1395, 1349, 1307, 1228, 1158, 1112, 1087, 1021, 998, 918, 862, 838, 811, 
131 
 
764, 735, 706, 676, 650, 633, 615 cm
-1
; HRMS (ESI) m/z calcd for 
[C26H27N3O2S+H]
+
: 446.1897; found: 446.1893. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.12-8.08 (m, 1 H), 7.92-7.82 (m, 3 H), 
7.76-7.67 (m, 2 H), 7.57 (d, J = 8.0 Hz, 2 H), 7.43-7.39 (m, 2 H), 7.23 (d, J = 8.0 Hz, 
2 H), 3.06 (s, 3 H), 2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 151.8 (s), 
144.1 (s), 141.5 (s), 140.3 (s), 139.2 (s), 134.6 (s), 134.5 (s), 130.7 (d), 130.5 (d), 
129.8 (d), 129.5 (d), 129.4 (d), 129.3 (d), 129.2 (d), 128.9 (d), 128.4 (d), 127.4 (d), 
36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2924, 2854, 1598, 1571, 1486, 1466, 1452, 
1440, 1426, 1389, 1352, 1305, 1254, 1223, 1182, 1160, 1136, 1088, 1069, 1038, 1012, 
968, 916, 855, 817, 803, 770, 744, 706, 693, 677, 664, 639, 615 cm
-1
; HRMS (ESI) 
m/z calcd for [C22H18ClN3O2S+H]
+
: 424.0881; found: 424.0876.  
 
 




H NMR (500 MHz, CDCl3) δ = 8.12-8.06 (m, 1 H), 7.85-7.81 (m, 1 H), 
7.75-7.62 (m, 6 H), 7.39-7.33 (m, 1 H), 7.28-7.20 (m, 3 H), 2.99 (s, 3 H), 2.40 (s, 3 H), 
2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 153.3 (s), 148.2 (s), 143.9 (s), 
141.5 (s), 140.1 (s), 138.4 (s), 137.2 (s), 135.1 (s), 130.4 (d), 130.3 (d), 130.1 (d), 
129.8 (d), 129.3 (d), 129.2 (d), 128.9 (d), 128.5 (d), 128.3 (d), 126.2 (d), 36.8 (q), 21.7 
(q), 21.6 (q) ppm; IR (ATR): ṽ = 3053, 3034, 2925, 1599, 1545, 1486, 1454, 1441, 
1389, 1351, 1317, 1304, 1249, 1223, 1177, 1158, 1141, 1088, 1071, 1024, 966, 918, 
870, 828, 806, 784, 770, 750, 700, 688, 670, 639, 615 cm
-1
; HRMS (ESI) m/z calcd 
for [C23H21N3O2S+Na]
+








H NMR (500 MHz, CDCl3) δ = 8.13-8.09 (m, 1 H), 7.87-7.83 (m, 1 H), 7.77-7.68 (m, 
4 H), 7.63-7.57 (m, 2 H), 7.32 (d, J = 8.5 Hz, 2 H), 7.04-7.00 (m, 1 H), 4.36-4.30 (m, 
4 H), 3.12 (s, 3 H), 2.49 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 152.2 (s), 
148.0 (s), 145.1 (s), 143.9 (s), 143.6 (s), 141.5 (s), 139.8 (s), 135.0 (s), 130.6 (s), 
130.3 (d), 129.9 (d), 129.3 (d), 129.1 (d), 129.0 (d), 128.2 (d), 122.7 (d), 118.5 (d), 
117.5 (d), 64.6 (t), 64.3 (t), 36.9 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2939, 1586, 1510, 
1484, 1464, 1432, 1392, 1344, 1304, 1285, 1255, 1225, 1175, 1156, 1129, 1087, 1063, 
1048, 1016, 933, 918, 900, 870, 835, 816, 802, 773, 758, 744, 707, 672, 651, 633, 618, 
609 cm
-1
; HRMS (ESI) m/z calcd for [C24H21N3O4S+Na]
+








H NMR (500 MHz, CDCl3) δ = 8.51-8.46 (m, 1 H), 8.16-8.11 (m, 1 H), 
8.08-8.04 (m, 1 H), 7.85-7.76 (m, 4 H), 7.75-7.69 (m, 1 H), 7.50-7.44 (m, 1 H), 
7.40-7.34 (m, 2 H), 3.18 (s, 3 H), 2.51 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
148.1 (s), 147.5 (s), 144.1 (s), 141.6 (s), 139.7 (s), 138.0 (s), 134.5 (s), 130.6 (d), 
129.8 (d), 129.3 (d), 129.2 (d), 129.1 (d), 128.8 (d), 128.5 (d), 128.2 (d), 125.7 (d), 
37.1 (q), 21.7 (q) ppm; IR (ATR): ṽ = 3116, 2923, 1598, 1537, 1482, 1463, 1429, 
1338, 1254, 1225, 1185, 1166, 1155, 1139, 1072, 1017, 903, 884, 851, 805, 789, 772, 
748, 704, 677, 651, 626 cm
-1
; HRMS (ESI) m/z calcd for [C20H17N3O2S2+H]
+
: 








H NMR (500 MHz, CDCl3) δ = 8.12-8.04 (m, 1 H), 7.97-7.86 (m, 3 H), 
7.75-7.65 (m, 2 H), 7.51-7.37 (m, 3 H), 3.24 (s, 3 H), 3.00 (s, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 152.2 (s), 148.3 (s), 141.7 (s), 139.9 (s), 136.8 (s), 130.5 (d), 
130.4 (d), 129.7 (d), 129.3 (d), 129.1 (d), 128.7 (d), 128.4 (d), 39.4 (q), 37.2 (q) ppm; 
IR (ATR): ṽ = 3062, 3030, 2931, 1738, 1563, 1544, 1483, 1445, 1395, 1345, 1250, 
1227, 1166, 1149, 1088, 1068, 1033, 1004, 964, 915, 857, 793, 767, 738, 698, 634, 
613 cm
-1
; HRMS (EI) m/z calcd for C16H15N3O2S: 313.0885; found: 313.0875. 
 
 




H NMR (500 MHz, CDCl3) δ = 8.07-8.02 (m, 1 H), 7.91-7.86 (m, 1 H), 
7.71-7.65 (m, 2 H), 7.52 (d, J = 8.0 Hz, 2 H), 7.50-7.46 (m, 2 H), 7.39-7.30 (m, 3 H), 
7.20 (d, J = 8.0 Hz, 2 H), 7.05-6.99 (m, 1 H), 6.97-6.92 (m, 2 H), 6.83-6.77 (m, 2 H), 
4.60 (s, 2 H), 2.39 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 154.8 (s), 146.9 (s), 
144.1 (s), 141.4 (s), 140.2 (s), 137.5 (s), 135.5 (s), 134.2 (s), 130.6 (d), 130.1 (d), 
129.7 (d), 129.6 (d), 129.3 (d), 129.2 (d), 129.1 (d), 128.9 (d), 128.4 (d), 128.3 (d), 
128.2 (d), 127.9 (d), 53.9 (t), 21.7 (q) ppm; IR (ATR): ṽ = 3064, 3031, 2952, 2925, 
1705, 1598, 1542, 1496, 1482, 1456, 1445, 1399, 1347, 1305, 1195, 1161, 1139, 1089, 
1024, 983, 917, 903, 851, 814, 760, 737, 696, 672 cm
-1
; HRMS (ESI) m/z calcd for 
[C28H23N3O2S+H]
+









H NMR (500 MHz, CDCl3) δ = 8.32 (d, J = 8.5 Hz, 2 H), 8.16-8.11 (m, 1 H), 
8.06 (d, J = 8.0 Hz, 2 H), 7.98-7.91 (m, 2 H), 7.83-7.69 (m, 3 H), 7.54-7.41 (m, 3 H), 
3.37 (t, J = 8.0 Hz, 2 H), 1.12-1.04 (m, 2 H), 0.98-0.89 (m, 2 H), 0.57 (t, J = 7.0 Hz, 3 
H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 153.8 (s), 150.2 (s), 146.3 (s), 145.2 (s), 
141.7 (s), 140.1 (s), 136.9 (s), 131.1 (d), 130.6 (d), 130.3 (d), 129.6 (d), 129.5 (d), 
129.4 (d), 128.7 (d), 128.2 (d), 123.8 (d), 50.6 (t), 29.7 (t), 19.9 (t), 13.5 (q) ppm; IR 
(ATR): ṽ = 3105, 2962, 2930, 2873, 1606, 1528, 1480, 1466, 1444, 1401, 1347, 1314, 
1246, 1198, 1166, 1151, 1128, 1112, 1080, 1035, 1014, 983, 913, 886, 857, 811, 786, 
763, 746, 736, 700, 682, 649, 627, 615 cm
-1
; HRMS (ESI) m/z calcd for 
[C24H22N4O4S+H]
+
: 463.1435; found: 463.1431. 
 
 




H NMR (500 MHz, CDCl3) δ = 7.89 (d, J = 7.0 Hz, 1 H), 7.82 (s, 1 H), 7.62 (d, J 
= 7.5 Hz, 2 H), 7.56 (s, 1 H), 7.49-7.37 (m, 3 H), 7.25-7.19 (m, 2 H), 2.97 (s, 3 H), 
2.41 (s, 3 H), 2.40 (s, 3 H), 2.37 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 152.2 
(s), 147.3 (s), 143.8 (s), 141.1 (s), 140.8 (s), 140.6 (s), 139.1 (s), 137.7 (s), 135.1 (s), 
129.3 (d), 129.2 (d), 129.1 (d), 129.0 (d), 128.6 (d), 128.3 (d), 127.4 (d), 36.8 (q), 21.7 
(q), 20.5 (q), 20.4 (q) ppm; IR (ATR): ṽ = 2971, 1739, 1598, 1483, 1448, 1401, 1338, 
1301, 1272, 1214, 1183, 1153, 1118, 1084, 1022, 1004, 894, 879, 835, 804, 777, 753, 
696, 662, 638, 628, 613 cm
-1
; HRMS (ESI) m/z calcd for [C24H23N3O2S+Na]
+
: 
440.1403; found: 440.1406. 
 
 
Compound 4o: Yield 51 %, Rf = 0.29 (PE/EA = 4:1), colourless soild; 
1
H NMR (500 
MHz, CDCl3) δ = 8.27-8.24 (m, 0.26 H), 8.01-7.98 (m, 0.67 H), 7.97-7.88 (m, 2.62 H), 
7.80-7.70 (m, 1 H), 7.70-7.65 (m, 0.3 H), 7.64-7.55 (m, 2 H), 7.50-7.39 (m, 3 H), 
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7.28-7.19 (m, 2 H), 3.03-2.93 (m, 3 H), 2.43-2.33 (m, 3 H) ppm; 
13
C NMR (125 MHz, 
CDCl3) δ = 154.0 (s), 153.4 (s), 148.9 (s), 148.4 (s), 144.16 (s), 144.10 (s), 142.0 (s), 
140.6 (s), 140.2 (s), 138.8 (s), 137.1 (s), 137.0 (s), 134.7 (s), 133.9 (d), 133.7 (d), 
131.5 (d), 130.6 (d), 130.5 (d), 129.8 (d), 129.7 (d), 129.6 (d), 129.4 (d), 129.3 (d), 
129.2 (d), 129.1 (d), 128.92 (d), 128.91 (d), 128.75 (d), 128.72 (d), 124.4 (s), 124.2 (s), 
36.83 (q), 36.80 (q), 21.71 (q), 21.70 (q) ppm; IR (ATR): ṽ = 2926, 2854, 1738, 1597, 
1540, 1494, 1463, 1447, 1395, 1338, 1290, 1251, 1201, 1175, 1155, 1082, 1033, 1005, 
932, 867, 835, 811, 769, 739, 703, 678, 629 cm
-1
; HRMS (ESI) m/z calcd for 
[C22H18BrN3O2S+Na]
+
: 490.0195; found: 490.0200. 
 
 




H NMR (500 MHz, CDCl3) δ = 7.98-7.94 (m, 1 H), 7.92-7.84 (m, 2 H), 7.60 (d, J 
= 7.5 Hz, 2 H), 7.49-7.37 (m, 3 H), 7.37-7.29 (m, 1 H), 7.22 (d, J = 7.0 Hz, 2H), 
7.13-7.08 (m, 1 H), 3.89 (s, 3 H), 3.00 (s, 3 H), 2.40 (s, 3 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 161.1 (s), 150.6 (s), 148.2 (s), 143.8 (s), 141.9 (s), 137.8 (s), 137.6 
(s), 135.0 (s), 130.2 (d), 129.3 (d), 129.1 (d), 129.0 (d), 128.9 (d), 128.6 (d), 123.6 (d), 
105.8 (d), 55.9 (q), 36.8 (q), 21.7 (q) ppm; IR (ATR): ṽ = 2925, 1618, 1598, 1535, 
1486, 1448, 1413, 1342, 1292, 1238, 1215, 1182, 1167, 1122, 1074, 1017, 997, 963, 
875, 848, 826, 814, 801, 752, 729, 704, 688, 668, 647, 624 cm
-1
; HRMS (ESI) m/z 
calcd for [C23H21N3O3S+Na]
+
: 442.1196; found: 442.1198. 
 
 
Compound 4q: Rf = 0.13 (PE/EA = 4:1), Yield 52 %, colourless soild; 
1
H NMR (500 
MHz, CDCl3) δ = 7.99-7.95 (m, 0.2 H), 7.95-7.90 (m, 1.7 H), 7.65 (d, J = 8.5 Hz, 2 
H), 7.61-7.54 (m, 1 H), 7.50-7.37 (m, 4 H), 7.27 (d, J = 8.0 Hz, 0.2 H), 7.22 (d, J = 
8.0 Hz, 1.9 H), 7.03-7.00 (m, 1 H), 4.03-3.95 (m, 3 H), 2.96 (s, 2.7 H), 2.83 (s, 0.3 H), 
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2.41-2.34 (m, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 155.3 (s), 151.5 (s), 148.5 
(s), 143.9 (s), 141.2 (s), 137.4 (s), 135.1 (s), 133.6 (s), 130.4 (d), 129.4 (d), 129.3 (d), 
129.2 (d), 129.0 (d), 128.6 (d), 120.0 (d), 108.6 (d), 56.4 (q), 36.8 (q), 21.7 (q) ppm; 
IR (ATR): ṽ = 2970, 2936, 1738, 1598, 1571, 1541, 1496, 1478, 1461, 1445, 1347, 
1269, 1229, 1157, 1120, 1087, 1033, 1006, 972, 847, 814, 789, 761, 734, 697, 671, 
650, 606 cm
-1
; HRMS (ESI) m/z calcd for [C23H21N3O3S+Na]
+








H NMR (500 MHz, CDCl3) δ = 8.03-7.97 (m, 2 H), 7.63 (d, J = 8.0 Hz, 2 H), 
7.48-7.37 (m, 4 H), 7.35 (s, 1 H), 7.22 (d, J = 8.5 Hz, 2 H), 2.98 (s, 3 H), 2.69 (s, 3 H), 
2.45 (s, 3 H), 2.37 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 150.4 (s), 147.6 (s), 
143.8 (s), 140.5 (s), 140.4 (s), 139.3 (s), 137.8 (s), 137.2 (s), 135.1 (s), 132.7 (d), 
129.4 (d), 129.3 (d), 129.2 (d), 129.0 (d), 128.5 (d), 124.9 (d), 36.8 (q), 21.9 (q), 21.7, 
17.2 (q) ppm; IR (ATR): ṽ = 2925, 1738, 1617, 1596, 1572, 1537, 1477, 1455, 1435, 
1374, 1340, 1305, 1278, 1256, 1234, 1208, 1182, 1163, 1148, 1117, 1085, 1065, 1034, 
1008, 961, 908, 855, 814, 777, 740, 706, 693, 683, 664, 636, 607 cm
-1
; HRMS (ESI) 
m/z calcd for [C24H23N3O2S+Na]
+
: 440.1403; found: 440.1405. 
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Chapter 5: Gold-Catalyzed Oxidative [2+2+1] Annulation of 
Ynamides with Quinoxaline N-Oxides toward 
Fully-Functionalized Furans 
5.1 Introduction 
Gold-catalyzed oxidative cyclizations have attracted enormous attention as powerful, 
flexible and abundant tool for the construction of heterocyclic frameworks.
[1]
 Therein 
the facile alkyne oxidation by N-oxides to access -oxo gold carbene instead of using 
hazardous diazo carbonyl compounds as carbenoid precursors significantly expands 
the substrate generality and the synthetic horizon of gold catalysis.
[2,3]
 However, the 
published cyclization processes involve mostly intramolecular trappings of -oxo 
gold carbenes via tethered nucleophiles.
[4]
 Currently, intermolecular cyclization 
patterns for -oxo gold carbenes is still limited to the reaction with external nitriles[5a] 
or amides
[5b]
 leading to oxazole derivatives (Scheme 1 A). For more challenging 
C-nucleophiles, despite of spectacular achievements on intermolecular oxygenative 
C-C bond couplings of alkynes with electron-rich arenes via N-oxides,
[6]
 further 
tandem cyclizations are no reported. Moreover, the exploitation of new 
C-nucleophiles in combination with matching N-oxides for gold-catalyzed 
oxygenative reactions with alkynes remains highly desirable.  
 
Ynamides are easily accessible and significant building blocks for synthetic 
chemists.
[7]
 Due to the polarization of the triple bond, ynamides possess both 
electrophilic and nucleophilic properties. In recent years, the introduction of ynamides 
into gold catalysis has greatly promoted the boom of ynamide chemistry.
[8]
 Yet, most 
of transformations were invoked by only one role of the ynamide, either acting as an 
electrophile or a nucleophile. A scarce case of a gold-catalyzed ynamide 
self-dimerization enabled by its amphoteric character was reported by Skrydstrup and 
co-workers (Scheme 1 B).
[9]
 Inspired by this study and in continuation of our interest 
on ynamide transformations,
[10]
 we envisaged that a-oxo gold carbene generated via 
the electrophilic character of the ynamide would be electrophilic enough to be trapped 
via the nucleophilic character of the other molecule of ynamide. In fact, the major 
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obstacle for the reaction design was that under the oxidative condition the in-situ 
generated gold carbenes are easily over-oxidized by nucleophilic N-oxides, as 
competing reaction to the presumed trapping with the weakly nucleophilic ynamide.  
 
Herein, we achieved the unique gold-catalyzed oxidative [2+2+1] annulation of two 
molecules of ynamide with an oxygen atom transferred from 2,3-dichloroquinoxaline 
N-oxide (Scheme 1 C). This give rise to densely substituted furans that are widely 
embed in functional materials and pharmaceuticals.
[11]
 2,3-Dichloroquinoxaline 
N-oxide was found to suit for the cascade reaction and successfully restrain the 
formation of over-oxidized by-product. Symmetric and unsymmetric furans can be 
prepared by the homo- or cross-coupling of ynamides. Furthermore, we applied this 
methodology for the intramolecular transformation of di-ynamides resulting in a 
variety of valuable macrocyclic furan-containing frameworks. 
 
Scheme 1. Gold-catalyzed oxidative cyclization with ynamide starting materials 
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5.2 Results and Discussion 
5.2.1 Optimization of the Reaction Conditions 
Initially, we focused on the reaction of ynamide 2a with different N-oxides using 5 
mol% of tBuXPhosAuCl/AgNTf2 at 70 
o
C. As shown in Table 1, pyridine N-oxide 1a 
or quinoline N-oxides 1b and 1c delivered no furan product 3a even if the N-oxide 
reagents were slowly added to the reaction mixture (entry 1-3). To our delight, 2, 
3-diphenyl quinoxaline N-oxide 1d produced the furan 3a in 63 % yield accompanied 
by 24 % of 3a’ resulting from ynamide over-oxidation (entry 4). This revealed that the 
less nucleophilic N-oxides can prevent from the over-oxidation of ynamides. 
Following this principle, the chloro-substituted quinoxaline N-oxide 1e was tested, the 
formation of 3a’ was almost suppressed and 3a was gained in 84 % yield (entry 5). In 
order to increase the yield further, some acids were screened. 0.5 equiv. MsOH led to 
61 % yield of furan and the by-product of ynamide hydrolysis (entry 6). Anhydrous 
acids, such as HBF4·Et2O and HCl dioxane solevent gave rise to 89% yield of 3a 
(entry 7-8). 0.1 equiv. HCl dioxane solevent affored the furan in 90 % isolated yield 
(entry 9). Other common gold catalysts in combination with the acid did not improve 
the reaction (entry 10-12). The controlled experiment presented the reaction could not 
proceed without gold catalyst (entry 13). 
 











1 tBuXPhosAuCl/AgNTf2 1a — 0 % 99 % 
2 tBuXPhosAuCl/AgNTf2 1b — 0 % 99 % 
3 tBuXPhosAuCl/AgNTf2 1c — 0 % 99 % 
4 tBuXPhosAuCl/AgNTf2 1d — 63 % 24 % 
5 tBuXPhosAuCl/AgNTf2 1e — 84 % < 5 % 
6 tBuXPhosAuCl/AgNTf2 1e 0.5 equiv. MsOH
[c]
 61 % < 5 % 
7 tBuXPhosAuCl/AgNTf2 1e 0.5 equiv. HBF4.Et2O 89 % < 5 % 
8 tBuXPhosAuCl/AgNTf2 1e 0.5 equiv. HCl
[d]
 89 % < 5 % 







< 5 % 




 < 5 % 




 < 5 % 




 < 5 % 
13 — 1e 0.1 equiv. HCl
[d]
 0 % 0 % 
[a] Reaction conditions: 2a (0.3 mmol), N-oxide reagent (0.1 mmol), additives and 5 
mol% catalyst in 1 ml 1,2-DCE at 70 
o
C for 30 mins. [b] Measured by 
1
H NMR with 
dibromomethane as the internal standard. [c] Methanesulfonic acid. [d] 4 M HCl in 
dioxane. [e] Isolated yield. 
5.2.2 Mechanism Investigation 
 
Scheme 2. Proposed gold carbenoid intermediate. 
 
Remarkably, while the presumed -oxo gold carbene, produced by 
2,3-dichloroquinoxaline N-oxide, performed the furan in the excellent selectivity, the 
gold carbene species generated via pyridine N-oxides could not promote the furan 
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formation with an excess of ynamide. The distinct result suggests that the actual 
intermediate is not a free carbene species. Instead, the addition of the leaving 
N-heterocycle to the -oxo gold carbene takes place (Scheme 2).[12] The so formed 
gold carbenoid I with weakly nucleophilic quinoxaline could facilitate the selective 
formation of furan and disable the reaction with quinoxaline N-oxide, whereas the 
gold carbenoid II can not be trapped by the ynamide due to the stronger coordinating 
pyridine which reduces the reactivity of the carbenoid. 
5.2.3 Scope and Limitation 
With the optimized condition in hand, a vast range of aryl substituted ynamides was 
employed to prepare symmetric furans (Table 2). The reaction tolerated various 
functional groups, including methoxy (3c), halogen (3d, 3j, 3m), trifluoromethyl (3e), 
ester groups (3h) and a dioxane moiety (3n). Due to the steric effect, low yields were 
obtained with bulky 3, 5-disubstituted phenyl ynamides (3k, 3l). Alkyl substituted 
ynamides decomposed under the oxidizing condition. Next we varied the amide 
moiety of the ynamide. A set of protecting groups and substituents at the R-position 
were checked (3r-t). Both mesyl (3r) and an easily removable nosyl group (3t) were 









   




   
3d, 85 % 3e, 65 % 3f, 95 % 
   
3g, 95 % 3h, 66 % 3i, 70 % 
   




3m, 64 % 3n, 91 % 3o, 84 % 
   






X-ray of 3a 3s, 54 % 3t, 83 % 
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[a] Reaction conditions: 1e (0.1 mmol), 2 (0.3 mmol), 10 mol% HCl solvent(4 M HCl 
in dioxane), and 5 mol% tBuXPhosAuCl /AgNTf2 at 70 
o
C for 30 mins in 1 ml 
1,2-DCE. [b] Isolated yields. 
 
In order to enhance the synthetic utility, our attention was turned to the construction 
of unsymmetrical furan skeletons as well (Table 3). The reaction of quinoxaline 
N-oxide 1e, a threefold excess of ynamide 2, and another more nulecophilic ynamide 
2’ under the standard condition could delivered unsymmetrical furans by the 
cross-coupling of different ynamides. Ynamides containing different aryl substituents 
and protecting groups were tested together to suit the principle. A whole series of 
unsymmetrical furans 4 were obtained in moderate to good yields with well tolerance 
to diverse functional groups (4a-h). Besides of sulfamides, the transformation of an 
oxazolidinone-derived ynamide together with ynamide 2a also afforded the product 4i 
in 21 % yield. However, the cross dimerization of aryl substituted ynamide with alkyl 
substituted ynamides failed to produce the furan. 




   
4a, 70 %
 
4b, 65 % 4c, 60 % 
   
4d
[c]





4g, 61 % 4h, 64 % 4i, 21 % 
[a] Reaction conditions: 1e (0.1 mmol), 2 (0.3 mmol), 2' (0.1 mmol), 10 mol% HCl 
solvent (4 M HCl in dioxane), and 5 mol% tBuXPhosAuCl /AgNTf2 at 70 
o
C for 1 h 




Macrocyclic furan derivatives widely exist in natural products, such as lophotoxin and 
bipinnatin.
[14]
 The conventional entry to macrocyclic furans mainly focused on the 
furan synthesis inside of a macrocycle. As a complementary strategy, this 
methodology was applied in the intramolecular macrocyclization of di-ynamides to 
construct furan motifs incorporated in macrocyclic systems during the 
macrocylization step (Table 4). The use of 10 mol% gold catalyst and diluted 
concentration (0.01 M) led to the strained 10-membered ring 6a in 20 % yield and 11- 
to 13-membered rings in good yields (6b-e). The solid state structure of 6b was 
disclosed by X-ray diffraction.
[13]
 The synthesis of unsymmetric macrocyclic furan 6f 
was accomplished as well. In addition, the efficient approach to macrolactone 6g from 
Boc-protected 2-aminoethanol and 4-aminobutanoic acid was demonstrated (Scheme 
3). 









Scheme 3. Application in the synthesis of macrolactone. 
5.3 Summary  
In summary, gold-catalyzed oxidative [2+2+1] cycloaddition of ynamides with 2, 
3-dichloroquinoxaline N-oxide has been disclosed. A whole series of densely 
subtituted symmetric and asymmetric furans was prepared with excellent tolerance to 
diverse functional groups. The method was further employed to the intramolecular 
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5.5 Experimental Section  
General information: Chemicals were purchased from commercial suppliers and 
used as delivered. The pyridine N-oxide 1a and quinoline N-oxides 1b, 1c are bought 
from SigmaAldrich. Quinoxaline N-oxides 1d, 1e and ynamides were prepared 
according to related literatures.
[1-4]
 Deuterated solvents were bought from Euriso-Top. 
NMR spectra were, if not mentioned otherwise, recorded at room temperature on the 
following spectrometers: Bruker Avance-III-300, Bruker Avance DRX-300, 
Bruker-Avance DRX-500 and Bruker Avance-III-500. Chemical shifts are given in 





NMR spectra to indicate the signal multiplicity: s (singlet), brs (broad singlet), d 
(doublet), t (triplet), q (quartet), quint (quintet), sext (sextet), sept (septet) and m 
(multiplet) as well as combinations of them. When combinations of multiplicities are 
given the first character noted refers to the biggest coupling constant. All 
13
C NMR 
spectra were measured with 
1
H-decoupling. The multiplicities mentioned in these 
spectra [s (singlet, quaternary carbon), d (doublet, CH-group), t (triplet, CH2-group), q 
(quartet, CH3-group)] were determined by DEPT135 and HSQC spectra. Mass spectra 
(MS and HRMS) were determined at the chemistry department of the University of 
Heidelberg under the direction of Dr. J. Gross. EI
+ 
-spectra were measured on a JOEL 
JMS-700 spectrometer. For ESI
+
-spectra a Bruker ApexQu FT-ICR-MS spectrometer 
was applied. Infrared Spectroscopy (IR) was processed on an FT-IR Bruker (IF528), 
IR Perkin Elmer (283) or FT-IR Bruker Vector 22. The solvent or matrix is denoted in 
brackets. For the most significant bands the wave number ν (cm-1) is given. X-ray 
crystal structure analyses were measured at the chemistry department of the 
University of Heidelberg under the direction of Dr. F. Rominger on a Bruker Smart 
CCD or Bruker APEX-II CCD instrument using Mo-Kα-radiation. Diffraction 
intensities were corrected for Lorentz and polarization effects. An empirical 
absorption correction was applied using SADABS based on the Laue symmetry of 
reciprocal space. Heavy atom diffractions were solved by direct methods and refined 
against F2 with full matrix least square algorithm. Hydrogen atoms were either 
isotropically refined or calculated. The structures were solved and refined by Dr. F. 
Rominger using the SHELXTL software package. Gas Chromatography / Mass 
Spectrometry (GC/MS) spectra were measured on two different hardware systems: 1. 
HP 5972 Mass Selective Detector, coupled with a HP 5890 SERIES II plus gas 
chromatograph. 2. Agilent 5975C Mass Selective Detector, coupled with an Agilent 
7890A gas chromatograph. In both cases, as a capillary column, an OPTIMA 5 
cross-linked Methyl Silicone column (30 m x 0.32 mm, 0.25 µm) was employed and 
helium was used as the carrier gas. Gas Chromatography (GC) was carried out on a 
HP 5890 SERIES II plus gas chromatograph. As a capillary column, an OPTIMA 5 
cross-linked Methyl Silicone column (30 m x 0.32 mm, 0.25 µm) was employed and 
nitrogen was used as the carrier gas. Melting Points were measured in open glass 
capillaries in a Büchi melting point apparatus (according to Dr. Tottoli) and were not 
corrected. Flash Column Chromatography was accomplished using Silica gel 60 (0.04 
- 0.063 mm / 230 - 400 mesh ASTM) purchased from Macherey-Nagel or Aluminium 
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oxide (neutral or basic) purchased from Macherey-Nagel. As eluents, mixtures of 
petroleum ether (PE), ethyl acetate (EA), dichloromethane (DCM) and diethylether 
(Et2O) were used. Analytical Thin Layer Chromatography (TLC) was carried out on 
precoated Macherey-Nagel POLYGRAM
®
 SIL G/UV254 or POLYGRAM
®
 ALOX 
N/UV254 plastic sheets. Detection was accomplished using UV-light (254 nm), 
KMnO4 (in 1.5 M Na2CO3 (aq.)), molybdatophosphoric acid (5 % in ethanol), 
vanillin/H2SO4 (in ethanol) or anisaldehyde/HOAc (in ethanol). IUPAC names of the 






A round bottom flask equipped with a magnetic stirrer bar was charged with 
tBuXPhosAuCl (5 mol%, 3.2 mg), AgNTf2 (5 mol%, 2 mg), and 1,2-DCE (1 ml). The 
mixture was stirred for 5 minutes at room temperature. Then the ynamide (0.3 mmol) 
and 2,3-dichloroquinoxaline N-oxide (0.1 mmol, 21.5 mg) and 2.5 mL HCl (4M HCl 
in dioxane) were added. The reaction was heated at 70 
o
C for 30 mins. After cooling 
to room temperature, the solvent was reduced in vacuo, and the residue was purified 
by column chromatography (SiO2, hexanes/EtOAc) to provide the symmetric furan 
product. The characterization data of the products are listed in part 3.  
 
 
A round bottom flask equipped with a magnetic stirrer bar was charged with 
tBuXPhosAuCl (5 mol%, 3.2 mg), AgNTf2 (5 mol%, 2 mg), and 1,2-DCE (1 ml). The 
mixture was stirred for 5 minutes at room temperature. Then the ynamide 2 (0.3 mmol 
or 0.4 mmol), another ynamide 2’ (0.1 mmol), 2,3-dichloroquinoxaline N-oxide (0.1 
mmol) and 2.5 mL HCl (4M HCl in dioxane) were added. The reaction was heated at 
70 
o
C for 1 h. After cooling to room temperature, the solvent was reduced in vacuo, 
and the residue was purified by column chromatography (SiO2, hexanes/EtOAc) to 
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provide the unsymmetric furan product. The characterization data of the products are 
listed in part 3. 
 
 
A round bottom flask equipped with a magnetic stirrer bar was charged with 
tBuXPhosAuCl (10 mol%, 6.4 mg), AgNTf2 (5 mol%, 4 mg), and 1,2-DCE (1 ml). 
The mixture was stirred for 5 minutes at room temperature. Then the di-ynamide 5 
(0.12 mmol) and 2,3-dichloroquinoxaline N-oxide (0.1 mmol) in 9 ml 1,2-DCE were 
added. The reaction was heated at 70 
o
C for 30 mins. After cooling to room 
temperature, the solvent was reduced in vacuo, and the residue was purified by 
column chromatography (SiO2, hexanes/EtOAc) to provide the macrocyclic furan 
compound. The characterization data of the products are listed in part 3. 
Characterization  
 




H NMR (300 MHz, 
CDCl3) δ = 7.56-7.48 (m, 4 H), 7.20-7.06 (m, 14 H), 2.94 (s, 6 H), 2.33 (s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 143.8 (s), 140.3 (s), 135.0 (s), 130.3 (s), 129.5 (d), 
129.4 (d), 128.21 (d), 128.19 (d), 127.5 (d), 122.9 (s), 37.7 (q), 21.6 (q) ppm; IR 
(ATR): ṽ = 3064, 2927, 1614, 1598, 1587, 1495, 1447, 1385, 1350, 1305, 1209, 1168, 
1151, 1120, 1088, 1063, 1018, 992, 981, 890, 829, 813, 786, 773, 734, 704, 684, 664, 
608cm
-1
; HRMS (ESI) m/z calcd for [C32H30N2O5S2+Na]
+










H NMR (500 MHz, 
CDCl3) δ = 7.51 (d, J = 8.0 Hz, 4 H), 7.09 (d, J = 8.0 Hz, 4 H), 7.02 (d, J = 8.0 Hz, 4 
H), 6.96 (d, J = 8.0 Hz, 4 H), 2.92 (s, 6 H), 2.32 (s, 6 H), 2.24 (s, 6 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 143.7 (s), 140.0 (s), 137.1 (s), 135.1 (s), 129.4 (d), 129.3 (d), 
128.9 (d), 128.2 (d), 127.4 (s), 122.9 (s), 37.7 (q), 21.6 (q), 21.3 (q) ppm; IR (ATR): ṽ 
= 2925, 1683, 1595, 1515, 1453, 1353, 1306, 1164, 1120, 1087, 981, 891, 815, 737, 
706, 668, 628 cm
-1










H NMR (500 MHz, 
CDCl3) δ = 7.52 (d, J = 8.5 Hz, 4 H), 7.10 (d, J = 8.0 Hz, 4 H), 7.07 (d, J = 8.5 Hz, 4 
H), 6.71 (d, J = 8.5 Hz, 4 H), 3.72 (s, 6 H), 2.92 (s, 6 H), 2.33 (s, 6 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 158.9 (s), 143.7 (s), 139.7 (s), 135.1 (s), 130.6 (d), 129.4 (d), 
128.2 (d), 122.6 (s), 122.5 (s), 113.6 (d), 55.2 (q), 37.7 (q), 21.6 (q) ppm; IR (ATR): ṽ 
= 2949, 2924, 2832, 1685, 1593, 1513, 1457, 1391, 1349, 1294, 1246, 1212, 1167, 
1112, 1087, 1068, 1036, 981, 894, 836, 808, 746, 704, 666, 628 cm
-1
; HRMS (ESI) 
m/z calcd for [C34H34N2O7S2+H]
+









H NMR (500 MHz, 
CDCl3) δ = 7.53-7.48 (m, 4 H), 7.15-7.07 (m, 8 H), 6.90-6.85 (m, 4 H), 2.93 (s, 6 H), 
2.34 (s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 162.3 (J = 245.7 Hz, s), 144.0 (s), 
140.3 (s), 134.8 (s), 131.2 (J = 7.5 Hz, d), 129.5 (d), 128.1 (d), 126.0 (J = 2.8 Hz, s), 
122.0 (s), 115.4 (J = 21.5 Hz, d), 37.7 (q), 21.6 (q) ppm; IR (ATR): ṽ = 1585, 1509, 
1387, 1360, 1340, 1307, 1218, 1188, 1157, 1091, 1061, 1018, 994, 982, 894, 836, 815, 
741, 704, 688, 670, 660, 642, 625 cm
-1
; HRMS (ESI) m/z calcd for 
[C32H28F2N2O5S2+Na]
+
: 645.1300; found: 645.1313. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.48 (d, J = 8.0 Hz, 4 H), 7.44 (d, J = 8.5 Hz, 4 H), 7.23 (d, J = 8.0 Hz, 4 
H), 7.54 (d, J = 8.5 Hz, 4 H), 2.98 (s, 6 H), 2.33 (s, 6 H) ppm; 
13
C NMR (125 MHz, 
CDCl3) δ = 144.2 (s), 141.3 (s), 134.6 (s), 133.6 (J = 0.9 Hz, s), 129.8 (J = 32.3 Hz, s), 
129.7 (d), 129.5 (d), 128.1 (d), 126.2 (J = 270 Hz, s), 125.4 (J = 3.7 Hz, d), 121.6 (s), 
37.7 (q), 21.6 (q) ppm; IR (ATR): ṽ = 2928, 1683, 1621, 1598, 1461, 1409, 1357, 
1322, 1164, 1123, 1089, 1067, 1019, 986, 895, 831, 814, 776, 758, 733, 705, 691, 667, 
635, 615 cm
-1
; HRMS (ESI) m/z calcd for [C34H28F6N2O5S2+Na]
+










H NMR (500 MHz, 
CDCl3) δ = 7.53-7.48 (m, 8 H), 7.41 (d, J = 8.0 Hz, 4 H), 7.36-7.30 (m, 4 H), 
7.26-7.21 (m, 6 H), 7.07 (d, J = 8.0 Hz, 4 H), 2.98 (s, 6 H), 2.26 (s, 6 H) ppm; 
13
C 
NMR (125 MHz, CDCl3) δ = 143.9 (s), 140.5 (s), 140.1 (s), 135.0 (s), 129.9 (d), 129.5 
(d), 129.3 (s), 128.8 (d), 128.2 (d), 127.4 (d), 126.9 (d), 126.8 (d), 122.6 (s), 37.8 (q), 
21.6 (q) ppm; IR (ATR): ṽ = 3031, 2937, 1748, 1684, 1595, 1488, 1449, 1353, 1306, 
1165, 1119, 1087, 981, 893, 842, 813, 770, 739, 697, 668, 610 cm
-1
; HRMS (ESI) m/z 
calcd for [C44H38N2O5S2+Na]
+
: 761.2114; found: 761.2119. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.51 (d, J = 8.0 Hz, 4 H), 7.16 (d, J = 8.5 Hz, 4 H), 7.10-7.04 (m, 8 H), 
2.92 (s, 6 H), 2.31 (s, 6 H), 1.23 (s, 18 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
150.2 (s), 143.7 (s), 140.0 (s), 135.0 (s), 129.4 (d), 129.1 (d), 128.3 (d), 127.3 (s), 
125.0 (d), 122.9 (s), 37.7 (q), 34.6 (s), 31.4 (q), 21.6 (q) ppm; IR (ATR): ṽ = 2962, 
2904, 2867, 1739, 1599, 1582, 1461, 1380, 1359, 1345, 1269, 1169, 1153, 1109, 1090, 
1066, 1021, 996, 982, 890, 826, 813, 756, 740, 706, 669, 620 cm
-1
; HRMS (ESI) m/z 
calcd for [C40H46N2O5S2+Na]
+









H NMR (500 MHz, 
CD2Cl2) δ = 7.81 (d, J = 8.0 Hz, 4 H), 7.45 (d, J = 8.0 Hz, 4 H), 7.17 (d, J = 8.0 Hz, 4 
H), 7.12 (d, J = 8.5 Hz, 4 H), 3.80 (s, 6 H), 2.95 (s, 6 H), 2.31 (s, 6 H) ppm; 
13
C NMR 
(125 MHz, CD2Cl2) δ = 166.5 (s), 144.4 (s), 141.1 (s), 134.8 (s), 134.6 (s), 129.6 (d), 
129.5 (d), 129.4 (d), 129.3 (s), 127.9 (d), 121.9 (s), 52.0 (q), 37.7 (s), 21.3 (q) ppm; IR 
(ATR): ṽ = 2953, 1715, 1614, 1596, 1510, 1438, 1408, 1355, 1276, 1186, 1165, 1111, 
1088, 1066, 1020, 983, 891, 860, 816, 779, 737, 706, 668, 634, 617 cm
-1
; HRMS (ESI) 
m/z calcd for [C36H34N2O9S2N +Na]
+
: 725.1598; found: 725.1599. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.52 (d, J = 8.0 Hz, 4 H), 7.11 (d, J = 8.0 Hz, 4 H), 7.05-7.00 (m, 2 H), 
6.99-6.91 (m, 4 H), 6.89-6.85 (m, 2 H), 2.94 (s, 6 H), 2.33 (s, 6 H), 2.15 (s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 143.8 (s), 140.1 (s), 137.6 (s), 135.1 (s), 130.2 (s), 
130.1 (d), 129.4 (d), 128.2 (d), 128.1 (d), 127.9 (d), 126.6 (d), 122.9 (s), 37.7 (q), 21.6 
(q), 21.4 (q) ppm; IR (ATR): ṽ = 2924, 1684, 1598, 1453, 1351, 1306, 1224, 1165, 
1122, 1088, 1064, 1027, 982, 924, 844, 812, 789, 726, 706, 669, 612 cm
-1
; HRMS 
(ESI) m/z calcd for [C34H34N2O5S2+Na]
+
: 637.1801; found: 637.1828. 
 
 




H NMR (500 MHz, 
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CDCl3) δ = 7.51 (d, J = 8.5 Hz, 4 H), 7.18-7.09 (m, 8 H), 7.05-7.03 (m, 2 H), 
6.99-6.95 (m, 2 H), 2.97 (s, 3 H), 2.34 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
144.2 (s), 140.8 (s), 134.6 (s), 134.1 (s), 131.7 (s), 129.63 (d), 129.60 (d), 129.3 (d), 
128.1 (d), 127.9 (d), 127.7 (d), 121.5 (s), 37.7 (q), 21.7 (q) ppm; IR (ATR): ṽ = 1768, 
1681, 1611, 1597, 1565, 1494, 1475, 1450, 1419, 1351, 1308, 1295, 1170, 1151, 1121, 
1087, 1062, 995, 916, 902, 816, 795, 762, 737, 708, 669, 610 cm
-1
; HRMS (ESI) m/z 
calcd for [C32H28Cl2N2O5S2+H]
+
: 655.0889; found: 655.0893.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.56 (d, J = 8.0 Hz, 4 H), 7.13 (d, J = 8.0 Hz, 4 H), 6.38 (d, J = 2.5 Hz, 4 
H), 6.30 (t, J = 2.5 Hz, 2 H), 3.59 (s, 12 H), 2.94 (s, 6 H), 2.34 (s, 6 H) ppm; 
13
C 
NMR (125 MHz, CDCl3) δ = 160.3 (s), 143.8 (s), 140.2 (s), 135.1 (s), 131.8 (s), 129.5 
(d), 128.1 (d), 122.9 (s), 107.3 (d), 100.7 (d), 55.4 (q), 37.8 (q), 21.6 (q) ppm; IR 
(ATR): ṽ = 2932, 2841, 1738, 1684, 1595, 1455, 1424, 1351, 1291, 1205, 1155, 1088, 
1065, 1018, 926, 835, 814, 784, 732, 706, 668, 616 cm
-1
; HRMS (ESI) m/z calcd for 
[C36H38N2O9S2+Na]
+
: 729.1911; found: 729.1932. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.72 (s, 2 H), 7.53 (s, 4 H), 7.49 (d, J = 8.0 Hz, 4 H), 7.13 (d, J = 8.0 Hz, 
4 H), 3.04 (s, 6 H), 2.33 (s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 144.6 (s), 
142.1 (s), 134.3 (s), 132.0 (J = 33 Hz, s), 131.6 (s), 129.7 (d), 129.4 (J = 4.1 Hz, d), 
128.0 (d), 122.8 (J = 271 Hz, s), 121.7 (J = 3.0 Hz, d), 119.1 (s), 37.7 (q), 21.6 (q) 
ppm; IR (ATR): ṽ = 2970, 2929, 1740, 1684, 1597, 1465, 1359, 1343, 1278, 1168, 
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1133, 1064, 1032, 1014, 899, 848, 813, 777, 740, 706, 672, 613 cm
-1
; HRMS (ESI) 
m/z calcd for [C36H26F12N2O5S2+Na]
+
: 881.0984; found: 881.0998. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.45 (d, J = 8.5 Hz, 4 H), 7.17-7.12 (m, 2 H), 7.10 (d, J = 8.0 Hz, 4 H), 
7.08-7.03 (m, 2 H), 6.95-6.90 (m, 2 H), 6.88-6.81 (m, 2 H), 3.00 (s, 6 H), 2.30 (s, 6 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 159.7 (J = 246.7 Hz, s), 143.9 (s), 141.0 (s), 
134.9 (s), 131.7 (J = 2.8 Hz, d), 129.7 (J = 8.5 Hz, d), 129.5 (d), 127.9 (d), 123.9 (J = 
3.5 Hz, d), 118.4 (J = 15.7 Hz, s), 117.9 (s), 115.5 (J = 22.1 Hz, d), 37.1 (q), 21.6 (q) 
ppm; IR (ATR): ṽ = 1596, 1494, 1453, 1351, 1307, 1267, 1229, 1188, 1168, 1152, 
1105, 1088, 1066, 985, 896, 814, 761, 706, 668, 610 cm
-1
; HRMS (ESI) m/z calcd for 
[C32H28F2N2O5S2+H]
+
: 623.1480; found: 623.1483. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.52 (d, J = 8.0 Hz, 4 H), 7.11 (d, J = 8.0 Hz, 4 H), 6.67-6.53 (m, 6 H), 
4.20-4.07 (m, 8 H), 2.93 (s, 6 H), 2.33 (s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
143.7 (s), 143.2 (s), 143.1 (s), 139.8 (s), 135.1 (s), 129.4 (d), 128.2 (d), 123.5 (s), 
122.8 (d), 122.4 (s), 118.3 (d), 117.0 (d), 64.4 (t), 64.2 (t), 37.8 (q), 21.6 (q) ppm; IR 
(ATR): ṽ = 2927, 2877, 1749, 1685, 1581, 1508, 1458, 1352, 1303, 1283, 1251, 1162, 
1125, 1087, 1067, 1000, 932, 918, 891, 870, 813, 756, 734, 706, 667, 625 cm
-1
; 
HRMS (ESI) m/z calcd for [C36H34N2O9S2+Na]
+








H NMR (500 MHz, 
CDCl3) δ = 7.62-7.60 (m, 2 H), 7.54-7.43 (m, 8 H), 7.14-7.10 (m, 2 H), 7.03-6.97 (m, 
8 H), 3.84 (s, 6 H), 3.01 (s, 6 H), 2.26 (s, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
157.9 (s), 143.8 (s), 140.5 (s), 135.2 (s), 133.8 (s), 129.8 (d), 129.4 (d), 128.7 (s), 
128.4 (d), 128.1 (d), 127.9 (d), 126.6 (d), 125.6 (s), 122.9 (s), 118.7 (d), 105.5 (d), 
55.4 (q), 37.8 (q), 21.6 (q) ppm; IR (ATR): ṽ = 2940, 1631, 1606, 1487, 1462, 1390, 
1352, 1262, 1216, 1188, 1162, 1087, 1030, 1000, 957, 911, 878, 854, 811, 733, 706, 
667, 614 cm
-1
; HRMS (ESI) m/z calcd for [C42H38N2O7S2Na]
+








H NMR (500 MHz, 
CDCl3) δ = 7.53 (d, J = 8.0 Hz, 4 H), 7.22-7.20 (m, 2 H), 7.18-7.15 (m, 2 H), 7.12 (d, 
J = 8.5 Hz, 4 H), 6.93-6.90 (m, 2 H), 2.91 (s, 3 H), 2.33 (s, 3 H) ppm; 
13
C NMR (125 
MHz, d
6
-DMSO) δ = 143.9 (s), 140.0 (s), 134.8 (s), 130.1 (s), 129.5 (d), 128.2 (d), 
128.1 (d), 125.1 (d), 124.5 (d), 118.4 (s), 37.7 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3108, 
2946, 1762, 1685, 1597, 1521, 1493, 1450, 1415, 1344, 1304, 1292, 1215, 1164, 1087, 
1069, 1018, 999, 923, 891, 861, 849, 813, 789, 730, 707, 669, 630, 609 cm
-1
; HRMS 
(ESI) m/z calcd for [C28H26N2O5S4+H]
+









H NMR (500 MHz, 
CDCl3) δ = 7.56 (d, J = 8.5 Hz, 4 H), 7.24-7.21 (m, 2 H), 7.15 (d, J = 8.5 Hz, 4 H), 
6.92-6.87 (m, 4 H), 2.98 (s, 3 H), 2.34 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
144.0 (s), 140.6 (s), 134.8 (s), 130.3 (s), 129.6 (d), 128.3 (d), 128.2 (d), 127.0 (d), 
126.6 (d), 116.9 (s), 37.6 (q), 21.7 (q) ppm; IR (ATR): ṽ = 3110, 2871, 2928, 2855, 
1688, 1640, 1598, 1520, 1449, 1353, 1342, 1305, 1225, 1156, 1087, 1035, 940, 867, 
829, 814, 705, 667 cm
-1










H NMR (500 MHz, 
CDCl3) δ = 7.35-7.22 (m, 10 H), 3.25 (s, 6 H), 2.89 (s, 6 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 140.3 (s), 130.1 (s), 129.4 (d), 128.5 (d), 127.9 (d), 122.7 (s), 39.1 
(q), 38.3 (q) ppm; IR (ATR): ṽ = 2931, 1738, 1605, 1584, 1496, 1463, 1444, 1411, 
1386, 1344, 1209, 1147, 1077, 1057, 1031, 963, 890, 832, 776, 756, 730, 702, 671 
cm
-1
; HRMS (ESI) m/z calcd for [C20H22N2O5S2+H]
+
: 435.1043; found: 435.1045.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.54 (d, J = 8.5 Hz, 4 H), 7.12 (d, J = 8.5 Hz, 4 H), 7.08-7.03 (m, 4 H), 
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7.02-6.95 (m, 8 H), 6.75-6.66 (m, 8 H), 4.23 (s, 4 H), 2.37 (s, 6 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 143.7 (s), 138.2 (s), 136.1 (s), 134.2 (s), 130.0 (s), 129.6 (d), 
129.4 (d), 129.2 (d), 128.3 (d), 128.2 (d), 128.0 (d), 127.8 (d), 127.2 (d), 125.0 (s), 
54.0 (t), 21.7 (q) ppm; IR (ATR): ṽ = 3064, 3033, 2925, 1598, 1581, 1495, 1456, 
1400, 1353, 1306, 1163, 1090, 1012, 965, 915, 843, 813, 768, 731, 697, 663 cm
-1
; 
HRMS (ESI) m/z calcd for [C44H38N2O5S2+H]
+
: 739.2295; found: 739.2283.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 8.08 (d, J = 9.0 Hz, 4 H), 7.83 (d, J = 9.0 Hz, 4 H), 7.18-7.12 (m, 2 H), 
7.12-7.07 (m, 4 H), 7.02-6.97 (m, 4 H), 3.36 (t, J = 7.0 Hz, 4 H), 1.30-1.22 (m, 4 H), 
1.11-1.02 (m, 4 H), 0.64 (t, J = 6.0 Hz, 6 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 
150.2 (s), 144.5 (s), 138.6 (s), 129.6 (s), 129.3 (d), 129.2 (d), 128.3 (d), 127.9 (d), 
125.2 (s), 123.9 (d), 51.5 (t), 30.5 (t), 19.6 (t), 13.5 (q) ppm; IR (ATR): ṽ = 3103, 
2961, 2930, 2862, 1608, 1586, 1525, 1485, 1444, 1401, 1351, 1311, 1173, 1146, 1108, 
1087, 1073, 1037, 1023, 1007, 996, 977, 901, 855, 803, 775, 737, 701, 685, 616 cm
-1
; 
HRMS (ESI) m/z calcd for [C36H36N4O9S2+H]
+
: 733.1996; found: 733.1995.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.55-7.49 (m, 4 H), 7.20-7.13 (m, 7 H), 7.13-7.06 (m, 4 H), 7.05-7.01 (m, 
4 H), 2.94 (s, 3 H), 2.93 (s, 3 H), 2.33 (s, 3 H), 2.32 (s, 3 H), 1.22 (s, 9 H) ppm; 
13
C 
NMR (125 MHz, CDCl3) δ = 150.3 (s), 143.78 (s), 143.72 (s), 140.2 (s), 140.0 (s), 
135.0 (s), 130.5 (s), 129.6 (d), 129.4 (d), 129.3 (d), 129.0 (d), 128.24 (d), 128.21 (d), 
128.1 (d), 127.4 (d), 127.1 (s), 125.0 (d), 123.0 (s), 122.9 (s), 37.8 (q), 34.6 (s), 31.3 
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(q), 21.6 (q) ppm; IR (ATR): ṽ = 2961, 2871, 1686, 1598, 1495, 1448, 1353, 1306, 
1271, 1164, 1121, 1087, 1020, 982, 889, 836, 813, 774, 731, 703, 667, 621 cm
-1
; 
HRMS (ESI) m/z calcd for [C36H38N2O5S2+H]
+
: 643.2295; found: 643.2291.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.55-7.49 (m, 4 H), 7.20-7.15 (m, 3 H), 7.15-7.08 (m, 6 H), 6.64-6.61 (m, 
2 H), 6.57-6.53 (m, 1 H), 4.17-4.10 (m, 4 H), 2.95 (s, 3 H), 2.92 (s, 3 H), 2.32 (d, 6 H) 
ppm; 
13
C NMR (125 MHz, CDCl3) δ = 143.8 (s), 143.7 (s), 143.2 (s), 143.1 (s), 140.1 
(s), 140.0 (s), 135.1 (s), 135.0 (s), 130.3 (s), 129.5 (d), 129.45 (d), 129.42 (d), 128.2 
(d), 127.5 (d), 123.5 (s), 122.88 (s), 122.86 (d), 122.4 (s), 118.3 (d), 116.9 (d), 64.4 (t), 
64.2 (t), 37.8 (q), 37.7 (q), 21.63 (q), 21.62 (q) ppm; IR (ATR): ṽ = 2935, 2876, 1697, 
1581, 1509, 1456, 1351, 1303, 1283, 1251, 1159, 1125, 1067, 1009, 985, 936, 907, 
889, 850, 812, 776, 752, 703, 665, 624 cm
-1
; HRMS (ESI) m/z calcd for 
[C34H32N2O7S2+Na]
+
: 667.1543; found: 667.1552.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.60 (d, J = 8.5 Hz, 2 H), 7.19 (d, J = 8.0 Hz, 2 H), 7.09 (d, J = 9.0 Hz, 2 
H), 6.95 (s, 4 H), 6.74 (d, J = 8.5 Hz, 2 H ), 3.71 (s, 3 H), 3.06 (s, 3 H), 3.01 (s, 3 H), 
2.72 (s, 3 H), 2.36 (s, 3 H), 2.24 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 159.1 
(s), 144.0 (s), 140.1 (s), 139.7 (s), 137.3 (s), 135.3 (s), 130.6 (d), 129.5 (d), 129.2 (d), 
128.9 (d), 128.1 (d), 127.2 (s), 122.7 (s), 122.5 (s), 122.1 (s), 113.8 (d), 55.1 (q), 38.8 
(q), 38.2 (q), 37.8 (q), 21.6 (q), 21.3 (q) ppm; IR (ATR): ṽ = 3030,, 2934, 2839, 1748, 
1682, 1641, 1590, 1514, 1456, 1386, 1347, 1293, 1249, 1150, 1086, 1032, 981, 964, 
894, 817, 763, 736, 707, 671, 626 cm
-1





: 577.1437; found: 577.1453.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.57 (d, J = 8.0 Hz, 2 H), 7.22-7.17 (m, 2 H), 7.16-7.12 (m, 1 H), 
7.10-7.04 (m, 3 H), 6.99-6.97 (m, 1 H ), 6.96-6.92 (m, 1 H), 6.75 (d, J = 8.5 Hz, 2 H),  
3.72 (s, 3 H), 3.06 (s, 3 H), 3.05 (s, 3 H), 2.74 (s, 3 H), 2.36 (s, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 159.2 (s), 144.3 (s), 140.5 (s), 140.1 (s), 134.8 (s), 134.0 (s), 
132.2 (s), 130.5 (d), 129.6 (d), 129.5 (d), 129.3 (d), 128.1 (d), 127.74 (d), 127.71 (d), 
122.0 (s), 121.8 (s), 121.5 (s), 114.0 (d), 55.2 (q), 38.9 (q), 38.1 (q), 37.8 (q), 21.6 (q) 
ppm; IR (ATR): ṽ = 2936, 2840, 1748, 1682, 1600, 1514, 1456, 1347, 1293, 1250, 
1211, 1163, 1084, 1032, 986, 964, 899, 834, 815, 792, 772, 732, 705, 672, 628 cm
-1
; 
HRMS (ESI) m/z calcd for [C27H27ClN2O6S2+Na]
+
: 597.0891; found: 597.0902.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.61 (d, J = 8.0 Hz, 2 H), 7.53-7.48 (m, 2 H), 7.46 (d, J = 8.5 Hz, 2 H), 
7.37-7.32 (m, 2 H), 7.28-7.24 (m, 1 H), 7.24-7.18 (m, 4 H), 7.12-7.06 (m, 2 H ), 
6.90-6.83 (m, 2 H), 3.08 (s, 3 H), 3.04 (s, 3 H), 2.74 (s, 3 H), 2.36 (s, 3 H) ppm; 
13
C 
NMR (125 MHz, CDCl3) δ = 162.3 (J = 246 Hz, s), 144.3 (s), 140.5 (J = 2.2 Hz, s), 
140.3 (s), 140.2 (s), 135.1 (s), 131.2 (J = 8.1 Hz, d), 129.7 (d), 129.6 (d), 128.9 (s), 
128.8 (d), 128.2 (d), 127.6 (d), 127.1 (d), 127.0 (s), 126.9 (d), 126.1 (J = 3.3 Hz, s), 
122.0 (s), 121.9 (s), 115.4 (J = 21 Hz, d), 38.9 (q), 38.2 (q), 37.8 (q), 21.6 (q) ppm; IR 
(ATR): ṽ = 2935, 1680, 1590, 1510, 1489, 1450, 1348, 1222, 1159, 1087, 982, 963, 
895, 838, 813, 770, 738, 700, 671, 629 cm
-1
; HRMS (ESI) m/z calcd for 
[C32H29FN2O5S2+H]
+








H NMR (500 MHz, 
CDCl3) δ = 7.58 (d, J = 8.5 Hz, 2 H), 7.37-7.32 (m, 2 H), 7.21 (d, J = 8.0 Hz, 2 H), 
7.06-7.00 (m, 4 H), 6.91-6.83 (m, 2 H), 3.04 (s, 3 H), 3.03 (s, 3 H), 2.77 (s, 3 H), 2.36 
(s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 162.4 (J = 246 Hz, s), 144.3 (s), 140.5 
(s), 140.3 (s), 135.0 (s), 131.7 (d), 131.1 (J = 7.8 Hz, d), 130.9 (d), 129.6 (d), 128.8 (s), 
128.1 (d), 125.8 (J = 3.3 Hz, s), 122.2 (s), 121.7 (s), 121.4 (s), 115.5 (J = 22 Hz, d), 
38.7 (q), 38.1 (q), 37.8 (q), 21.6 (q) ppm; IR (ATR): ṽ = 1682, 1597, 1581, 1510, 
1491, 1456, 1349, 1223, 1160, 1072, 1014, 981, 964, 893, 831, 813, 764, 736, 706, 
670, 634 cm
-1
; HRMS (ESI) m/z calcd for [C26H24BrFN2O5S2+Na]
+








H NMR (500 MHz, 
CDCl3) δ = 7.64-7.60 (m, 3 H), 7.57-7.52 (m, 2 H), 7.22-7.17 (m, 3 H), 7.17-7.13 (m, 
2 H), 7.12-7.06 (m, 3 H), 7.06-7.00 (m, 2 H ), 3.83 (s, 3 H), 3.07 (s, 3 H), 3.05 (s, 3 
H), 2.72 (s, 3 H), 2.36 (s, 3 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 158.1 (s), 144.1 
(s), 140.4 (s), 140.3 (s), 135.1 (s), 133.8 (s), 130.2 (s), 129.8 (d), 129.6 (d), 129.4 (d), 
128.7 (s), 128.4 (d), 128.2 (d), 128.1 (d), 127.6 (d), 127.5 (d), 126.8 (d), 125.3 (s), 
122.8 (s), 122.4 (s), 119.0 (d), 105.6 (d), 55.4 (q), 38.9 (q), 38.2 (q), 37.9 (q), 21.6 (q) 
ppm; IR (ATR): ṽ = 2933, 2850, 1748, 1681, 1628, 1600, 1486, 1456, 1350, 1261, 
1163, 1085, 1030, 963, 924, 887, 855, 813, 764, 700, 669, 611 cm
-1
; HRMS (ESI) m/z 
calcd for [C31H30N2O6S2+Na]
+








H NMR (500 MHz, 
CDCl3) δ = 7.65 (d, J = 8.5 Hz, 2 H), 7.23 (d, J = 8.5 Hz, 2 H), 7.17-7.13 (m, 2 H), 
7.12-7.09 (m, 1 H), 7.07-7.05 (m, 1 H), 6.86-6.83 (m, 1 H ), 6.82-6.78 (m, 2 H), 3.74 
(s, 3 H), 3.04 (s, 3 H), 3.03 (s, 3 H), 2.68 (s, 3 H), 2.36 (s, 3 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 159.4 (s), 144.2 (s), 140.0 (s), 139.8 (s), 135.0 (s), 130.7 (d), 130.1 
(s), 129.6 (d), 128.3 (d), 127.9 (d), 124.9 (d), 124.2 (d), 122.5 (s), 122.0 (s), 118.4 (s), 
113.9 (d), 55.2 (q), 38.9 (q), 38.2 (q), 37.6 (q), 21.6 (q) ppm; IR (ATR): ṽ = 3007, 
2935, 2839, 1710, 1596, 1514, 1456, 1348, 1291, 1250, 1222, 1156, 1087, 1032, 988, 
965, 916, 877, 836, 817, 793, 762, 731, 707, 674, 631 cm
-1
; HRMS (ESI) m/z calcd 
for [C25H26N2O6S3+Na]
+
: 569.0845; found: 569.0852.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.68-7.63 (m, 2 H), 7.26-7.13 (m, 12 H), 7.12-7.07 (m, 2 H), 4.33 (t, J = 
7.5 Hz, 2 H), 3.65 (t, J = 8.0 Hz, 2 H), 2.95 (s, 3 H), 2.38 (s, 3 H) ppm; 
13
C NMR 
(125 MHz, CDCl3) δ = 156.7 (s), 144.2 (s), 140.5 (s), 136.7 (s), 135.0 (s), 130.2 (s), 
130.1 (s), 129.7 (d), 129.4 (d), 129.2 (d), 128.5 (d), 128.3 (d), 128.2 (d), 127.8 (d), 
127.6 (d), 123.0 (s), 121.2 (s), 62.9 (t), 46.4 (t), 37.7 (q), 21.6 (q) ppm; IR (ATR): ṽ = 
3061, 2958, 2923, 1766, 1693, 1645, 1613, 1596, 1494, 1479, 1445, 1409, 1352, 1219, 
1167, 1123, 1076, 1045, 1002, 983, 937, 856, 815, 773, 759, 701, 660, 608 cm
-1
; 
HRMS (ESI) m/z calcd for [C27H24N2O5S+Na]
+









H NMR (500 MHz, 
CDCl3) δ = 7.26-7.22 (m, 2 H), 7.20-7.16 (m, 2 H), 7.01-6.62 (m, 14 H), 4.30-3.88 (m, 
3 H), 3.28-3.17 (m, 1 H), 2.23 (s, 6 H), 1.92-1.52 (m, 6 H) ppm; 
13
C NMR (125 MHz, 
CDCl3) δ = 145.0 (s), 142.7 (s), 137.3 (s), 133.5 (s), 132.4 (s), 132.3 (s), 130.0 (d), 
129.9 (s), 129.8 (d), 129.3 (d), 129.2 (d), 128.2 (d), 127.8 (d), 127.5 (d), 127.0 (d), 
125.9 (d), 125.2 (d), 120.6 (s), 119.9 (s), 111.8 (s), 54.8 (t), 42.3 (t), 31.2 (t), 27.2 (t), 
24.9 (t), 21.6 (q), 21.4 (q) ppm; IR (ATR): ṽ = 2962, 1738, 1600, 1542, 1374, 1334, 
1259, 1049, 1020, 871, 798, 696, 675, 625 cm
-1
; HRMS (ESI) m/z calcd for 
[C35H34N2O5S2+Na]
+
: 649.1801; found: 649.1817.  
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.58-7.48 (m, 4 H), 7.23-7.09 (m, 14 H), 3.33-3.18 (m, 4 H), 2.34 (s, 6 H), 
1.31-1.18 (m, 4 H), 0.86-0.74 (m, 4 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 143.9 
(s), 139.2 (s), 135.7 (s), 130.3 (s), 129.6 (d), 129.3 (d), 128.2 (d), 128.1 (d), 127.5 (d), 
124.6 (s), 50.0 (t), 23.8 (t), 23.2 (t), 21.7 (q) ppm; IR (ATR): ṽ = 2926, 1697, 1598, 
1579, 1494, 1444, 1399, 1349, 1306, 1161, 1089, 1048, 1018, 981, 917, 871, 813, 771, 
693, 665 cm
-1
; HRMS (ESI) m/z calcd for [C36H36N2O5S2+Na]
+








H NMR (500 MHz, 
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CDCl3) δ = 7.63-7.58 (m, 4 H), 7.17-7.10 (m, 10 H), 7.09-7.03 (m, 4 H), 3.65-3.00 (m, 
4 H), 2.32 (s, 6 H), 1.41-0.88 (m, 10 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 143.7 
(s), 138.3 (s), 136.1 (s), 130.4 (s), 129.5 (d), 129.2 (d), 128.2 (d), 128.1 (d), 127.4 (d), 
124.6 (s), 49.0 (t), 25.8 (t), 25.3 (t), 23.1 (t), 21.6 (q) ppm; IR (ATR): ṽ = 2926, 2862, 
1600, 1579, 1495, 1444, 1403, 1352, 1341, 1307, 1188, 1160, 1113, 1074, 1022, 986, 
921, 896, 867, 809, 773, 701, 663 cm
-1
; HRMS (ESI) m/z calcd for 
[C37H38N2O5S2+Na]
+
: 677.2114; found: 677.2112. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.70-7.50 (m, 12 H), 7.40-7.30 (m, 4 H), 7.15-7.10 (m, 2 H), 7.03-6.96 (m, 
4 H), 3.78-3.03 (m, 4 H), 2.20 (s, 3 H), 1.43-0.93 (m, 10 H) ppm; 
13
C NMR (125 
MHz, CDCl3) δ = 143.7 (s), 138.8 (s), 136.3 (s), 133.2 (s), 132.6 (s), 129.4 (d), 128.3 
(d), 128.2 (d), 128.0 (d), 127.9 (s), 127.7 (d), 127.5 (d), 127.1 (d), 126.1 (d), 125.9 (d), 
124.5 (s), 49.2 (t), 26.0 (t), 25.4 (t), 23.2 (t), 21.5 (q) ppm; IR (ATR): ṽ = 2928, 2863, 
1598, 1495, 1458, 1350, 1186, 1162, 1126, 1089, 1069, 1019, 995, 943, 926, 894, 860, 
814, 753, 726, 705, 666 cm
-1
; HRMS (ESI) m/z calcd for [C45H42N2O5S2+Na]
+
: 
777.2427; found: 777.2438.  
 
  




H NMR (500 MHz, 
CDCl3) δ = 7.62 (d, J = 7.5 Hz, 4 H), 7.10 (d, J = 8.0 Hz, 4 H), 6.95-6.89 (m, 4 H), 
6.67-6.61 (m, 4 H), 3.70 (s, 3 H), 3.67-3.50 (m, 2 H), 3.23-3.07 (m, 2 H), 2.30 (s, 3 H), 
1.66-1.06 (m, 8 H), 1.04-0.93 (m, 4 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 158.8 
167 
 
(s), 143.4 (s), 138.5 (s), 136.6 (s), 130.3 (d), 129.3 (d), 128.0 (d), 123.3 (s), 122.8 (s), 
113.6 (d), 55.1 (q), 50.4 (t), 27.5 (t), 25.3 (t), 22.5 (t), 21.6 (q) ppm; IR (ATR): ṽ = 
2931, 2859, 1713, 1577, 1513, 1458, 1397, 1348, 1291, 1247, 1158, 1110, 1089, 1067, 
1031, 993, 976, 945, 908, 832, 813, 754, 706, 686, 664, 626 cm
-1
; HRMS (ESI) m/z 
calcd for [C40H44N2O7S2+Na]
+
: 751.2482; found: 751.2486.  
 
 




H NMR (500 MHz, 
CD2Cl2) δ = 7.52-7.46 (m, 4 H), 7.32-7.28 (m, 2 H), 7.22-7.12 (m, 9 H), 7.06-7.01 (m, 
2 H), 3.31-3.15 (m, 4 H), 2.35 (s, 3 H), 2.34 (s, 3 H), 1.29-1.18 (m, 4 H), 0.84-0.71 (m, 
4 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 144.4 (s), 144.3 (s), 139.4 (s), 139.3 (s), 
135.7 (s), 135.6 (s), 131.3 (d), 131.0 (d), 130.2 (s), 129.7 (s), 129.6 (d), 129.5 (d), 
129.3 (d), 128.2 (d), 128.0 (d), 127.9 (d), 127.7 (d), 124.5 (s), 123.4 (s), 121.7 (s), 
50.06 (t), 50.02 (t), 23.8 (t), 23.7 (t), 23.2 (t), 23.0 (t), 21.4 (q), 21.3 (q) ppm; IR 
(ATR): ṽ = 2957, 1598, 1576, 1492, 1447, 1350, 1305, 1161, 1090, 1046, 1011, 981, 
918, 870, 813, 770, 705, 665 cm
-1
; HRMS (ESI) m/z calcd for [C36H35BrN2O5S2+H]
+
: 
719.1244; found: 719.1242. 
 
 




H NMR (500 MHz, 
CDCl3) δ = 7.56 (d, J = 8.5 Hz, 2 H), 7.42 (d, J = 8.5 Hz, 2 H), 7.24-7.14 (m, 12 H), 
7.10-7.06 (m, 2 H), 4.49-2.80 (m, 6 H), 2.34 (s, 3 H), 2.32-2.23 (m, 5 H), 2.04-1.91 
(m, 2 H) ppm; 
13
C NMR (125 MHz, CDCl3) δ = 171.5 (s), 144.2 (s), 144.1 (s), 139.4 
(s), 139.3 (s), 136.6 (s), 134.7 (s), 130.7 (s), 130.2 (s), 129.9 (d), 129.7 (d), 129.4 (d), 
129.2 (d), 128.4 (d), 128.3 (d), 128.2 (d), 127.8 (d), 127.7 (d), 127.4 (d), 124.0 (s), 
122.7 (d), 62.8 (t), 48.7 (t), 46.7 (t), 31.0 (t), 24.1 (t), 21.7 (q), 21.6 (q) ppm; IR 
168 
 
(ATR): ṽ = 2955, 1736, 1598, 1494, 1444, 1353, 1251, 1213, 1159, 1088, 988, 904, 
847, 813, 769, 693, 665 cm
-1
; HRMS (ESI) m/z calcd for [C36H34N2O7S2+Na]
+
: 
693.1700; found: 693.1697.  
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